

101 PheillePheArgLeuValTrpArgArgHis 110
|||||
301 TTTATCTTCGCTGCTGATGAGAAGGCAT 330

seq_name: gb_un:AX031305

seq_documentation_block:
LOCUS AX031305 332 bp DNA 20-SEP-2000
DEFINITION Sequence 1 from Patent WO9914321.
ACCESSION AX031305
VERSION AX031305.1 GI:10278633
KEYWORDS
SOURCE unidentified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 332)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S., Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HANSA (AU) ; REILLY LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

FEATURES
source
1..332
/organism="unidentified"
/db_xref="taxon:32644"
1..>330
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09658.1"
/db_xref="GI:10278633"
/translation="MAKQPSDVSSCDREGGOLQPAERPPOLRPGAPTSLQTEPOASI
RQSQEPEDLRPEIRIAQELRRIGDEFNETYTRRVFANDYREADHPQMVILQLLRFI
FLVWRRH"

BASE COUNT 87 a 85 c 91 g 69 t
ORIGIN

alignment_scores:
Quality: 574.00 Length: 110
Ratio: 5.218 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-2 x AX031305 ..

Align seg 1/1 to: AX031305 from: 1 to: 332

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGly 17
|||||
1 ATGCCAAGCAACCTCTTGATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTGCTGAGAGGCTCCCAAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnAlaSerIleArgGlnSerGlnGlu 50
|||||
101 CCTCCCTACAGACAGAACCCAGACTTCCATACAGACTCTCAGAGAGAA 150
51 ProGluAspLeuArgProGluIleArgIleAlaGlnGlnLeuArgI 67
|||||
151 CCTGAAGATCTGCCCGCGGAGATACGATTGCACAGAGCTGCGCGGGAT 200
67 eGlyAspGluPheAsnGluThrTrpThrArgArgValPheAlaAsnAsp 84
|||||
201 CGAGAGAGAGTTCACGAACCTTACACAGAGAGGGGTGTTGCAATGATT 250
84 yrArgGluAlaGluAspHisProGlnMetValIleLeuGlnLeuLeu 100
|||||
251 ACCGCCGAGGCTGAAGACCACCCTCAATGGTTATCTTACAACCTGTTACGC 300

101 PheillePheArgLeuValTrpArgArgHis 110
|||||
301 TTTATCTTCGCTGCTGATGAGAAGGCAT 330

seq_name: gb_ro:AF032461

seq_documentation_block:
LOCUS AF032461 333 bp mRNA 19-FEB-1998
DEFINITION Mus musculus Bims mRNA, complete cds.
ACCESSION AF032461
VERSION AF032461.1 GI:2895503
KEYWORDS
SOURCE house:mouse.
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 333)
AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M., Cory,S. and Huang,D.C.
TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis
JOURNAL EMBO J. 17 (2), 384-395 (1998)
MEDLINE 98094360
PUBMED 9430630
REFERENCE 2 (bases 1 to 333)
AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M., Cory,S. and Huang,D.C.S.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter & Eliza Hall Institute of Medical Research, PO Royal Melbourne Hospital, Parkville, Victoria 3050, Australia

FEATURES
source
1..333
/organism="Mus musculus"
/db_xref="taxon:10090"
1..333
/note="pro-apoptotic BH3-containing Bcl-2 family member"

CDS

BASE COUNT 88 a 85 c 91 g 69 t
ORIGIN

alignment_scores:

Quality: 574.00 Length: 110
Ratio: 5.218 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-2 x AF032461 ..

Align seg 1/1 to: AF032461 from: 1 to: 333

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGly 17
|||||
1 ATGCCAAGCAACCTCTTGATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTGCTGAGAGGCTCCCAAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnAlaSerIleArgGlnSerGlnGlu 50
|||||
101 CCTCCCTACAGACAGAACCCAGACTTCCATACAGACTCTCAGAGAGAA 150
51 ProGluAspLeuArgProGluIleArgIleAlaGlnGlnLeuArgI 67
|||||
151 CCTGAAGATCTGCCCGCGGAGATACGATTGCACAGAGCTGCGCGGGAT 200

67 eGlyAspGluPheAsnGluThrTyrThrArgValPheAlaAsnAspT 84
 |||||
 201 CGGAGACGAGTTCAACGAAACTTACACAGGAGGTTTGCAGAAATGATT 250
 |||||
 84 yzArgGluAlaGluAspHisProGlnMetValIleLeuGlnLeuArg 100
 |||||
 251 ACCGGAGGCTGAGACACACCTCAATGATGTTATCTTACAACTGTTACGC 300
 |||||
 101 PheIlePheArgLeuValTrpArgHis 110
 |||||
 301 TTTATCTTCGCTGCTGATGGAGAGGCAT 330
 |||||

seq_name: gb_ro:AF065432

seq_documentation_block:
 LOCUS AF065432 333 bp mRNA ROD 11-MAR-1999
 DEFINITION Rattus norvegicus Bcl-2 related ovarian death gene product BOD-M
 mRNA, complete cds.
 ACCESSION AF065432
 VERSION AF065432.1 GI:3228567
 KEYWORDS
 SOURCE Norway rat.
 ORGANISM Rattus norvegicus

REFERENCE 1 (bases 1 to 333)
 AUTHORS Hsu,S.Y., Lin,P. and Hsueh,A.J.
 TITLE BOD (Bcl-2-related ovarian death gene) is an ovarian BH3
 domain-containing proapoptotic Bcl-2 protein capable of
 dimerization with diverse antiapoptotic Bcl-2 members
 Mol. Endocrinol. 12 (9), 1432-1440 (1998)

JOURNAL MEDLINE 98400436
 REFERENCE 2 (bases 1 to 333)
 AUTHORS Hsu,S.Y. and Hsueh,A.J.W.
 TITLE Direct Submission
 JOURNAL Submitted (15-MAY-1998) GVN/OB, Stanford University, MSOB S385,
 Stanford, CA 94305, USA
 FEATURES
 source
 1. .333
 /organism="Rattus norvegicus"
 /db_xref="taxon:10116"
 CDS
 1. .333
 /codon_start=1
 /product="Bcl-2 related ovarian death gene product BOD-M"
 /protein_id="AAC23594.1"
 /db_xref="GI:3228568"
 /translation="MAKQPSDVNSECDREGGQLOPAERPPQLRPGAPTSQTESQASI
 RQSCDEPDLPRIAEQLRRIGDEFNYTTRAFANDYREADHPQMWILQLLRFI
 FRLVWRRH"

BASE COUNT 88 a 86 c 94 g 65 t

ORIGIN

alignment_scores:

Quality: 556.00 Length: 110
 Ratio: 5.101 Gaps: 0
 Percent Similarity: 99.091 Percent Identity: 96.364

alignment_block:

US-09-508-832-2 x AF065432 ..

Align seg 1/1 to: AF065432 from: 1 to: 333

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyCl 17
 |||||
 1 ATGGCCAGCAGCACCTTCGATGTAATTTCTGAGTGTGACAGAGAGGTGG 50
 |||||
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
 |||||
 51 ACAATTGACGCTGCTGAGAGGCCTCCCGAGCTCAGGCTGGGGCCCTA 100
 |||||

34 hrSerLeuGlnThrGluProGlnAlaSerIleArgGlnSerGlnGluGlu 50
 |||||
 101 CCTCCCTACAGACAGAAATCCGAAGCTTCCATTAAGGCAGTCTCAGGAGGAC 150
 |||||
 51 ProGluAspLeuArgProGluIleArgIleAlaGlnGluLeuArgArgI 67
 |||||
 151 CCGAGAGGCTGCGCCAGAGATACGATCGCACAGGAGCTGCGCGGAT 200
 |||||
 67 eGlyAspGluPheAsnGluThrTyrThrArgValPheAlaAsnAspT 84
 |||||
 201 CGGAGACGAGTTCAATGACACTTACACAGGAGGCGGTTTGCAGAGATT 250
 |||||
 84 yzArgGluAlaGluAspHisProGlnMetValIleLeuGlnLeuArg 100
 |||||
 251 ACCGAGGCGGAGAACACACCCGCAAAATGTTATCTTACAACTGTTACGA 300
 |||||
 101 PheIlePheArgLeuValTrpArgHis 110
 |||||
 301 TTTATCTTCGCTGCTGCTGAGAGAGGCAC 330
 |||||

seq_name: gb_pat:AX031281

seq_documentation_block:
 LOCUS AX031281 422 bp DNA PAT 20-SEP-2000
 DEFINITION Sequence 3 from Patent WO9914321.
 ACCESSION AX031281
 VERSION AX031281.1 GI:10278612
 KEYWORDS
 SOURCE unidentified.
 ORGANISM unidentified.

REFERENCE 1 (bases 1 to 422)

AUTHORS Huang,D.C. and Strasser,A.

TITLE Novel therapeutic molecules

JOURNAL Patent: WO 9914321-A 3 25-MAR-1999;

INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HANSA (AU) ; REILLY

LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY

SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

FEATURES
 Location/Qualifiers

source 1..422

/organism="unidentified"

/db_xref="taxon:32644"

1..>420

/note="unnamed protein product"

/codon_start=1

/protein_id="CAC09654.1"

/db_xref="GI:10278613"

/translation="MAKQPSDVNSECDREGGQLOPAERPPQLRPGAPTSQTPEQDRS

PAPMSCDKSTQTPSPQCAFNYHLSAMISQSEPEDLRPEIRIAQLRRIGDEFN

ETVTRRVFANDYREADHPQMWILQLRRFRLVWRRH"

BASE COUNT 112 a 116 c 109 g 85 t

ORIGIN

alignment_scores:

Quality: 549.00 Length: 140
 Ratio: 4.991 Gaps: 1
 Percent Similarity: 78.571 Percent Identity: 78.571

alignment_block:

US-09-508-832-2 x AX031281 ..

Align seg 1/1 to: AX031281 from: 1 to: 422

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyCl 17
 |||||
 1 ATGGCCAGCAGCACCTTCGATGTAATTTCTGAGTGTGACAGAGAGGTGG 50
 |||||
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
 |||||
 51 ACAATTGACGCTGCTGAGAGGCCTCCCGAGCTCAGGCTGGGGCCCTA 100
 |||||

PAPMSCDKSTQTPSPPCOAFNHVLSAMASIROSEPEDLRPEIRIAQELRRIGDEFN

ETYTRVAFANDYREAEHPQMWILQLLRIFRLWRRH"

BASE COUNT 113 a 116 c 109 g 85 t

ORIGIN

alignment_scores:
Quality: 549.00 Length: 140
Ratio: 4.991 Gaps: 1
Percent Similarity: 78.571 Percent Identity: 78.571

alignment_block:
US-09-508-832-2 x AF032460

Align seg 1/1 to: AF032460 from: 1 to: 423

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17

1 ATGCCCAAGCAACCTTCTGATGTAAGTCTGAGTGTGACAGAGAAGTGG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34

51 ACAATTGCAGCCTGCTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTA 100

34 hrSerLeuGlnThrGluProGln..... 41

101 CCTCCTACAGACAGACCGCAAGACAGACAGGAGCCCGCACCATGAGTTGT 150

41

151 GACAAGTCAACACACAAACCCCAAGTCTCTTCCAGGCTTCAACCACTA 200

42AlaSerIleArgGlnSerGlnGluGluProGluAspL 54

201 TCTCAGTGAATGGCTTCCATACGACAGCTCTCAGGAGGAACCTGAAGATC 250

54 euArgProGluIleArgIleAlaGlnLeuArgArgIleGlyAspGlu 70

251 TGGCCCGGAGATACGATTTCACAGAGGCTGCGGCGGATCGGAGAGGAG 300

71 PheAsnGluThrTyThrArgArgValPheAlaAsnAspTyrArgGluA1 87

301 TTCAACGAACTTACACAGAGAGGCTTTCGCAATGATTACCGGAGGC 350

87 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 104

351 TGAAGACACCCCTCAATGGTATTATCTACAACTGTTACGCTTTATCTTCC 400

104 rgLeuValTyrArgArgHis 110

401 GTCTGGTATGGAGAGGCAT 420

seq_name: gb_ro:AF136927

seq documentation_block: 423 bp mRNA ROD 21-APR-1999

LOCUS AF136927 Rattus norvegicus Bcl-2 related apoptotic gene product BimL (bimL)

DEFINITION mRNA, complete cds.

ACCESSION AF136927

VERSION AF136927.1 GI:4590514

KEYWORDS Norway rat.

SOURCE Rattus norvegicus

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;

Rattus.

1 (bases 1 to 423)

Chen, D., Simon, R.P. and Chen, J.

Cloning of rat bimL and bimL, and their differential expression in

ischemia and normal rat brain

Unpublished

JOURNAL 2 (bases 1 to 423)

REFERENCE Chen, D., Simon, R.P. and Chen, J.

AUTHORS

TITLE

JOURNAL

AUTHORS

TITLE
JOURNAL

Submitted (24-MAR-1999) Department of Neurology, BST, S-526,
Pittsburgh University Medical School, 3500 Terrace Street,
Pittsburgh, PA 15213, USA

FEATURES

Location/Qualifiers

source

1..423

/organism="Rattus norvegicus"

/db_xref="taxon:10116"

1..423

/gene="bimL"

1..423

/gene="bimL"

/codon_start=1

/product="Bcl-2 related apoptotic gene product BimL"

/protein_id="AAD26594.1"

/db_xref="GI:4590515"

/translation="MAKQPSDVNSCEDREGGOLQAPERPQPLRPGAPTSLQTESQDRS

PAPMSCDKSTQTPSPPCOAFNHVLSAMASIROSEPEDLRPEIRIAQELRRIGDEFN

ETYTRVAFANDYREAEHPQMWILQLLRIFRLWRRH"

BASE COUNT 116 a 113 c 112 g 82 t

ORIGIN

alignment_scores:

Quality: 534.00 Length: 140

Ratio: 4.899 Gaps: 1

Percent Similarity: 77.857 Percent Identity: 76.429

alignment_block:

US-09-508-832-2 x AF136927

Align seg 1/1 to: AF136927 from: 1 to: 423

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17

1 ATGCCCAAGCAACCTTCTGATGTAAGTCTGAGTGTGACAGAGAAGTGG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34

51 ACAATTGCAGCCTGCTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTA 100

34 hrSerLeuGlnThrGluProGln..... 41

101 CCTCCTACAGACAGACCGCAAGACAGACAGGAGCCCGCACCATGAGTTGT 150

41

151 GACAAGTCAACACACAAACCCCAAGTCTCTTCCAGGCTTCAACCACTA 200

42AlaSerIleArgGlnSerGlnGluGluProGluAspL 54

201 TCTTAGCGCAATGGCTTCCATAGGACAGTCTCAGGAGGAACCTGAAGATC 250

54 euArgProGluIleArgIleAlaGlnLeuArgArgIleGlyAspGlu 70

251 TGGCCCGGAGATACGATTTCACAGAGGCTGCGGCGGATCGGAGAGGAG 300

71 PheAsnGluThrTyThrArgArgValPheAlaAsnAspTyrArgGluA1 87

301 TTCAATGAGACTTACACAGAGGAGGCTTTCGCAACGATTACCGAGAGGC 350

87 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 104

351 GGAAGACACCCGCAATGGTATTATCTTCAAACTGTTACGATTCATCTTCC 400

104 rgLeuValTyrArgArgHis 110

401 GTCTGGTATGGAGAGGCAT 420

seq_name: gb_pat:AX031283

seq documentation_block:

LOCUS AX031283 590 bp DNA PAT 20-SEP-2000

DEFINITION Sequence 5 from Patent WO9914321.
 ACCESSION AX031283
 VERSION AX031283.1 GI:10278614
 KEYWORDS
 SOURCE
 ORGANISM
 unclassified.
 unclassified.
 1 (bases 1 to 590)
 O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.
 Novel therapeutic molecules
 Patent: WO 9914321-A 5 25-MAR-1999;
 INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
 LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
 SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
 LOCATION/Qualifiers
 1. 590
 /organism="unclassified"
 /db_xref="taxon:32644"
 1. >587
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC09655.1"
 /db_xref="GI:10278615"
 /translation="MAKQPSDVSECDREGGLOQPAERPPOLRPGAPTSLQTEPQGNP
 DGEDRCPHGSPOGPLAPPSPGFATRSPLFIKRSLSLSRSSGYSFSDTDRSPA
 PMSCDKSTQTPSPCQAFNHVLSAMASIROQEPEDLRPEIRIAQELRLRIGDEFNET
 YTRRVFANDYREADHPQMVILQLLRFILRVWRR"
 137 a 178 c 150 g 125 t
 BASE COUNT
 ORIGIN

alignment_scores:
 Quality: 521.00 Length: 196
 Ratio: 4.736 Gaps: 1
 Percent Similarity: 56.122 Percent Identity: 56.122

alignment_block:

US-09-508-832-2 x AX031283 ..
 Align seg 1/1 to: AX031283 from: 1 to: 590
 1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 1 ATGGCCCAAGCAACCTCTCTGATGTAAGTTCTGAGTGTGACAGAGAAGGTG 50
 17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaPro 34
 51 ACAATTGCAGCGCTGCTGAGAGCGCTCCCGAGCTCAGGCTGGGGCCCTTA 100
 34 hrSerLeuGlnThrGluProGln..... 41
 101 CCTCCCTACAGACAGAACCGCAAGGTAATCCCGAGCGGCAAGGGACCGC 150
 41 41
 151 TGCCCCCAGCGAGCCCTCAGGCGCGCTGGCCCCACCGCCAGCCCTGG 200
 41 41
 201 CCCTTTTGTCACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTC 250
 41 41
 251 TGCTGTCCCGGTCTCCAGTGGGTATTCTCTTTTGACACAGACAGAGC 300
 41 41
 301 CCGGCACCCATGAGTTGTGACAGTCAACACAAACCCCAAGTCTCTCTG 350
 42AlaSerIleArgGlnSerG 48
 351 CCAGGCGCTCAACCACTATCTCAGTCAATGGCTTCCATACGACAGCTTC 400

48 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 64
 401 AGGAGGAACCTGAAGATCTGCGCCGAGATACGATTGCACAGGAGCTG 450
 65 ArgArgIleGlyAspGluPheAsnGluThrThrArgArgValPheAl 81
 451 CGCGGATCGGAGACAGTTCACAGAACTTACACAGGAGGCTGTTGC 500
 81 asnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGln 98
 501 AATGATTACCGAGCGCTGAAGACCACTCAATGGTTATCTTACAAC 550
 98 euLeuArgPheIlePheArgLeuValTrpArgArgHis 110
 551 TGTTACGCTTATCTTCCTCGTCTGGTATGGAGAAGCAT 588
 seq_name: gb_un:AX031309
 seq_documentation_block:
 LOCUS AX031309 590 bp DNA UNA 20-SEP-2000
 DEFINITION Sequence 5 from Patent WO9914321.
 ACCESSION AX031309
 VERSION AX031309.1 GI:10278637
 KEYWORDS
 SOURCE
 ORGANISM
 unclassified.
 unclassified.
 1 (bases 1 to 590)
 O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.
 Novel therapeutic molecules
 Patent: WO 9914321-A 25-MAR-1999;
 INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
 LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
 SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
 LOCATION/Qualifiers
 1. 590
 /organism="unclassified"
 /db_xref="taxon:32644"
 1. >587
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC09660.1"
 /db_xref="GI:10278638"
 /translation="MAKQPSDVSECDREGGLOQPAERPPOLRPGAPTSLQTEPQGNP
 DGEDRCPHGSPOGPLAPPSPGFATRSPLFIKRSLSLSRSSGYSFSDTDRSPA
 PMSCDKSTQTPSPCQAFNHVLSAMASIROQEPEDLRPEIRIAQELRLRIGDEFNET
 YTRRVFANDYREADHPQMVILQLLRFILRVWRR"
 137 a 178 c 150 g 125 t
 BASE COUNT
 ORIGIN

alignment_scores:

Quality: 521.00 Length: 196
 Ratio: 4.736 Gaps: 1
 Percent Similarity: 56.122 Percent Identity: 56.122

alignment_block:

US-09-508-832-2 x AX031309 ..
 Align seg 1/1 to: AX031309 from: 1 to: 590
 1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 1 ATGGCCCAAGCAACCTCTCTGATGTAAGTTCTGAGTGTGACAGAGAAGGTG 50
 17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaPro 34
 51 ACAATTGCAGCGCTGCTGAGAGCGCTCCCGAGCTCAGGCTGGGGCCCTTA 100
 34 hrSerLeuGlnThrGluProGln..... 41

```
101 CCTCCTACAGACAGACACCGCAAGTAATCCGAGCGCGAAGGGACGCG 150
41 ..... 41
151 TGCCCCCAGCGAGCCCTCAGGCGCCGCTGCGCCACCGCCAGCCCTGG 200
41 ..... 41
201 CCCTTTTCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 250
41 ..... 41
251 TGCTGTCCTCCGTCCTCCAGTGGTATTTCTTTTGACACAGACAGGAGC 300
41 ..... 41
301 CCGGCAACCATGAGTTGTGACAAGTCAACACAAACCCCAAGTCTCTCTG 350
42 ..... AlasertleArgGlnSerG 48
351 CCAGGCTTCAACCACTATCTCAGTGCAATGGCTTCCATACGACAGTCTC 400
48 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 64
401 AGGAGAACCTGAAGATCTGCGCGGAGATACGAGTTGCACAGAGCTG 450
65 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgValPheAl 81
451 CCGCGGATCGGAGAGGAGTTCACGAAACTTACACAGGAGGCTTTTGC 500
81 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGln 98
501 AAATGATTACCGCGAGGCTGAAGACCCCTCAATGGTTATCTTACAAC 550
98 euLeuArgPheIlePheArgLeuValTyrArgArgHis 110
51 TGTTACGCTTTATCTTCCGCTGCTGGTATGGAGAGGCAT 588
```

seq_name: gb_ro:AF032459

```
seq_documentation_block:
LOCUS AF032459 591 bp mRNA ROD 19-FEB-1998
DEFINITION Mus musculus BimEL mRNA, complete cds.
ACCESSION AF032459
VERSION AF032459.1 GI:2895499
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 591)
O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.
Bim: a novel member of the Bcl-2 family that promotes apoptosis
EMBO J. 17 (2), 384-395 (1998)
8094360
PUBMED 9430630
REFERENCE
2 (bases 1 to 591)
O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.S.
Direct Submission
JOURNAL Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia
FEATURES
source 1..591
/organism="Mus musculus"
/db_xref="taxon:10090"
1..591
/notes="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimEL"
/protein_id="AAC40029.1"
```

```
/db_xref="GI:2895500"
/translation="MAKPSDVSSSECDREGGQLQPAERPQRLPAPGAPTSLQTEPQGNP
DGEGRCPHGSPQGLAPSPAPFATRSLPLTFVRRSLSSSSGYSFSDTRSPA
PMSCDKSTQTPSPPCQAFNHYSAMASIRQSEPEDLRLPEIRIAQELRRIGDEFNET
YTRRVFANDYREAEHPQWVILQLLRFILVRRH"
BASE COUNT 138 a 178 c 150 g 125 t
ORIGIN
```

```
alignment_scores:
Quality: 521.00 Length: 196
Ratio: 4.736 Gaps: 1
Percent Similarity: 56.122 Percent Identity: 56.122
alignment_block:
US-09-508-832-2 x AF032459 ..
Align seg 1/1 to: AF032459 from: 1 to: 591
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTTCTGATGTAAGTCTGAGTGACAGAGAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATGCGAGCTGCTGAGAGGCTTCCCGAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCTACAGACAGACCGCAAGTAATCCGAGCGCGAAGGGACGCG 150
41 ..... 41
151 TGCCCCCAGCGAGCCCTCAGGCGCCGCTGCGCCACCGCCAGCCCTGG 200
41 ..... 41
201 CCCTTTTCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 250
41 ..... 41
251 TGCTGTCCTCCGTCCTCCAGTGGTATTTCTTTTGACACAGACAGGAGC 300
41 ..... 41
301 CCGGCAACCATGAGTTGTGACAAGTCAACACAAACCCCAAGTCTCTCTG 350
42 ..... AlasertleArgGlnSerG 48
351 CCAGGCTTCAACCACTATCTCAGTGCAATGGCTTCCATACGACAGTCTC 400
48 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 64
401 AGGAGAACCTGAAGATCTGCGCGGAGATACGAGTTGCACAGAGCTG 450
65 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgValPheAl 81
451 CCGCGGATCGGAGAGGAGTTCACGAAACTTACACAGGAGGCTTTTGC 500
81 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGln 98
501 AAATGATTACCGCGAGGCTGAAGACCCCTCAATGGTTATCTTACAAC 550
98 euLeuArgPheIlePheArgLeuValTyrArgArgHis 110
51 TGTTACGCTTTATCTTCCGCTGCTGGTATGGAGAGGCAT 588
```

seq_name: gb_ro:AF065433

```
seq_documentation_block:
LOCUS AF065433 591 bp mRNA ROD 11-MAR-1999
DEFINITION Rattus norvegicus Bcl-2 related ovarian death gene product BOD-L
mRNA, complete cds.
```

```

ACCESSION AF065433.1 GI:3228569
VERSION AF065433.1
KEYWORDS Norway rat.
SOURCE Rattus norvegicus
ORGANISM Rattus norvegicus
REFERENCE 1 (bases 1 to 591)
AUTHORS Hsu,S.Y., Lin,P. and Hsueh,A.J.
TITLE BOD (Bcl-2-related ovarian death gene) is an ovarian BH3
domain-containing proapoptotic Bcl-2 protein capable of
dimerization with diverse antiapoptotic Bcl-2 members
Moll. Endocrinol. 12 (9), 1432-1440 (1998)
JOURNAL
MEDLINE 98400436
REFERENCE 2 (bases 1 to 591)
AUTHORS Hsu,S.Y. and Hsueh,A.J.W.
TITLE Direct Submission
JOURNAL Submitted (15-MAY-1998) GYN/OB, Stanford University, MSOB S385,
Stanford, CA 94305, USA
FEATURES
source
1..591
/organism="Rattus norvegicus"
/db_xref="taxon:10116"
CDS
1..591
/codon_start=1
/product="Bcl-2 related ovarian death gene product BOD-L"
/protein_id="AAC23595.1"
/db_xref="GI:3228570"
/translation="MAKQPSDVNSECDREGQLOPAERPPOLRPGAPTSLQTESQGNP
DGEGRCPHGPSQGLPAPSPGPFATRSPLFIKRRSSLLSSSSGFFSFDTRSPA
PMSCDKSTQTPSPQCAFNHYSAMASIQSEEDLPRIEIRIAQELRLRGDEFNET
YTRAFANDYREADHPQMTVLQLLIRFLVWRHH"
BASE COUNT 139 a 177 c 153 g 122 t
ORIGIN
1
|||||
17
yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
|||||
51
ACAATTGCAGCTGCTGAGAGGCTCCCCAGCTCAGCGCTGGGGCCCTA 100
|||||
34
hrSerLeuGlnThrGluProGln..... 41
|||||
101
CTTCTTACAGAGAATCGCAAGGTAATCCCGAGCGGAAAGGGACCGC 150
|||||
41
..... 41
151
TGCCCCCAGGCGCCTCAGGGCCCGCTGGGCCCCACCGGCCAGCCCTGG 200
|||||
41
..... 41
201
TCCTTTTGCTACCATGCCACCTTTTCATCTTTGTGAGAGATCTTCTC 250
|||||
41
..... 41
251
TGCTGTCCCGTCTCCAGTGGGTATTTCTTTTGACACACAGAGAGC 300
|||||
41
..... 41

```

```

301 CCGGCCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTTG 350
42 .....AlaSerIleArgGlnSerG 48
|||||
351 CAGAGCGTTCAACCAATTATCTCAGTCAATGGCTTCCATAAGGCAGTCTC 400
|||||
48 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 64
|||||
401 AGGAGGAACCTGAAGATCTGCGCCAGAGATACGGATCGCACAGGAGCTG 450
|||||
65 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 81
|||||
451 CGCGCGATCGGAGACGAGTTCATGAGACTTACACGAGGAGCGGCTTGC 500
|||||
81 aaAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 98
|||||
501 AAACGATTACCGAGAGCGGAGAGACCCCGCAATGGTTATCTTACAAC 550
|||||
98 euLeuArgPheIlePheArgLeuValTrpArgArgHis 110
|||||
551 TGTTCAGATTCACTTTCGCTGGTCTGGAGAAGGCAC 588
seq_name: gb_pat:AX031285
seq_documentation_block:
LOCUS AX031285 416 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 7 from Patent WO9914321.
ACCESSION AX031285
VERSION AX031285.1 GI:10278616
KEYWORDS unidentified.
SOURCE unidentified.
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 416)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL Patent: WO 9914321-A 7 25-MAR-1999;
INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY
LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
FEATURES
source
1..416
/organism="unidentified"
/db_xref="taxon:32644"
1..>414
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09656.1"
/db_xref="GI:10278617"
/translation="MAKQPSDVNSECDREGQLOPAERPPOLRPGAPTSLQTEPDQRS
PAPMSCDKSTQTPSPQCAFNHYSAMASIQSEEDLPRIEIRIAQELRLRGDEFNET
YTRAFVFLNNYQAEDHPRMVILRLIRYIVRLVWRHH"
BASE COUNT 113 a 113 c 103 g 87 t
ORIGIN
1
|||||
1
MetAlaLysGlnProSerAspValSerGluCysAspArgGluGly 17
|||||
1
ATGGCCAAGCAACCTTCTGATGTAATTCGTAGTGTGACAGAGAAGGTGG 50
|||||
17
yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
|||||
51
ACAATTGCAGCTGCTGAGAGGCTCCCCAGCTCAGCGCTGGGGCCCTA 100
|||||
34
hrSerLeuGlnThrGluProGln..... 41
|||||
101
CTTCTTACAGAGAATCGCAAGGTAATCCCGAGCGGAAAGGGACCGC 150
|||||
41
..... 41
151
TGCCCCCAGGCGCCTCAGGGCCCGCTGGGCCCCACCGGCCAGCCCTGG 200
|||||
41
..... 41
201
TCCTTTTGCTACCATGCCACCTTTTCATCTTTGTGAGAGATCTTCTC 250
|||||
41
..... 41
251
TGCTGTCCCGTCTCCAGTGGGTATTTCTTTTGACACACAGAGAGC 300
|||||
41
..... 41

```



```

Align_Seg 1/1 to: AX031311 from: 1 to: 416

1 MetAlaLysGlnProSerAspValSerSerGluCyAspArgGluGlyG1 17
|||||
1 ATGGCAAAAGCAACCTTCTGATGTAGTCTTGAAGTCTGAGTGTGACCGAGAAGGTAG 50
|||||
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGGCGAGAGCCCTCCCCAGCTCAGACCTGGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCTACAGACAGACGACAGACAGAGAGCCAGAGCCCATGAGTTGT 150
|||||
41 ..... 41
|||||
151 GACAAATCAACAAACCCCAAGTCTCTCTCCAGGCGTTCAACCACTA 200
|||||
42 .....AlaSerIleArgGlnSerGlnGluProGluAspL 54
|||||
201 TCTCAGTGCATGGCTTCCATCAGGCAGGCT.....GAACCTGCAGATA 244
|||||
54 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 70
|||||
245 TCGGCCACAGAGATATGGATCGGCCCAAGAGTTTCGGCGTATCGGAGACGAG 294
|||||
71 PheAsnGluThrTyThrArgArgValPheAlaAsnAspTyrArgGluAl 87
|||||
295 TTTTACGCTTACTATGCAAGGAGGATTTTTCATTAATTAATCAACGACGC 344
|||||
87 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 104
|||||
345 CGAAGACCAACCCACGAAATGGTTATCTTAGGACTGTTACGTTACATTGCC 394
|||||
104 rgLeuValTrpArgHis 110
|||||
395 GCCTGGTGGGAGATGCAT 414
|||||

seq_name: gb_pr:AF032458

seq_documentation_block:
LOCUS AF032458 417 bp mRNA PRI 1
DEFINITION Homo sapiens BimL mRNA, complete cds.
ACCESSION AF032458
VERSION AF032458.1 GI:2895497
KEYWORDS
SOURCE human..
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea;
O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G.
Cory,S. and Huang,D.C.
Bim: a novel member of the Bcl-2 family that promotes
EMBO J. 17 (2), 384-395 (1998)
MEDLINE 98094360
PUBMED 9430630
REFERENCE 2 (bases 1 to 417)
AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G.
Cory,S. and Huang,D.C.S.
Direct Submission
TITLE Submitted (03-NOV-1997) Molecular Genetics of Cancer
JOURNAL Eliza Hall Institute of Medical Research, PO Royal
Hospital, Parkville, Victoria 3050, Australia
FEATURES
source
1: 417
/organism="Homo sapiens"
/db_xref="taxon:9606"
1-417
CDS
1:417
/note="pro-apoptotic BH3-containing Bcl-2 f

```

```
/db_xref="GI:2895498"
/translation="MAKQPSDVSECDREGRLQPAERPPQLRPGCAPTSIQTEPDQDRS
PAPMSCDKSTQTPSPPOAFNHYLSAMSMQAPADMRPEIWIQAQLRLRIGDEFNAY
YARVFLNNYQAAEDHPRMVLRLRLRYIVRLVWRMH"
BASE COUNT      114 a      113 c      103 g      87 t
ORIGIN
```

```
alignment_scores:
  Quality: 436.00      Length: 140
  Ratio: 4.404        Gaps: 2
  Percent Similarity: 70.714      Percent Identity: 64.286
```

```
alignment_block:
US-09-508-832-2 x AF032458 ..
```

```
Align seg 1/1 to: AF032458 from: 1 to: 417
```

```
1 MetAlaIysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTTCTGATGAAGTTCTGAGTGTGACCGAGAAGGTAG 50
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProf 34
|||||
51 ACAATTGCAGCTGCGGAGAGGCTCCCCAGCTCAGACCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCCTACAGACAGAGCCACAGACAGGAGCCAGCAGCCCATGAGTTGT 150
41 ..... 41
151 GACAAATCAACACAAACCCCAAGTCTCTTGCAGGCGCTTCAACCACCTA 200
201 TCTCAGTGCATGGCTTCCATGAGGAGGCT.....GACCTGCAGATA 244
54 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 70
:::|||||
245 TGGGCCCAGAGATATGATCGCCCAAGAGTTGGCGGTATCGGAGACGAG 294
71 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 87
|||||
295 TTTAAGCGCTTACTGCAAGGAGGATTTTGAATAATATACCAACGACG 344
87 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 104
|||||
345 CGAAGACCCACCAAGATGGTTATCTTACGACTGTTACGTTACATTGTCC 394
104 rgLeuValTrpArgArgHis 110
|||||
395 GCCTGTGTGGAGATGCAT 414
```

Walz M;

6/22.

tubulin from *Acremonium chrysogenum* - and relates DNA, and transformed cells, for co-transformations of a wide variety of *A. chrysogenum* strains with foreign genes

Fig 4; Page 9-10; 31pp; German.

Vectors based upon the beta tubulin coding sequence may be used to transform *Acremonium chrysogenum*, optionally in combination with other vectors to introduce a required foreign gene such as the gene encoding glutaryl acylase, an enzyme involved in cephalosporin biosynthesis. The coding sequence may be used to transform a wide variety of *Acremonium chrysogenum* strains (wild type and mutants). Unlike known systems, it is not recipient-strain limited.

SQ Sequence 2206 BP; 449 A; 740 C; 541 G; 476 T; 0 other;

alignment_scores:
Quality: 84.50 Length: 95
Ratio: 1.536 Gaps: 6
Percent Similarity: 57.895 Percent Identity: 30.526

alignment_block:
US-09-508-832-2 x AAQ70754

Align seg 1/1 to: AAQ70754 from: 1 to: 2206

15 GlucGlyGlnLeuGlnProAlaGluArgProGln..... 27
1680 GAAGGAGTCCGACGACGAGATGCGCAACGTCGAGCAAGAACTCGTCCT 1729
21 LeuArgProGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerI 44
1730 ACTTCGTCGAGTGATCC.....CAACACATCCAGACGCTCTC 1770
44 leArgGlnSerGlnGluProGluAsp.....LeuArgProGlu 57
1771 TGCGCATTCCTCCCGGCGGCTCAAGATGTCCTCCACCTTCATCGGCAC 1820
58 IleArgIle..AlaGlnGluLeu...ArgArgIleGlyAspGluPheAsnG 73
1821 CTCACCTCCATCCAGGAGGCTTCAAGCGTGTCTCGTGAGCAGTCACTG 1870
73 IuThrTyrThrArgArgValPheAlaAsn..... 82
1871 CCATGTTCCGTCGCAAGCGTTCCTGTCATTGTCATCTGAGGGCATG 1920
83AspTyrArgGluAlaGluAspHis 90
1921 GACGAGATGGAGTTTACCGAGCGCGAGTCCAAC 1953

seq_name: /SIDS2/gcdata/geneseq/geneseqn/NA1993.DAT:AAQ48230

seq_documentation_block:

ID AAQ48230 standard; DNA; 3445 BP.

AC AAQ48230;

DT 22-FEB-1994 (first entry)

DE *Acremonium chrysogenum* beta-tubulin gene.

KW Beta tubulin; mutant; chemical resistance; selective marker;
KW cephalosporin; antibiotic production; ds.

OS *Acremonium chrysogenum*.

XX

XX Key Location/Qualifiers

XX

XX

XX

True

FT exon 1..1298 /tag= a /number= 1 /note= "ATG initiation codon is located at nucleotides 1287..1289"

FT intron 1299..1460 /tag= b

FT exon 1461..1484 /tag= c /number= 2

FT intron 1485..1551 /tag= d /number= 2

FT exon 1552..1674 /tag= e /number= 3

FT intron 1675..1748 /tag= f /number= 3

FT exon 1749..2539 /tag= g /number= 4

FT intron 2540..2602 /tag= h /number= 4

FT exon 2603..3445 /tag= i /number= 5

FT /note= "TAA termination codon is located at nucleotides 2994..2996"

XX JP05192157-A.

XX 03-AUG-1993.

XX 26-MAY-1992; 92JP-0133384.

XX 27-MAY-1991; 91JP-0121276.

XX (TAKE) TAKEDA CHEM IND LTD.

XX WPI; 1993-277472/35.

XX P-PSDB; AAR40226.

XX DNA fragment contg. DNA coding mutant beta-tubulin - originates from *Acremonium chrysogenum*, used as selective marker for transformation of *A. chrysogenum*

XX Example 5; Fig 4-6; 16pp; Japanese.

XX The wild-type coding sequence for beta-tubulin was isolated from *Acremonium chrysogenum* ATCC 11550 and sequenced (AAQ48230). Primers CTU-3 and CTU-6 were used to introduce mutations at codon 100 (Asn to Ile) and 167 (Phe to Tyr), respectively. Expression of the mutant proteins encoded by these sequences confers chemical resistance (e.g. to carbendazim and to ansamitocin) on transformed microorganisms. See AAQ55405 and AAQ55406 for mutated sequences.

XX SQ Sequence 3445 BP; 723 A; 1061 C; 892 G; 769 T; 0 other;

alignment_scores:
Quality: 84.50 Length: 95
Ratio: 1.536 Gaps: 6
Percent Similarity: 57.895 Percent Identity: 30.526

alignment_block:
US-09-508-832-2 x AAQ48230

Align seg 1/1 to: AAQ48230 from: 1 to: 3445

15 GlucGlyGlnLeuGlnProAlaGluArgProGln..... 27

BEST AVAILABLE COPY

THIS PAGE BLANK (USPTO)

BEST AVAILABLE COPY

[illegible]

seq_name: /SIDS2/gcdata/geneseq/geneseq/NA1994.DAT:AAQ70754

seq_documentation_block:

seq_documentation_block.
ID AAQ70754 standard; DNA; 2206 BP.

AA
AC
AA070754:

DT 22-MAR-1995 (first entry)

XX
DE Beta tubulin gene of *Acremonium chrysogenum*.

Beta tubulin; Acremonium chrysogenum; transformation;
KW
XX
co-transformation; biosynthesis; cephalosporins; ss.
KW

AA
OS
Acromonium chrysogenum.

XX	Key	Location/Qualifiers
FH		

FT	key	LOCATION
FT	exon	346..357

```

ET      /*lagm = E
ET      /label= E

```

```

F1 intron
358..519
/*tag= b

```

ET	.	/label= I
EE	0000	543

```

ET
.cref=
/*tag= c

```

FT intron 544..610

ET . . . /label= I

$$\frac{F_T}{\tau_{tag}} = e$$

intron
734..807

FT /label= I
/label= I
/label= I

```

TTT      nova
TTT/*tag= q
TTT000::TJ38

```

FI	FT	intron	/label=E
1599..166			

```
ET /tag= n
ET /label= T
```

FT¹ exon
1662...205
/tag= f

```

ET
XX
/label= E

```

PN EP610842-A.

PD 17-AUG-1994.

PF 07-FEB-1994; 94EP-01017

PR 12-FEB-1993; 93DE-43043

PA (FARH) HOECHST AG.

WY

THIS PAGE BLANK (USPTO)

Sequence	Strd Orig	zScore	EScore	Len	Documentation
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX24993 +			574.00	1102.40	332
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX24994 +			549.00	1051.96	422
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX24995 +			521.00	994.85	590
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX24996 +			436.00	834.40	416
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX24997 +			406.00	773.20	596
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAQ4501 +			87.50	149.42	1747
/SID22/gcgdata/geneseq/geneseq/NA1994.DAT:AAQ70734 +			84.50	141.43	2206
/SID22/gcgdata/geneseq/geneseq/NA1993.DAT:AAQ848230 +			84.50	137.21	3445
/SID22/gcgdata/geneseq/geneseq/NA1993.DAT:AAQ55405 +			84.50	137.21	3445
/SID22/gcgdata/geneseq/geneseq/NA1993.DAT:AAQ55406 +			84.50	137.21	3445
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAAG63340 -			83.00	117.12	21185
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAAG63348 -			83.00	106.77	63164
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAAZ30014 +			79.50	137.90	1158
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH50546 +			79.00	131.37	2085
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH311146 +			79.00	131.37	2085
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH311243 +			79.00	131.37	2085
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAAD04443 +			79.00	131.37	2085
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAAG161371 +			79.00	83.24	335913
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAI61372 +			79.00	83.24	335913
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAH36918 +			78.00	132.75	1471
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAI24461 -			77.00	139.36	1097
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH115287 -			77.00	128.04	1972
/SID22/gcgdata/geneseq/geneseq/NA1998.DAT:AAV73325 +			76.50	131.10	1290
/SID22/gcgdata/geneseq/geneseq/NA1999.DAT:AAAX32491 +			76.50	130.28	1407
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH02918 +			76.50	130.25	1412
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH33759 +			76.50	130.15	1427
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAH70056 -			76.00	143.14	327
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAAT77741 -			76.00	143.02	331
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAI128479 -			76.00	143.02	331
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAH83514 +			76.00	140.81	418
/SID22/gcgdata/geneseq/geneseq/NA1997.DAT:AAAT91561 +			76.00	133.10	944
/SID22/gcgdata/geneseq/geneseq/NA1988.DAT:AAH80309 +			76.00	124.70	2291
/SID22/gcgdata/geneseq/geneseq/NA1993.DAT:AAQ38230 +			75.50	129.14	1295
/SID22/gcgdata/geneseq/geneseq/NA1998.DAT:AAVA42919 +			75.50	128.65	1363
/SID22/gcgdata/geneseq/geneseq/NA1998.DAT:AAVA42918 +			75.50	128.61	1369
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAZ298405 +			75.50	127.59	1535
/SID22/gcgdata/geneseq/geneseq/NA2001.DAT:AAQ32369 +			75.50	127.51	1571
/SID22/gcgdata/geneseq/geneseq/NA1991.DAT:AAQ13113 +			75.50	122.75	2541
/SID22/gcgdata/geneseq/geneseq/NA1992.DAT:AAQ24235 +			75.50	122.75	92.38
/SID22/gcgdata/geneseq/geneseq/NA2000.DAT:AAQ25288 +			75.50	122.04	2740

CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.
 XX
 SQ Sequence 332 BP; 87 A; 85 C; 91 G; 69 T; 0 other;

alignment_scores:
 Quality: 574.00 Length: 110
 Ratio: 5.218 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:
 US-09-508-832-2 x AAX24993 ..

Align seg 1/1 to: AAX24993 from: 1 to: 332

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 1 ATGGCCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaPro 34
 51 ACAATTGCAGCCTGCTGAGAGCGCTCCAGCTCAGGCTGGGGCCCTTA 100
 34 hrSerLeuGlnThrGluProGlnAlaSerIleArgGlnSerGlnGlu 50
 101 CCTCCCTACAGACAGAACCGCAAGCTTCCATACGACAGTCTCAGAGGAA 150
 51 ProGluAspLeuArgProGluIleArgIleAlaGlnGluLeuArg 67
 151 CCGAAGATCTGCGCCGAGATACCGATGTCACAGGAGCTGCGGCGGAT 200
 67 eGlyAspGluPheAsnGluThrTyrThrArgArgValPheAlaAsnAsp 84
 201 CGGAGACGAGTTCACGAACTTACACAGGAGGTTGTTGCAAAATGATT 250
 84 yrArgGluAlaGluAspHisProGlnMetValIleLeuGlnLeuLeuArg 100
 251 ACCGCGAGGCTGAAGACCAACCTCAATGTTATCTTACAACCTGTTACGC 300
 101 PheIlePheArgLeuValTrpArgArgHis 110
 301 TTTATCTTCGCTGTTGATGGAGAAGGCAT 330

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT: AAX24994

seq_documentation_block:
 ID AAX24994 standard; cDNA; 422 BP.

XX AC AAX24994;

XX 05-JUL-1999 (first entry)

XX Murine Bcl-2 interacting mediator of cell death Bim-L cDNA.
 XX Bim-L; Bcl-2 interacting mediator of cell death; apoptosis;
 KW cell cycle; mouse; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;
 KW isoform; ss.

XX Mus musculus.

XX W09914321-A1.

XX PD 25-MAR-1999.

XX

PF 17-SEP-1998; 98WO-AU00772.
 XX
 PR 24-SEP-1997; 97AU-0009373.
 PR 17-SEP-1997; 97AU-0009263.
 XX
 PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.
 XX
 PI Adams J, Cory S, Huang PCS, O'Connor L, O'Reilly L;
 PI Puthalakath H, Strasser A;
 XX
 DR WPI: 1999-244030/20.
 DR P-PSDB; AAW98155.
 XX

New isolated member of the Bcl-2 family, Bim used in, e.g. cancer treatment

Claim 3; Page 94-95; 145pp; English.

CC The present sequence encodes the long form (L) of murine Bim, or
 CC Bcl-2 interacting mediator of cell death (see AAW98155), a novel
 CC member of the Bcl-2 family that is capable of inducing cell death
 CC (apoptosis) and which acts as a 'death-ligand' for certain members
 CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 CC only BH3-only protein region which it encompasses is BH3. It is the
 CC result in the expression of a variety of isoforms, i.e. Bim-S,
 CC Bim-L and Bim-EL (see AAW98154-56). cDNAs encoding these murine Bim
 CC isoforms were obtained from a T lymphoma cDNA library using human
 CC recombinant Bcl-2 protein. The murine Bim gene has been mapped to
 CC chromosome 2 at bands F3-G. Human Bim-L and Bim-EL isoforms have
 CC also been identified (see AAW98157-58). Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-68) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC treatment or prophylaxis in conditions such as cancer and deletion
 CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.

SQ Sequence 422 BP; 112 A; 116 C; 109 G; 85 T; 0 other;

alignment_scores:
 Quality: 549.00 Length: 140
 Ratio: 4.991 Gaps: 1
 Percent Similarity: 78.571 Percent Identity: 78.571

alignment_block:

US-09-508-832-2 x AAX24994 ..

Align seg 1/1 to: AAX24994 from: 1 to: 422

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 1 ATGGCCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaPro 34


```

|||||
51 ACAATTGAGCCTGCTGAGAGCCCTCCAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCTACAGACACACCGCAAGACAGGAGCGCGCAGCCATGATGTGT 150
41 ..... 41
151 GACAAAGTCAACACAAACCCCAAGTCTCTCTGCCAGGCTTCAACCACTA 200
42 .....AlaSerIleArgGlnSerGlnGluGluProGluAspL 54
|||||
201 TCTCAGTCAATGGCTTCCATACGACAGCTCTCAGGAGAACTGAAGATC 250
54 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 70
|||||
251 TGCGCCCGGAGATACGATGTCACAGGAGCTGCGCGGATCGGAGACGAG 300
71 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 87
|||||
301 TCAACGAACTTACACAAAGGAGGTGTTGCAATGATTACCGGAGGC 350
87 agluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 104
|||||
351 TGAACACCACTCAATGGTTATCTTACAACTGTTCAGCTTTATCTTCC 400
104 rgLeuValTrpArgRHis 110
|||||
401 GTCCTGATGGAGAAGGCAT 420

```

seq_name: /SIDS2/gcdata/geneseq/geneseq/NA1999.DAT: AAX24995

seq_documentation_block:

ID AAX24995 standard; cDNA; 590 BP.

AC AAX24995;

DT 05-JUL-1999 (first entry)

DE Murine Bcl-2 interacting mediator of cell death Bim-EL cDNA.

KW Bim-EL; Bcl-2 interacting mediator of cell death; apoptosis;
 KW cell cycle; mouse; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;
 KW isoform; ss.

XX Mus musculus.

XX W09914321-A1.

XX 25-MAR-1999.

XX 17-SEP-1998; 98WO-AU00772.

XX 24-SEP-1997; 97AU-0009373.

XX 17-SEP-1997; 97AU-0009263.

XX (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.

XX Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;
 PI Puchalakath H, Strasser A;

XX WPI; 1999-244030/20.

XX P-PSDB; AAW98156.

XX New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
 PT treatment

XX Claim 3; Page 96-97; 145pp; English.

XX The present sequence encodes the extra long form (EL) of murine Bim,
 CC or Bcl-2 interacting mediator of cell death (see AAW98156), a novel

CC member of the Bcl-2 family that is capable of inducing cell death
 CC (apoptosis) and which acts as a 'death-ligand' for certain members
 CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 CC only Bcl-2 homology region which it encompasses is BH3. It is the
 CC only BH3-only protein for which splice variants exist. These
 CC result in the expression of a variety of isoforms, i.e. Bim-S,
 CC Bim-L and Bim-EL (see AAW98154-56). cDNAs encoding these murine Bim
 CC isoforms were obtained from a T lymphoma cDNA library using human
 CC recombinant Bcl-2 protein. The murine Bim gene has been mapped to
 CC chromosome 2 at bands F3-G. Human Bim-L and Bim-EL isoforms have
 CC also been identified (see AAW98157-58). Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-68) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC of autoreactive lymphocytes in conditions such as cancer and deletion
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.

XX Sequence 590 BP; 137 A; 178 C; 150 G; 125 T; 0 other;

alignment_scores:

Quality: 521.00 Length: 196
 Ratio: 4.736 Gaps: 1
 Percent Similarity: 56.122 Percent Identity: 56.122

alignment_block:

US-09-508-832-2 x AAX24995 ..

Align' seg 1/1 to: AAX24995 from: 1 to: 590

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyGcl 17
|||||
1 ATGGCCAAAGCAACCTTCTGTATGTAAGTTCTGAGTGTGACAGAGAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
|||||
51 ACAATTCAGCCTGCTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
101 CCTCCGTACAGACAGACCGCAAGGTAATCCGACGCGGAGGGGACCGC 150
41 ..... 41
151 TGCCCCCAGCGCAGCCCTCAGGCGCCGCTGGCCCGCCAGCCGCTGG 200
41 ..... 41
201 CCCTTTTGTCTACCATCCCACTTTTTCATCTTTGTGAGAGATCTTCTC 250
41 ..... 41
251 TGCTGTCGGGTCTCTCCAGTGGGTATTTCTCTTTTGACACAGACAGGAGC 300
41 ..... 41

```

```

301 CCGGCCACCCATGAGTCTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTTG 350
42 .....AlaSerIleArgGlnSerG 48
351 CCAGGCGCTTCAACCACTATCTCAAGTCAATGGCTTCCATACGACAGTCTC 400
48 lnGluGluProGluAspLeuArgProGluIleAlaGlnGluLeu 64
401 AGGAGGAACCTGAAGATCTCGCCGCGAGATACGGATTGCACAGGAGCTG 450
65 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 81
451 CGCGGATCGGACGACGAGTTCAACGAACCTTACACAGGAGGAGTGTTCG 500
81 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 98
501 AATGATATCCGCGAGGCTGAACACCACTCAATGGTTATCTTACAAC 550
98 euLeuArgPheIlePheArgLeuValTrpArgHis 110
551 TGTATACGCTTTATCTTCGCTGCTGATGGAGAAGCAT 588

```

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT:AAx24996

seq_documentation_block:

ID AAX24996 standard; cDNA; 416 BP.

AC AAX24996;

XX 05-JUL-1999 (first entry)

DE Human Bcl-2 interacting mediator of cell death Bim-L cDNA.

XX Bim-L; Bcl-2 interacting mediator of cell death; apoptosis;
 KW cell cycle; human; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;
 KW isoform; ss.

XX Homo sapiens.

XX WO914321-A1.

XX 25-MAR-1999.

XX 17-SEP-1998; 98WO-AU00772.

XX 24-SEP-1997; 97AU-0009373.

XX 17-SEP-1997; 97AU-0009263.

PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.

XX Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;

PI Puthalakath H, Strasser A;

XX WPI; 1999-244030/20.

DR P-PSDB; AAW98157.

XX New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
 PT treatment

XX Claim 7; Page 99-100; 145pp; English.

XX The present sequence encodes the long form (L) of human Bim, or
 CC Bcl-2 interacting mediator of cell death (see AAW98157), a novel
 CC member of the Bcl-2 family that is capable of inducing cell death
 CC (apoptosis) and which acts as a 'death-ligand' for certain members
 CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 CC only Bcl-2 homology region which it encompasses is BH3. It is the
 CC result in the expression of a variety of splice variants exist. These
 CC Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see
 CC AAW98158) were isolated from embryo and liver cDNA libraries using

CC mouse bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see
 CC AAW98154-56) are also provided. The human Bim gene maps to
 CC chromosome 2 at bands 2q12-2q13. Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-68) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC treatment or prophylaxis in conditions such as cancer and deletion
 CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.
 XX
 SQ Sequence 416 BP; 113 A; 113 C; 103 G; 87 T; 0 other;

alignment_scores:

Quality: 436.00 Length: 140
 Ratio: 4.404 Gaps: 2
 Percent Similarity: 70.714 Percent Identity: 64.286

alignment_block:

US-09-508-832-2 x AAX24996 ..

Align seg 1/1 to: AAX24996 from: 1 to: 416

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG 17
|||||
1 ATGGCAAGCAACCTTCTGATGTAAGTTCTGAGTGACCGAGAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGluValaProf 34
|||||
51 ACAATTGCAGCTCGCGAGGAGGCTCCCGAGCTCAGACCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCTACAGACAGAGCCACAGACAGGAGCCAGCCATGAGTTGT 150
41 ..... 41
151 GACAAATCAACACAAACCCCAAGTCTCTTCCAGGCGCTTCAACCACTA 200
42 .....AlaSerIleArgGlnSerGlnGluGluProGluAspL 54
|||||
201 TCTCAGCTGCANTGGCTTCCATGAGGAGGCT.....GAACCTGCAGATA 244
54 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 70
|||||
245 TGGCCGACAGATATGGATCGCCCAAGAGTTGGCGGTATCGGAGACGAG 294
71 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 87
|||||
295 TTTAACGCTTACTATCAAGAGGGGTATTTTGAATAATATACCAACGAGC 344
87 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePhe 104
|||||
345 CGAAGACCAACCCAGCAATGTTATCTTACGACTGTTACGTTACATTGTCC 394
104 rgLeuValTrpArgArgHis 110

```

The present sequence encodes the extra long form (EL) of human Bim, or Bcl-2 interacting mediator of cell death (see AAW98158), a novel member of the Bcl-2 family that is capable of inducing cell death (apoptosis) and which acts as a 'death-ligand' for certain members of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the only Bcl-2 homology region which it encompasses is BH3. It is the only BH3-only protein for which splice variants exist. These result in the expression of a variety of isoforms, i.e. Bim-S, Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see AAW98158) were isolated from embryo and liver cDNA libraries using mouse Bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see AAW98154-56) are also provided. The human Bim gene maps to chromosome 2 at bands 2q12-q13. Binding the dynein light chain was shown to regulate the pro-apoptotic activity of Bim. Bim-S, the splice variant which does not bind to dynein light chain, is a much more potent killer than either Bim-L or Bim-EL. The invention provides variants (see AAW98159-68) of murine and human Bim-L or Bim-EL that cannot bind, couple or otherwise associate with a dynein light chain. The identification of Bim permits the identification and rational design of a range of products for use in therapy, diagnosis, antibody generation and involving modulation of physiological cell death. These therapeutic molecules may act as either antagonists or agonists of Bim's function and will be useful in cancer, autoimmune or degenerative disease therapy. Increased Bim expression or Bim activity is useful, e.g. for treatment or prophylaxis in conditions such as cancer and deletion of autoreactive lymphocytes in autoimmune disease. Decreased Bim expression of Bim activity is useful in regulating inhibition or prevention of cell death or degeneration such as under cytotoxic conditions during e.g. gamma-irradiation and chemotherapy or during

AC AAC44501;
XX
DT 18-OCT-2000 (first entry)
XX
DE
XX
XX Zea mays DNA fragment SEQ ID NO: 43060.
KW Hybridisation assay; genetic mapping; gene expression control;
KW protein identification; signal transduction pathway; metabolic;
KW pathway; promoter; termination sequence; corn; ss.
XX
OS
XX Zea mays subsp. mays.
XX
PN EP1033405-A2.
XX
PD
XX
XX 06-SEP-2000.
XX
XX 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132489.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137508.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.

PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144332.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149910.
PR 25-AUG-1999; 99US-0150566.

```
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

alignment_scores:
  Quality: 87.50      Length: 110
  Ratio: 1.458        Gaps: 4
  Percent Similarity: 54.545  Percent Identity: 26.364

alignment_block:
US-09-508-832-2 x AAC44501 ..
Align seg 1/1 to: AAC44501 from: 1 to: 1747

      8 ValSerSerGluCysAspArgGlyGlyGlnLeuGlnProAlaGluAr 24
      ||| ||| .....:|||||
1094 GTTCCCGGAGATGATGACCAAGAGGTGGAGCAGATGCTCAACG 1143
      ||| ||| .....:|||||

      24 gProProGln.....LeuArgProGlyAlaProThrSerLeug 37
      ||| ||| .....:|||||
1144 TCCAGAACAAAGACTCGTCTACTTCGTGGAGTGGATGCCCAACACGTC 1193
      ||| ||| .....:|||||

      37 InThrGluProGlnAlaSerIleArgGlnSerGlnGluProGluAsp 53
      ||| ||| .....:|||||
```

```
1194 AAGTCAGCGGTGTGCGACATCCCGCCAGGGCCCTGAGATGGCGGGGAC 1243
54 LeuArgProGluIleArgIleAlaGlnGluLeu...ArgArgIleGlyA 69
||| ||| .....:|||||
1244 CTTCTGTTGGGAATCCACCTCCATCCAGAGATGTTCCGACGGTGCAGG 1293
69 spGluPheAsnGluThrTyrThrArgArgValPheAlaAsn..... 82
||| ||| .....:|||||
1294 AGCAGTTACCGCCCATGTTTCAGGCGCAAGGCCTCTCTGCATGTTACAC 1343
83 .....:|||||
1344 GCGGAGGGATGGATGAGATGAGTCACTAGCGCGGAGAGCAACATGAA 1393
92 nMetValIleLeuGlnLeuLeuArgPhe 101
||| ||| .....:|||||
1394 CGATCTGTCGCGGAGTACCAGCAGTAC 1421

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1994.DAT:AAQ70754
seq_documentation_block:
ID AAQ70754 standard; DNA; 2206 BP.
XX
AC AAQ70754;
XX
DT 22-MAR-1995 (first entry)
XX
DE Beta tubulin gene of Acremonium chrysogenum.
XX
KW Beta tubulin; Acremonium chrysogenum; transformation;
KW co-transformation; biosynthesis; cephalosporins; ss.
XX
OS Acremonium chrysogenum.
XX
FH Key Location/Qualifiers
FT exon 346..357
FT FT /*tag= a
FT FT /label= Exon 1.
FT FT 358..519
FT FT /*tag= b
FT FT /label= Intron 1.
FT FT 520..543
FT FT /*tag= c
FT FT /label= Exon 2.
FT FT 544..610
FT FT /*tag= d
FT FT /label= Intron 2.
FT FT 611..733
FT FT /*tag= e
FT FT /label= Exon 3.
FT FT 734..807
FT FT /*tag= f
FT FT /label= Intron 3.
FT FT 808..1598
FT FT /*tag= g
FT FT /label= Exon 4.
FT FT 1599..1661
FT FT /*tag= h
FT FT /label= Intron 4.
FT FT 1662..2055
FT FT /*tag= i
FT FT /label= Exon 5.
XX
XX EP610842-A.
XX
XX 17-AUG-1994.
XX
XX 07-FEB-1994; 94EP-0101794.
XX
XX 12-FEB-1993; 93DE-4304312.
XX
XX (FARH ) HOECHST AG.
XX
```

PI Kueck U, Nowak C, Walz M;
 DR WPI: 1994-256686/32.
 DR P-PSDB; AAR56512.
 XX
 PT New beta-tubulin from Acremonium chrysogenum - and relates DNA,
 PT vectors and transformed cells, for co-transformations of a wide
 PT range of A. chrysogenum strains with foreign genes
 XX
 PS Claim 4; Page 9-10; 3lpp; German.
 XX
 CC Vectors based upon the beta tubulin coding sequence may be used to
 CC transform Acremonium chrysogenum, optionally in combination with
 CC other vectors to introduce a required foreign gene such as the gene
 CC encoding glutaryl acylase, an enzyme involved in cephalosporin
 CC biosynthesis. The coding sequence may be used to transform a wide
 CC variety of Acremonium chrysogenum strains (wild type and mutants).
 CC Unlike known systems, it is not recipient-strain limited.
 XX
 SQ Sequence 2206 BP; 449 A; 740 C; 541 G; 476 T; 0 other;

alignment_scores:
 Quality: 84.50 Length: 95
 Ratio: 1.536 Gaps: 6
 Percent Similarity: 57.895 Percent Identity: 30.526

alignment_block:
 US-09-508-832-2 x AAQ070754 ..

Align seg 1/1 to: AAQ070754 from: 1 to: 2206

15 GluGlyGlnLeuGlnProAlaGluArgProGln..... 27
 1680 GAGGAGGTCGAGCAGCAGATGGCAACGTCACAGCAAGAACTCGTCCT 1729

26 LeuArgProGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerI 44
 1730 ACTTCGTCGAGTGGATCCC.....CAACAACATCCAGACGCGCTCTC 1770

44 LeArgInSerGlnGluProGluAsp.....LeuArgProGlu 57
 1771 TGGCCATTCTCCCGGCGCTCAAGATGCTCCACCTTCATCGCAA 1820

58 IleArgIleAlaGlnGluLeu...ArgArgIleGlyAspGluPheAsnG 73
 1821 CTCACCTCCATCCAGGAGCTGTTCAGCGTGTGCGTGAGCAGTTCACGT 1870

73 LuThrThrThrArgArgValPheAlaAsn..... 82
 1871 CCATGTTCCGTCGCAAGGCTTCTGTCATGTGTACACTGGTGAGGGCATG 1920

83AspTyrArgGluAlaGluAspHis 90
 1921 GACGAGATGGAGTTTACCGAGCGCGAGTCCCAAC 1953

seq_name: /SDS2/gcgdata/geneseq/geneseqn/NA1993.DAT.AAQ48230

seq_documentation_block:
 ID AAQ48230 standard; DNA; 3445 BP.
 XX
 AC AAQ48230;
 XX
 DT 22-FEB-1994 (first entry)
 XX
 DE Acremonium chrysogenum beta-tubulin gene.
 XX
 KW Beta tubulin; mutant; chemical resistance; selective marker;
 KW cephalosporin; antibiotic production; ds.
 XX
 OS Acremonium chrysogenum.
 XX
 FH Key Location/Qualifiers

FT exon 1..1298
 FT /*tag= a
 FT /number= 1
 FT /note= "ATG initiation codon is located at
 FT nucleotides 1287..1289"
 FT intron 1299..1460
 FT /*tag= b
 FT /number= 1
 FT /*tag= c
 FT 1461..1484
 FT /*tag= c
 FT intron 1485..1551
 FT /*tag= d
 FT /number= 2
 FT 1552..1674
 FT /*tag= e
 FT /number= 3
 FT 1675..1748
 FT /*tag= f
 FT /number= 3
 FT 1749..2539
 FT /*tag= g
 FT /number= 4
 FT 2540..2602
 FT /*tag= h
 FT /number= 4
 FT 2603..3445
 FT /*tag= i
 FT /number= 5
 FT /note= "TAA termination codon is located at
 FT nucleotides 2994..2996"
 FT
 XX JP05192157-A.
 PN
 XX 03-AUG-1993.
 PD
 XX 26-MAY-1992; 92JP-0133384.
 PF
 XX 27-MAY-1991; 91JP-0121276.
 PR
 XX (TAKE) TAKEDA CHEM IND LTD.
 PA
 XX WPI: 1993-277472/35.
 DR P-PSDB; AAR40226.
 XX
 PT DNA fragment contg. DNA coding mutant beta-tubulin - originates
 PT from Acremonium chrysogenum, used as selective marker for
 PT transformation of A. chrysogenum
 XX
 PS Example 5; Fig 4-6; 16pp; Japanese.
 XX
 CC The wild-type coding sequence for beta-tubulin was isolated from
 CC Acremonium chrysogenum ATCC 11550 and sequenced (AAQ48230). Primers
 CC CTU-3 and CTU-6 were used to introduce mutations at codon 100 (Asn
 CC to Ile) and 167 (Phe to Tyr), respectively. Expression of the
 CC mutant proteins encoded by these sequences confers chemical
 CC resistance (e.g. to carbendazim and to anisamitocin) on transformed
 CC microorganisms. See AAQ55405 and AAQ55406 for mutated sequences.
 XX
 SQ Sequence 3445 BP; 723 A; 1061 C; 892 G; 769 T; 0 other;

alignment_scores:
 Quality: 84.50 Length: 95
 Ratio: 1.536 Gaps: 6
 Percent Similarity: 57.895 Percent Identity: 30.526

alignment_block:
 US-09-508-832-2 x AAQ48230 ..

Align seg 1/1 to: AAQ48230 from: 1 to: 3445

15 GluGlyGlnLeuGlnProAlaGluArgProGln..... 27

```

|||||
2621 GAAGGAGTTCGAGGACGAGATCGGCAAGCTCCAGAGCAAGAACTCGTCCT 2670
      |||
28  .LeuArgProGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerI 44
      |||
2671 ACTTCGTGAGTGGATCC.....CAACAACATCCAGACCGCTCTC 2711
      |||
44  .LeuArgGlnSerGlnGluProGluAAsp.....LeuArgProGlu 57
      |||
2712 TCGGCATTCCTCCCGGCTCAAGATGCTCCACCTTCATCGGCAA 2761
      |||
58  .IleArgIleAlaGlnGluLeu...ArgArgIleGlyAspGluPheAsnG 73
      |||
2762 CTCACCTCCATCCAGAGAGCTGTTCAAGCGTGTCTCGTGAGCAGTTCACTG 2811
      |||
73  .LuThrTyrThrArgArgValPheAlaAsn..... 82
      |||
2812 CCATGTCGTGCGCAAGCTTTCCTGCATTTGTACACTGGTGAGGGCATG 2861
      |||
83  .....AspTyrArgGluAlaGluAspHis 90
      |||
2862 GACGAGATGGAGTTTACCGAGCGCGAGTCCAAC 2894
      |||

```

seq_name: /SIDS2/gcgdata/geneseq/geneseq/NAL1993.DAT:AAQ55405

seq_documentation_block:

ID AAQ55405 standard; DNA; 3445 BP.

XX AC AAQ55405;

XX XX 22-FEB-1994 (first entry)

XX DE A.chrysogenum beta-tubulin Ile(100) mutant coding sequence.
 XX KW Beta tubulin; mutant; chemical resistance; selective marker;
 XX KW cephalosporin; antibiotic production; ds.
 XX OS Acremonium chrysogenum.

Key	Location/Qualifiers
exon	1..1298
FT	/*tag= a
FT	/number= 1
FT	/note= "ATG initiation codon is located at nucleotides 1287..1289"
intron	1299..1460
FT	/*tag= b
FT	/number= 1
exon	1461..1484
FT	/*tag= c
FT	/number= 2
intron	1485..1551
FT	/*tag= d
FT	/number= 2
exon	1552..1674
FT	/*tag= e
FT	/number= 3
intron	1675..1748
FT	/*tag= f
FT	/number= 3
exon	1749..2539
FT	/*tag= g
FT	/number= 4
FT	/note= "wild-type AAC (Asn) codon at position 1887..1889 is mutated to ATC (Ile) codon"
intron	2540..2602
FT	/*tag= h
FT	/number= 4
exon	2603..3445
FT	/*tag= i
FT	/number= 5
FT	/note= "TAA termination codon is located at nucleotides 2994..2996"

XX JF05192157-A.
 XX 03-AUG-1993.
 XX 26-MAY-1992; 92JP-0133384.
 XX 27-MAY-1991; 91JP-0121276.
 XX (TAKE) TAKEDA CHEM IND LTD.
 XX WPT; 1993-277472/35.
 XX P-PSDB; AAR48200.
 XX DNA fragment contg. DNA coding mutant beta-tubulin - originates from Acremonium chrysogenum, used as selective marker for transformation of A.chrysogenum
 XX Claim 3 and Example 6; Fig 4-6 and Fig 7; 16pp; Japanese.
 XX The wild-type coding sequence for beta-tubulin was isolated from Acremonium chrysogenum ATCC 11550 and sequenced (AAQ48230). Primers CCU-3 and CTU-6 were used to introduce mutations at codon 100 (Asn to Ile) and 167 (Phe to Tyr), respectively. Expression of the mutant proteins encoded by these sequences confers chemical resistance (e.g. to carbendazim and to ansamitocin) on transformed microorganisms. See also AAQ55406.
 XX SQ Sequence 3445 BP; 722 A; 1061 C; 892 G; 770 T; 0 other;

alignment_scores:
 Quality: 84.50 Length: 95
 Ratio: 1.536 Gaps: 6
 Percent Similarity: 57.895 Percent Identity: 30.526
 alignment_block:
 US-09-508-832-2 x AAQ55405 ..
 Align seg 1/1 to: AAQ55405 from: 1 to: 3445
 15 GluGlyGlnLeuGlnProAlaGluArgProGln..... 27
 |||||
 2621 GAAGGAGTTCGAGGACGAGATCGGCAAGCTCCAGAGCAAGAACTCGTCCT 2670
 28 .LeuArgProGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerI 44
 |||||
 2671 ACTTCGTGAGTGGATCC.....CAACAACATCCAGACCGCTCTC 2711
 44 .LeuArgGlnSerGlnGluProGluAAsp.....LeuArgProGlu 57
 |||||
 2712 TCGGCATTCCTCCCGGCTCAAGATGCTCCACCTTCATCGGCAA 2761
 58 .IleArgIleAlaGlnGluLeu...ArgArgIleGlyAspGluPheAsnG 73
 |||||
 2762 CTCACCTCCATCCAGAGAGCTGTTCAAGCGTGTCTCGTGAGCAGTTCACTG 2811
 73 .LuThrTyrThrArgArgValPheAlaAsn..... 82
 |||||
 2812 CCATGTCGTGCGCAAGCTTTCCTGCATTTGTACACTGGTGAGGGCATG 2861
 83AspTyrArgGluAlaGluAspHis 90
 |||||
 2862 GACGAGATGGAGTTTACCGAGCGCGAGTCCAAC 2894

seq_name: /SIDS2/gcgdata/geneseq/geneseq/NAL1993.DAT:AAQ55406

seq_documentation_block:

ID AAQ55406 standard; DNA; 3445 BP.

XX AC AAQ55406;

XX XX 22-FEB-1994 (first entry)

XX A.chrysogenum beta-tubulin Tyr(167) mutant coding sequence.
 XX Beta tubulin; mutant; chemical resistance; selective marker;
 KW cephalosporin; antibiotic production; ds.
 XX
 OS Acremonium chrysogenum.
 XX
 FH Key Location/Qualifiers
 FT exon 1..1298
 FT /tag= a
 FT /number= 1
 FT /note= "ATG initiation codon is located at
 FT nucleotides 1287..1289"
 FT intron 1299..1460
 FT /tag= b
 FT /number= 1
 FT exon 1461..1484
 FT /tag= c
 FT /number= 2
 FT intron 1485..1551
 FT /tag= d
 FT /number= 2
 FT exon 1552..1674
 FT /tag= e
 FT /number= 3
 FT intron 1675..1748
 FT /tag= f
 FT /number= 3
 FT exon 1749..2539
 FT /tag= g
 FT /number= 4
 FT /note= "wild-type TTC (Phe) codon at position
 FT 2088..2090 is mutated to TAC (Tyr) codon"
 FT intron 2540..2602
 FT /tag= h
 FT /number= 4
 FT exon 2603..3445
 FT /tag= i
 FT /number= 5
 FT /note= "TAA termination codon is located at
 FT nucleotides 2994..2996"
 FT
 PN JP05192157-A.
 XX
 XX 03-AUG-1993.
 XX
 XX 26-MAY-1992; 92JP-0133384.
 XX
 XX 27-MAY-1991; 91JP-0121276.
 XX
 XX (TAKE) TAKEDA CHEM IND LTD.
 XX
 XX WPI; 1993-277472/35.
 XX P-PSDB; AAR48201.
 XX
 PT DNA fragment contg. DNA coding mutant beta-tubulin - originates
 PT from Acremonium chrysogenum, used as selective marker for
 PT transformation of A.chrysogenum
 XX
 XX Claim 3 and Example 6; Fig 4-6 and Fig 7; 16pp; Japanese.
 XX
 CC The wild-type coding sequence for beta-tubulin was isolated from
 CC Acremonium chrysogenum ATCC 11550 and sequenced (AAQ48230). Primers
 CC CTU-3 and CTU-6 were used to introduce mutations at codon 100 (Asn
 CC to Ile) and 167 (Phe to Tyr), respectively. Expression of the
 CC mutant proteins encoded by these sequences confers chemical
 CC resistance (e.g. to carbendazim and to ansamitocin) on transformed
 CC microorganisms. See also AAQ55405.
 XX
 XX Sequence 3445 BP; 724 A; 1061 C; 892 G; 768 T; 0 other;

alignment_scores:
 Quality: 84.50 Length: 95
 Ratio: 1.536 Gaps: 6
 Percent Similarity: 57.895 Percent Identity: 30.526
 alignment_block:
 US-09-508-832-2.x AAQ55406 ..
 Align seg 1/1 to: AAQ55406 from: 1 to: 3445
 15 GluGlyGlyClnLeuGlnProAlaGluArgProGln..... 27
 |||||
 2621 GAAGGAGGTGAGGACCGACAGTGGCAACGTCAGCAGCACTCGTCTC 2670
 28 .LeuArgProGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerI 44
 |||||
 2671 ACTTCGTCGAGTGGATCCC.....CAACAACATCCAGACCGCTCTC 2711
 44 leArgGlnSerGlnGluGluProGluAsp.....LeuArgProGlu 57
 |||||
 2712 TGGGCCATTCTCCCGTGGCTCAAGATGTCCTCCACCTTCATCGCAA 2761
 58 IleArgIleAlaGlnGluLeu...ArgArgIleGlyAspGluPheAsnG 73
 |||||
 2762 CTCACCTCCATCCAGGAGCGTGTCAAGCGTGTGCGTGAGCAGTCACTG 2811
 73 LuThrTyrThrArgArgValPheAlaAsn..... 82
 |||||
 2812 CCATGTTCCGTCGCAAGGCTTCTCTCATTTGTTACACTGGTGAGGGCATG 2861
 83AspTyrArgGluAlaGluAspHis 90
 |||||
 2862 GACGAGATGAGGTTTACCGAGGCGGAGTCCCAAC 2894
 seq_name: /SIDS2/gcgdata/geneseq/NA2000.DAT:AAA63350
 seq_documentation_block:
 ID AAA63350 standard; DNA; 21185 BP.
 XX
 AC AAA63350;
 XX
 DT 06-MAR-2001. (first entry)
 XX
 DE Streptomyces globisporus C-1027 gene cluster ORF 25-42.
 KW Eneidiyne C-1027 biosynthesis gene cluster; apoprotein; chromophore;
 KW cancer; ds.
 XX
 OS Streptomyces globisporus.
 XX
 FH Key Location/Qualifiers
 FT CDS complement (1..632)
 FT /tag= a
 FT /product= "type II NRPS adenylation enzyme"
 FT 1966..4044
 FT /tag= b
 FT /product= "transmembrane transport protein"
 FT 4188..5192
 FT /tag= c
 FT /product= "O-methyl transferase"
 FT 5249..6505
 FT /tag= d
 FT /product= "P450 hydroxylase"
 FT complement (6628..7734)
 FT /tag= e
 FT /product= "oxidoreductase"
 FT 8370..9410
 FT /tag= f
 FT /product= "ORF 31 protein"
 FT complement (5539..10361)
 FT /tag= g
 FT /product= "oxidoreductase"
 FT 11261..12094
 FT

FT FT /*tag= h /product= "ORF 33 protein"
 FT CDS 1251..11399
 FT FT /*tag= i /product= "ORF 34 protein"
 FT CDS 14046..14900
 FT FT /*tag= j /product= "proline oxidase"
 FT CDS complement (14947..15756)
 FT FT /*tag= k /product= "ORF 36 protein"
 FT CDS complement (15853..16323)
 FT FT /*tag= l /product= "ORF 37 protein"
 FT CDS complement (16460..18115)
 FT FT /*tag= m /product= "P450 hydroxylase"
 FT CDS complement (18112..18642)
 FT FT /*tag= n /product= "ORF 39 protein"
 FT CDS 18960..20039
 FT FT /*tag= o /product= "ORF 40 protein"
 FT CDS 20065..20919
 FT FT /*tag= p /product= "ORF 41 protein"
 FT CDS complement (20807..21185)
 FT FT /*tag= q /product= "ORF 42 protein"
 FT CDS

W0200040596-A1.

13-JUL-2000.

06-JAN-2000; 2000WO-US00446.

06-JAN-1999; 99US-0115434.

03-JAN-2000; 2000US-0477962.

(REGC) UNIV CALIFORNIA.

Shen B, Liu W, Christenson SD, Standage S;

WPI; 2000-465947/40.

DR P-PSDB; AAB13588, AAB13589, AAB13590, AAB13591, AAB13592, AAB13593,
 DR AAB13594, AAB13595, AAB13596, AAB13597, AAB13598, AAB13600, AAB13601,
 DR AAB13602, AAB13603, AAB13607, AAB13606.

XX Isolated nucleic acid comprising a nucleic acid encoding any of C-1027
 PT open reading frames (ORFs) 7 to 42, excluding ORF 9 (cagA), useful for
 PT the production of enediyne C-1027 antitumour antibiotics -

XX Claim 1; Page 130-157; 160pp; English.

XX The present sequence is the last 21184 bases of the enediyne C-1027 gene
 CC cluster from Streptomyces globisporus. Enediyne C-1027 is an antibiotic,
 CC consisting of an apoprotein and a non-peptidic chromophore, which acts by
 CC damaging DNA. The sequences within the gene cluster, and the proteins
 CC they encode, can be used in the treatment of cancer, along with
 CC antagonists of the protein. Each of the open reading frames is
 CC specifically claimed, excluding ORF 9, which encodes CagA.

XX Sequence 21185 BP; 2903 A; 7529 C; 7587 G; 3166 T; 0 other;

alignment_scores:

Quality: 83.00 Length: 57
 Ratio: 2.243 Gaps: 1
 Percent Similarity: 64.912 Percent Identity: 42.105

alignment_block:

US-09-508-832-2 x AAA63350/rev

Align seg 1/1 to reverse of: AAA63350 from: 1 to: 21185
 14 ArgGluGlyGlnLeuGlnProAlaGluArgProGlnLeuArgPr 30
 |||:||||| :|||||:||||| ||| :||
 13432 CGGCGGTGGACCTCGGGAACCGCGCGGTGAGCGCGGTGGCGCC 13383
 30 oGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerIleArgGlns 47
 | :||| :|||:||||| |||:|||||
 13382 G.....CGGACCTTCCCGCGCGCGCATCAGGCATT 13351
 47 erGlnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGlu 63
 || :||||| |||:||||| |||:|||||
 13350 CCGC.CGGAGCCGCCAGATCTCGCGCGAGTTGATGTTGGAGTTCTC 13302
 64 LeuArgIleGlyAspGlu 70
 ||||| :|||||
 13301 CTGGCCTTCCCTCGGCGAGGAG 13281

seq_name: /SIDS2/gcdata/geneseq/NA2000.DAT.AAA63348

seq_documentation_block:

ID AAA63348 standard; DNA; 63164 BP.

XX AAA63348;

XX 06-MAR-2001. (first entry)

XX Streptomyces globisporus C-1027 gene cluster.

XX Enediyne C-1027 biosynthesis gene cluster; apoprotein; chromophore;
 KW cancer; ds.

XX Streptomyces globisporus.

XX Key Location/Qualifiers
 FT CDS complement (8..658)

FT /*tag= a /product= "ORF -7 protein"
 FT CDS complement (930..1478)

FT /*tag= b /product= "ORF -6 protein"
 FT CDS complement (1649..2713)

FT /*tag= c /product= "ORF -5 protein"
 FT CDS complement (2850..3237)

FT /*tag= d /product= "ORF -4 protein"
 FT CDS complement (3442..4971)

FT /*tag= e /product= "ORF -3 protein"
 FT CDS 5982..7479

FT /*tag= f /product= "glycerol phosphate transporter"
 FT CDS complement (7573..9900)

FT /*tag= g /product= "ABC transport/UvrA-like protein"
 FT CDS complement (9982..11349)

FT /*tag= h /product= "Na+/H+ transporter"
 FT CDS complement (11351..12835)

FT /*tag= i /product= "hydroxylase/halogenase"
 FT CDS 13012..14079

FT /*tag= j /product= "dNDP-glucose synthase"
 FT CDS complement (14212..14643)

FT /*tag= k /product= "CagA"
 FT CDS complement (14690..15922)

FT /*tag= l /product= "aminotransferase"
 FT CDS complement (15919..16653)

FT /*tag= m

CC The sequences within the gene cluster, and the proteins they encode, can
 CC be used in the treatment of cancer, along with antagonists of the

alignment_scores:
 Quality: 83.00 Length: 57
 Ratio: 2.243 Gaps: 1
 Percent Similarity: 64.912 Percent Identity: 42.105

alignment_block:

US-09-508-832-2 x AAA63348/rev ..

Align seg 1/1 to reverse of: AAA63348 from: 1 to: 63164

14 ArgGluGlyGlyGlnLeuGlnProAlaGluArgProGlnLeuArgPr 30

||||:||||| :|||:|||||:||||| :||| :||| :|||

55411 CGCGCGGTGGACCTCGGAACCGCGCGGTGAGCGCGGTGGCGCC 55362

30 oGlyAlaProThrSerLeuGlnThrGluProGlnAlaSerIleArgGlnS 47

||||:||||| :|||:|||||:||||| :||| :||| :|||

55361 G.....CGGACCTTCGCGCGCGCGCGCATCAGGCATT 55330

47 erGlnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGlu 63

|| :|||:||||| :|||:||||| :|||:||||| :|||:|||||

55329 CCGC.CGCGAGCGCGCAGATCTCCGCGCGAGGTGATGTTGGAGTTCTC 55281

64 LeuArgArgIleGlyAspGlu 70.

||||| :|||:|||||

55280 CTGCGCTCTCTCGCGCAGGAG 55260

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2000.DAT:AAZ90014

seq_documentation_block:

ID-AAZ90014 standard; DNA; 1158 BP.

XX AC

XX AAZ90014;

XX 05-MAY-2000 (first entry)

XX DE Metalloprotease MIFR clone nucleotide sequence.

XX XX Metalloprotease in the female reproductive tract; MIFR; human; ds;
 XX matrix metalloprotease; MWP.

XX OS Homo sapiens.

XX XX JP2000014387-A.

XX PD 18-JAN-2000.

XX PF 06-JUL-1998; 98JP-0190869.

XX XX 06-JUL-1998; 98JP-0190869.

XX PA (TAKA/) TAKAHASHI T;

XX PA (SDIS-) SDI KK.

XX DR WPI; 2000-154341/14.

XX DR P-PSDB; AAY78589.

XX XX

XX PT A new metalloprotease and a DNA coding it

XX XX Example 9; Page 19-20; 21pp; Japanese.

XX PS

XX CC This sequence represents a coding sequence of a human metalloprotease in

XX CC the female reproductive tract (MIFR) clone. MIFR is a matrix

XX CC metalloprotease (MWP). The invention relates to the metalloprotease

XX CC protein which is 390 amino acids in length. A recombinant vector

XX CC containing the MIFR gene can be used to create transformants which

XX CC produce the metalloprotease in culture.

XX XX

XX SQ Sequence 1158 BP; 163 A; 456 C; 372 G; 167 T; 0 other;

alignment_scores:

Quality: 79.50 Length: 66

Ratio: 2.149 Gaps: 3

Percent Similarity: 56.061 Percent Identity: 39.394

alignment_block:

US-09-508-832-2 x AAZ90014 ..

Align seg 1/1 to: AAZ90014 from: 1 to: 1158

16 SerAspValSerSerGluCysAspArgGluGlyGlnLeuGlnProAl 22

||||:||||| :|||:|||||:||||| :||| :||| :|||

364 AGCGAGGTGTCCTCCCTCAGCTTCGCGGAGTGGCCCGGAGCCAG 413

22 aglu.....ArgProGlnLeuArgProGlyAlaProT 34

||||:||||| :|||:|||||:||||| :||| :||| :|||

414 CGACCTCCGGATAGTGGGCGCGCGCGCGCGCGCGCGCGCGCG 460

34 hrSerLeuGlnThrGluProGlnAlaSerIleArgGlnSerGlnGlu 50

||||:||||| :|||:|||||:||||| :||| :||| :|||

461 CGGCGCGGCTCTCAGCCCGGTCTCCCGCGAGGCTTCTACCGATCAA 510

51 ProGluAspLeuArgProGluIleArgIleAlaGlnGluLeuArgArg 66

||||:||||| :|||:|||||:||||| :||| :||| :|||

511 CCACACGAGCTG...CTGGTCTCCGCGCTGCACACCTGCTTCGACGG 555

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2001.DAT:AAH50546

seq_documentation_block:

ID-AAH50546 standard; DNA; 2085 BP.

XX AC

XX AAH50546;

XX 21-AUG-2001 (first entry)

XX DE Insulin receptor gene exon 1 SEQ ID NO:1.

XX KW Insulin receptor; polymorphic site; single nucleotide polymorphism;
 XX SNP; migraine; cephalic pain; insulin receptor signalling pathway;
 XX antinigraine; vulnery; cluster headache; chronic paroxysmal hemicrania;
 XX vascular disorder associated headache; withdrawal; tension headache; ds.

XX OS Homo sapiens.

XX XX WO200128539-A2.

XX XX 26-APR-2001.

XX PF 19-OCT-2000; 2000WO-GB04031.

XX XX 19-OCT-1999; 99GB-0024713.

XX PR 19-OCT-1999; 99US-0160423.

XX XX (GLAX) GLAXO GROUP LTD.

XX XX Purvis IJ, McCarthy IC;

XX XX WPI; 2001-300274/31.

XX XX

XX PT Use of agent that modulates directly or indirectly insulin receptor or

XX PT insulin receptor signaling pathway in the manufacture of medicament for

XX PT preventing or treating cephalic pain

XX XX Disclosure; Page 39-40; 58pp; English.

XX XX The present invention describes the use of an agent (I) that modulates

XX CC directly or indirectly the insulin receptor or insulin receptor

XX CC signalling pathway in the manufacture of a medicament for preventing or

XX CC treating cephalic pain. Also described is an isolated polynucleotide (II)

XX CC or protein (III) comprising a polymorphism that causes susceptibility to

XX CC cephalic pain, or a naturally occurring polymorphism that is in linkage

XX CC disequilibrium with the first polymorphism. (I) has antimigraine and

XX CC vulnery activities. (I) is useful for treating cephalic pain which may

THIS PAGE BLANK (USPTO)

OM of: US-09-508-832-2 to: EST.* out_format : pfs

Date: Dec 11, 2001 1:03 AM

About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:

-MODE=framer-p2n.model -DEV=xlp
-Q/cn2_1/USPTO_spool/US09508832/runat_10122001_110349_29536/app_query.fasta_1.620
-DB=EST -QFMT=fastap -SUFFIX=rst -GAPOP=12.000 -GAPEXT=4.000
-MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000 -OGAPOP=4.500
-OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blossum62 -TRANS=human40.cdi
-LIST=45 -DOCALLIGN=200 -THRFMT=pct -THR_MIN=100 -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-MAXLEN=200000000 -USER=US09508832 @CGN1_1_0 -NCPU=6 -ICPU=3
-LONGLOG -NO_XLPXY -WAIT -THREADS=1

Search information block:

Query: US-09-508-832-2

Query length: 110

Database: EST.*

Database sequences: 11351937

Database length: 1077921985

Search time (sec): 2629.110000

score_list:

Sequence	Strd Orig	Zscore	EScore	Len	Documentation
gb_hic:AK011490	+ 493.50	833.29	3.0e-37	1206	AK011490 Mus musculus 10 days
gb_est2:BG921698	+ 435.00	735.82	8.0e-32	935	BG921698 60282518F1 NCI_CGAP_M
gb_est2:BF021882	+ 357.00	629.30	9.0e-25	452	BF021882 uy59b09.y1 McCarrey Ed
gb_est2:BF319454	+ 249.00	426.51	1.4e-14	389	BF319454 uy59b09.y1 McCarrey Ed
gb_gss:AZ706148	+ 218.00	370.12	1.9e-11	580	AZ706148 RPI-23-227P3.TV RPI-
gb_est2:BG171095	+ 218.00	368.86	2.2e-11	668	BG171095 60233666F1 NCI_CGAP_M
gb_est2:AI971169	- 209.00	356.24	1.1e-10	492	AI971169 wr24h12.x1 NCI_CGAP_P
gb_est2:AA629308	- 127.00	216.28	0.0070	501	AA629308 zu84g06.s1 Soares test
gb_est2:BF172831	- 126.00	222.30	0.0032	210	BF172831 PCL5805 Myeloma (PCL)
gb_est2:AA629050	- 123.00	209.46	0.0167	501	AA629050 zu84g06.s1 Soares test
gb_est2:AA629314	- 123.00	206.96	0.0231	664	AA629314 h56e02.s1 Soares test
gb_est2:AF209718	- 98.00	166.22	4.2e	537	AF209718 AF209718 Xenopus laevi
gb_est2:BG990772	- 92.00	161.50	7.85	289	BG990772 MRI-HT1136-260101-015
gb_gss:CN500856	+ 91.00	150.09	33.92	862	AL051751 Drosophila melanogaste
gb_est2:BG420514	+ 89.50	146.94	50.78	921	BG420514 602452566F1 NIH_MGC_14
gb_gss:CN50143V	+ 89.00	147.57	46.88	780	AL173092 Tetraodon nigroviridis
gb_est2:AA432805	+ 88.00	149.67	35.79	508	AA432805 sh81c06.y1 Gm-cl016 GI
gb_est2:BG335696	+ 86.50	148.93	39.35	414	BG335696 OV2_12_02.g1_A002_Ova
gb_est2:BB415908	+ 86.00	146.73	52.20	482	BE415908 MUG002.C09R990520 ITEC
gb_est2:BB416016	+ 86.00	144.78	66.99	600	BE416016 MUG003.D09R990523 ITEC
gb_est2:BB415913	+ 86.00	141.32	104.45	886	BE415913 MUG002.D02R990520 ITEC
gb_est2:AL558285	+ 85.50	140.19	120.72	914	AL558285 AL558285 LTI_NFL008_10
gb_est2:BB416351	+ 85.00	144.70	67.73	500	BE416351 MUG007.C07R990628 ITEC
gb_gss:CN500320	- 84.50	137.70	166.23	999	AL063754 Drosophila melanogaste
gb_est2:BB859529	+ 84.50	131.30	377.46	2052	BF859529 963002602.y4 C. reinh
gb_est2:BG335529	+ 84.00	138.73	145.62	808	BG335529 602403821F1 NIH_MGC_21
gb_est2:AI970428	- 83.00	155.85	16.19	97	AI970428 wr10d03.x1 NCI_CGAP_Lu
gb_est2:BF292486	- 83.00	141.61	100.59	482	BF292486 WHE2214.D03_G06ZS Aeg
gb_est2:AI166767	- 83.00	141.58	101.07	484	AI166767 xylem est 567 Poplar x
gb_est2:BF584857	- 83.00	138.97	141.17	649	BF584857 60209874F1 NCI_CGAP_C
gb_gss:AZ347259	- 83.00	138.48	150.38	686	AZ347259 IM0083H18F Mouse 10kb
gb_est2:AA132780	+ 82.00	141.59	100.93	399	AA132780 zol8a01.r1 Stratagene
gb_est2:AA099932	+ 82.00	141.41	103.24	407	AA099932 z179c04.r1 Stratagene
gb_est2:AA130795	+ 82.00	140.00	123.70	477	AA130795 zol3c06.r1 Stratagene
gb_est2:AA131161	+ 82.00	138.57	148.50	560	AA131161 zol6h07.r1 Stratagene
gb_gss:CN504TRG	- 82.00	135.07	232.82	831	AL306853 Tetraodon nigroviridis
gb_gss:CN5048M2	- 82.00	134.54	249.16	882	AL279443 Tetraodon nigroviridis
gb_est2:BB915234	+ 82.00	134.29	257.23	907	BE915234 60166740F1 NCI_CGAP_M
gb_est2:W91244	+ 81.50	140.51	115.81	409	W91244 mf72q11.r1 Soares mouse
gb_est2:AA575286	+ 81.50	139.86	125.86	440	AA575286 villb09.r1 Baystead m
gb_est2:AA028436	+ 81.50	139.07	139.31	481	AA028436 mil9h06.r1 Soares mous

gb_est2:AA008848 + 81.50 138.80 144.27 496 ! AA008848 mg98f07.r1 Soares m
gb_est2:AA015247 + 81.50 138.71 145.92 501 ! AA015247 mh21c06.r1 Soares m
gb_est2:BI182623 + 81.50 135.26 227.22 739 ! BI182623 UNL-P-FN-bm-c-09-0-
gb_est2:BF143712 + 81.50 135.13 231.07 750 ! BF143712 601789785F1 NCI_CGA

seq_name: gb_hic:AK011490

seq_documentation_block:

LOCUS AK011490 1206 bp mRNA HPC 05-JUL-2001
Mus musculus 10 days embryo cDNA, RIKEN full-length enriched
library, clone:2610020M23, full insert sequence.

ACCESSION AK011490

VERSION AK011490.1 GI:12847647

KEYWORDS CAP trapper.

SOURCE Mus musculus (strain:C57BL/6J) 10 days embryo cDNA to mRNA,

clone_lib:RIKEN full-length enriched mouse cDNA library

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 1206)

AUTHORS Carninci,P. and Hayashizaki,Y.

TITLE High-efficiency full-length cDNA cloning

JOURNAL Methods in enzymology. 303, 19-44 (1999)

MEDLINE 99279253

PUBMED 10349636

REFERENCE 2 (bases 1 to 1206)

AUTHORS Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K.,

Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.

Normalization and subtraction of cap-trapper-selected cDNAs to

prepare full-length cDNA libraries for rapid discovery of new genes

Genome research. 10 (10), 1617-1630 (2000)

JOURNAL MEDLINE 20499374

PUBMED 11042159

REFERENCE 3 (bases 1 to 1206)

AUTHORS Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P.,

Konno,H., Akiyama,J., Nishi,K., Kitsuai,T., Tashiro,H., Itoh,M.,

Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A.,

Yamanoto,R., Matsumoto,H., Sakauchi,S., Ikegami,T., Kashiwagi,K.,

Fujiwaka,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watahiki,M.,

Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S., Kawai,J.,

Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.

RIKEN integrated sequence analysis (RISA) system--384-format

sequencing pipeline with 384 multipillar sequencer

Genome research. 10 (11), 1757-1771 (2000)

JOURNAL MEDLINE 20530913

PUBMED 11076861

REFERENCE 4 (bases 1 to 1206)

AUTHORS The RIKEN Genome Exploration Research Group Phase II Team and the

FANTOM Consortium.

Functional annotation of a full-length mouse cDNA collection

Nature 409, 685-690 (2001)

JOURNAL MEDLINE 20530913

PUBMED 11076861

REFERENCE 5 (bases 1 to 1206)

AUTHORS Adachi,J., Aizawa,K., Akahira,S., Akimura,T., Aono,H., Arai,A.,

Arakawa,T., Carninci,P., Fukuda,S., Fukunishi,Y., Furuno,M.,

Hanagaki,T., Hara,A., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hori,F.,

Imotani,K., Ishii,Y., Itoh,M., Iyama,M., Kato,H., Kawai,J.,

Konno,Y., Konno,H., Kouda,M., Koyama,S., Kurihara,C., Matsuyama,T.,

Miyazaki,A., Nishi,K., Nomura,K., Numazaki,R., Ohno,M., Okazaki,Y.,

Okido,T., Owa,C., Saito,H., Saito,R., Sakai,C., Sakai,K., Sano,H.,

Sasaki,D., Shibata,K., Shibata,Y., Shinagawa,A., Shiraki,T.,

Soyabe,Y., Suzuki,H., Tagami,M., Takahashi,F., Takahashi,F.,

Tanaka,T., Tejima,Y., Toyota,T., Yamamura,T., Yasunishi,A.,

Yoshida,K., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.

Direct Submission

Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of

Physical and Chemical Research (RIKEN), Laboratory for Genome

Exploration Research Group, RIKEN Genomic Sciences Center (GSC),

RIKEN Yokohama Institute; 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,

Kanagawa 230-0045, Japan (E-mail:genome-res@gs.riken.go.jp,

URL:http://genome.gsc.riken.go.jp/, Tel:81-45-503-9222,

Fax:81-45-503-9216)

COMMENT Please visit our web site (<http://genome.gsc.riken.go.jp/>) for


```

|||||
208 ATGGCCAGCAACCTTCGATGTAAGTTCTGAGTGTGACAGAGAGGTGG 257
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
258 ACAATTGCAGCTGTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTA 307
|||||
34 hrSerLeuGlnThrGluPro.Gln..... 41
|||||
308 CCTCCCTACAGACAGACCGCAAGGTAATCCCGACGGCGAGGGGACCGC 357
|||||
41 ..... 41
358 TGCCTCCAGGATGCCCTCAGGGCCGCTGGCCGCCACCGCCAGCCCTG 407
|||||
41 ..... 41
408 GCCCTTTTGTACAGATCCCACTTTTTCATCTTTTGAGAGATCTTC 457
|||||
41 ..... 41
458 TCTGCTGTCCCGCTCTCCAGTGGTATTCTCTTTTGACACAGACAGA 507
|||||
41 ..... 41
508 GCCCGGCCCCATGAGTTGTGACAAGTCAACACAAACCAAGTCTCCTT 557
|||||
42 ..... 42
558 GCCAGGCTTCAACCACTATCTCAGTGCAGTGGCTTCATCAGCAGTCT 607
|||||
48 GlnGluGluProGluAspLeuArgProGluLeuArgLleAlaGlnGlu 64
|||||
608 CAGGAGGAACCTGAAGATCTGCGCCGGAGATACGATTCACAGAGCT 657
|||||
64 uArgArgLleGlyAspGluPheAsnGluThrTyrThrArgValPheA 81
|||||
658 CGCGCGGATCGGAGACGAGTTCAACGAACCTTACACAAGGAGGTGTG 707
|||||
81 laAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGln 97
|||||
708 CAAATGATTACCGCAGCTGAGGA.CACCTCAATGTTATCTTACAA 756
|||||
98 ..LeuLeuArgPheIlePheArgLeuValTrpArgArg 109
:::|||||
757 ACGTGTACGCTTTATCTTCGCTCTGATGGCGGAA 794

```

seq_name: gb_est2:BF021882

seq_documentation_block: 452 bp mRNA EST 29-DEC-2000
LOCUS BF021882
DEFINITION uy59b09.y1 McCarrey Eddy round spermatid Mus musculus cDNA clone
IMAGE:3663833 5' similar to TR:054918 054918 BCL2 INTERACTING
MEDIAN OF CELL DEATH ; mRNA sequence.

ACCESSION BF021882
VERSION BF021882.1 GI:10753214

KEYWORDS EST.

SOURCE house mouse.

ORGANISM

REFERENCE
AUTHORS
Marra, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, T.,
Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Person
B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter
E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R.,
Waterston, R. and Wilson, R.

TITLE
JOURNAL
COMMENT
The WashU-NCI Mouse EST Project 1999
Unpublished (1999)

Contact: Marra M/WashU-NCI Mouse EST Project 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800

Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:1424601
Seq primer: Primer name ambiguous
High quality sequence stop: 386.
Location/Qualifiers
1. .452
/organism="Mus musculus"
/strain="CD-1"
/db_xref="taxon:10090"
/clone="IMAGE:3663833"
/clone_lib="McCarrey Eddy round spermatid"
/sex="male"
/tissue_type="round spermatids, pooled from multiple mice"
/dev_stage="60 day"
/lab_host="DH10B (phage-resistant)"
/notes="Organ: testis; Vector: pBluescript SK+ (Stratagene
); Site:1: XhoI; Site:2: EcoRI; cDNA oligo dt-primed
[5'-(GA)10-ACTAGTCTCGAGTGTGTGTGTGTGT-3'] and directionally
cloned using 5' linkers 5'-AATCGGCACAG-3' and
5'-CTGTCGCG-3'. Size selection of >400bp material gives
average insert size ranging from 1-2 kb. Library was mass
excised (from lambda-UniZAP-XR) and resulting
single-stranded phagemids were prepped and transformed
into DH10B. Library contains 98.5% recombinants.
References: J. Androl. 20:635-639 and Gene 25:263-269.
Library constructed and donated by J. McCarrey, Ph.D.
(Southwest Foundation for Biomedical Research, Dept. of
Genetics); excision done by E.M. Eddy, Ph.D. (National
Institutes of Health, National Institute of Environmental
Health Sciences). Original lambda-based library is
available through ATCC, catalog #63423."

BASE COUNT 106 a 130 c 112 g 104 t
ORIGIN

alignment_scores:
Quality: 357.00 Length: 69
Ratio: 5.174 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:
US-09-508-832-2 x BF021882 ..

Align seg 1/1 to: BF021882 from: 1 to: 452

42 AlaSerIleArgGlnSerGlnGluProGluAspLeuArgProGlu1 58
|||||
211 GCTTCATACGACAGCTCTCAGGAGGAACCTGAAGATCTGCGCCGAGAT 260
|||||
58 eaArgIleAlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrT 75
|||||
261 ACGGATTCACAGGAGCTCGCGCGGATCGGAGGAGTTCAACGAACCTT 310
|||||
75 yrThrArgArgValPheAlaAsnAspTyrArgGluAlaGluAspHisPro 91
|||||
311 ACACAGGAGGAGGTGTTCGAATGATTACCGCGAGGCTGAAGACCACTCT 360
|||||
92 GlnMetValIleLeuGlnLeuLeuArgPheIlePheArgLeuValTrpAr 108
|||||
361 CAAATGTTATCTTACAACTGTTACGCTTTATCTTCTCCGCTGTTGAG 410
|||||
108 garHis 110
|||||
411 AAGGCAT 417

seq_name: gb_est2:BF319454

seq_documentation_block:
LOCUS BF319454

DEFINITION uy59b09.x1 McCarrey Eddy round spermatid Mus musculus cDNA clone
EST 29-DEC-2000
mRNA 389 bp
mRNA

IMAGE:3663833 3' similar to TR:054918 054918 BCL2 INTERACTING
MEDATOR OF CELL DEATH ;, mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BF319454
BF319454.1 GI:11268195

EST.

house mouse

Mus musculus

REFERENCE
AUTHORS

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 389)
Marra, M., Hillier, L., Kucaba, T., Martin, J., Beck, C., Wylie, T.,
Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Person
B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter
E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R.,
Waterston, R. and Wilson, R.

The WashU-NCI Mouse EST Project 1999

Unpublished (1999)

Other ESTs: uy59b09.y1

Contact: Marra M/WashU-NCI Mouse EST Project 1999

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@wustl.edu

This clone is available royalty-free through LNL; contact the

IMAGE Consortium (info@image.lnl.gov) for further information.

MG1:1424601

High quality sequence stop: 325.

Location/Qualifiers

FEATURES
Source

1..389
/organism="Mus musculus"
/strain="CD-1"
/db_xref="taxon:10090"
/clone="IMAGE:3663833"
/clone_lib="McCarrey Eddy round spermatid"
/sex="male"
/tissue_type="round spermatids, pooled from multiple mice"
/dev_stage="60 day"
/lab_host="DH10B (phage-resistant)"
/note="Organ: testis; Vector: pBluescript SK+ (Stratagene
); Site:1: XhoII; Site:2: EcoRI; cDNA oligo dt-primed
[5'-(GA)10-ACTAGTCTCGAGTTT-TTTT-3'] and directionally
cloned using 5' linkers 5'-AATTCGACGAG-3' and
5'-CTCGTCGC-3'. Size selection of >400bp material gives
average insert size ranging from 1-2 Kb. Library was mass
excised (from lambda-UnizAP-XR) and resulting
single-stranded phagemids were prepped and transfected
into DH10B. Library contains 98.5% recombinants.
References: J. Androl. 20:635-639 and Gene 25:263-269.
Library constructed and donated by J. McCarrey, Ph.D.
(Southwest Foundation for Biomedical Research, Dept. of
Genetics); excision done by E.M. Eddy, Ph.D. (National
Institutes of Health, National Institute of Environmental
Health Sciences). Original lambda-based library is
available through ATCC, catalog #63423."

BASE COUNT
ORIGIN

100 a 104 c 89 g 96 t

alignment_scores:

Quality: 249.00 Length: 53
Ratio: 4.882 Gaps: 1
Percent Similarity: 96.226 Percent Identity: 94.340

alignment_block:

US-09-508-832-2 x BF319454/rev ..

Align seg 1/1 to reverse of: BF319454 from: 1 to: 389

59 ArgTleAlaGlnLeuArgArgTleGly.AspGluPheAsnGluThrT 75
||||:|||||||||||||||||||||||||||||||||||||||||
389 CGATTGTCACAGAACTTCGGGGGCGGAAGACGAGTTCACGAAACTT 340

75 YrThrArgArgValPheAlaAsnAspTyrArgGluAlaGluAspHisPro 91
|||||||||||||||||||||||||||||||||||||||||||||
339 ACACAAGGAGGGTGTTCGCAATGATTACCGGAGCGTGAAGACCCCT 290
|||||||||||||||||||||||||||||||||||||||||||||
92 GlnMetValIleLeuGlnLeuLeuArgPheIlePheArgLeuValTtpAr 108
|||||||||||||||||||||||||||||||||||||||||||||
289 CAATGGTATCTATACACAGTTCAGCTTATCTTCGCTCTGGTATGGAG 240
|||||||||||||||||||||||||||||||||||||||||||||
108 gArgHis 110
|||||
239 AAGGCAT 233
|||||

seq_name: gb_gss:AZ706148

seq_documentation_block:

LOCUS AZ706148 580 bp DNA GSS 24-JAN-2001
DEFINITION RPCI-23-227P3.TV RPCI-23 Mus musculus genomic clone RPCI-23-227P3,
DNA sequence.

ACCESSION AZ706148

VERSION AZ706148.1 GI:12433319

KEYWORDS GSS.

SOURCE house mouse.

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 580)
Zhao, S., Nierman, W., Feldblyum, T., Malek, J., Shatsman, S., Aklnret
B., Levins, M., McGann, S., Tsegaye, G., Geer, K., Krol, M., de Jong, P.
and Fraser, C.M.

Mouse BAC End Sequences from Library RPCI-23

Unpublished (1999)

Other GSSs: RPCI-23-227P3.TJ

Contact: Shaying Zhao

Department of Eukaryotic Genomics

The Institute for Genomic Research

9712 Medical Center Dr., Rockville, MD 20850, USA

Tel: 301 838 0200

Fax: 301 838 0208

Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCI-23. For BAC
library availability, please contact Pieter de Jong
(pdejong@mail.cho.org). Clones may be purchased from BACPAC
Resources (<http://www.chori.org/bacpac/orderingframe.htm>). BAC end
page: http://www.tigr.org/tldb/bac_ends/mouse/bac_end_intro.html
Plate: 227 row: p column: 3

Seq primer: T7

Class: BAC ends.

Location/Qualifiers

1..580

/organism="Mus musculus"

/strain="C57Bl/6J"

/db_xref="taxon:10090"

/clone="RPCI-23-227P3"

/clone_lib="RPCI-23"

/sex="Female"

/lab_host="DH10B"

/note="Organ: Kidney/Brain; Vector: pBACe3.6; Site:1:
EcoRI; Site:2: EcoRI; Female C57Bl/6J mouse kidney and/or
brain genomic DNA was isolated and partially digested
with a combination of EcoRI and EcoRI Methylase. Size
selected DNA was cloned into the pBACe3.6 vector at the
EcoRI sites. The ligation products were transformed into
DH10B electrocompetent cells (BRL Life Technologies)."

BASE COUNT
ORIGIN

138 a 162 c 138 g 142 t

alignment_scores:

Quality: 218.00 Length: 43
Ratio: 5.070 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 95.349

alignment_block:

1 MetalalyslnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 |||||
 425 ATGCCAAGCAACCTTCTGATGTAAAGTCTCGAGTGTGACCGAGAAGTAG 376
 |||||
 17 YGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProF 34
 |||||
 375 ACAATYGCACCTCGCGAGAGGGCTCCCAAGCTCAGACCTGGGGCCCCCTA 326
 |||||
 34 hrSerLeuGlnThrGluProGln 41
 |||||
 325 CCTCCCTACAGACAGACCCACAA 303

seq_name: gb_est1:AA629308

seq_documentation_block: 501 bp mRNA EST 16-OCT-1997
 LOCUS AA629308
 DEFINITION zu84g06.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:744730
 3', mRNA sequence.
 ACCESSION AA629308
 VERSION AA629308.1 GI:2541695
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 501)
 AUTHORS Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
 Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin,
 J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,
 White, Y., Wyllie, T., Waterston, R. and Wilson, R.
 TITLE WashU-NCI human EST Project
 JOURNAL Unpublished (1997)
 COMMENT Contact: wilson RK
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lnl.gov) for further information.
 Seq primer: -40m13 fwd. ET from Amersham
 High quality sequence stop: 471.

FEATURES

source
 1..501
 /organism="Homo sapiens"
 /db_xref="GDB:5932418"
 /db_xref="taxon:9606"
 /clone="IMAGE:744730"
 /clone_lib="Soares_testis_NHT"
 /sex="male"
 /lab_host="DH10B"
 /note="Vector: pT7T3D-Pac (Pharmacia) with a modified
 polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
 was prepared from mRNA obtained from Clontech Laboratories
 , Inc., and primed with a Not I - oligo(dT) primer [5',
 TGTACCAATGTAAGTGGGCGGCCGCCCAATTTTTTTTTT 3'].
 Double-stranded cDNA was ligated to Eco RI adaptors
 (Pharmacia), digested with Not I and cloned into the Not I
 and Eco RI sites of the modified pT7T3 vector. Library
 went through one round of normalization to Cot5, and was
 constructed by Rento Soares and M. Fatima Bonaldo."
 BASE COUNT 155 a 112 c 97 g 137 t

alignment_scores:
 Quality: 127.00 Length: 32
 Ratio: 4.536 Gaps: 0
 Percent Similarity: 87.500 Percent Identity: 71.875

alignment_block:

US-09-508-832-2 x AA629308/rev ..

Align seg 1/1 to reverse of: AA629308 from: 1 to: 501
 79 ValPheAlaAsnAspTyArgGluAlaGluAspHisProGlnMetValI1 95
 |||||
 501 GTATTTTGAATTAATTTACCAAGCAGCGAAGACCCACCCAGCAATGGTAT 452
 |||||
 95 eLeuGlnLeuArgPheIlePheArgLeuValTIpArgArgHis 110
 |||||
 451 CTTACGACTGTTACGTTACATTTGTCGCTGGTGGAGAAATGCAT 406
 |||||

seq_name: gb_est2:BF172831

seq_documentation_block: 210 bp mRNA EST 23-MAR-2001
 LOCUS BF172831
 DEFINITION PCL5805 Myeloma (PCL) cDNA library Homo sapiens cDNA, mRNA
 sequence.
 ACCESSION BF172831
 VERSION BF172831.1 GI:13439045
 KEYWORDS EST.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 REFERENCE 1 (bases 1 to 210)
 AUTHORS Claudio, J.O., Tang, H., Khan, E.M., Voralia, M., Li, Z., Cukerman, E.,
 Francisco-Pabalan, O., Liew, C.C. and Stewart, A.K.
 TITLE The transcriptional phenotype of myeloma cells
 JOURNAL Unpublished (2000)
 COMMENT Contact: A. Keith Stewart, M.D.
 Oncology Research
 University Health Network
 610 University Ave., 5-126, Toronto, Ontario, M5G 2M9, Canada
 Tel: (416) 946-4639
 Fax: (416) 946-6546
 Email: k.stewart@utoronto.ca
 PCR Primers
 FORWARD: 5'-CCCAAGCTCGAATTAACCCCTCACTAAAGGG-3'
 BACKWARD: 5'-CCAGTGAATTGTAATAGCTACTATAGGGCG-3'
 Seq primer: 5'-GAAATTAACCTCACTAAAGG-3'.

FEATURES

source
 1..210
 Location/Qualifiers
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 /clone_lib="Myeloma (PCL) cDNA library"
 /sex="male"
 /tissue_type="Blood"
 /cell_type="myeloma"
 /dev_stage="Plasma cell leukemia"
 /note="Vector: Lambda Zap Express; Site_1: EcoRI; Site_2:
 XhoI; mRNA was purified from plasma cell leukemia
 patient's peripheral blood containing >95% myeloma. An
 oligo d(T)18 primer containing XhoI restriction site was
 used to prime first strand synthesis using M-MLV reverse
 transcriptase. To protect the cDNAs from XhoI digestion in
 subsequent cloning step, the nucleotide analogue
 5-methyl-dCTP was added to the nucleotide mixture and
 la-32PIdATP was added to monitor the quantity and quality
 of first strand synthesis. After second-strand synthesis
 and blunting of cDNA termini, EcoRI adapters were ligated
 , followed by kinase treatment and digestion with XhoI.
 The cDNAs were then size-fractionated using Sephacryl
 S-500 column and then ligated into EcoRI and XhoI digested
 Lambda Zap Express vector. The ligation product was
 packaged using Gigapack II packaging extract. The library
 had primary titre of approx. 1x10⁶. Clones from the
 primary library were randomly selected for single pass
 sequencing."
 BASE COUNT 49 a 40 c 57 g 59 t 5 others

alignment_scores:


```
13 AspArgGluGlyGlnLeuGlnProAlaGluArgProProGlnLeuAr 29
   ::||| ||| :::: ||| ||| ||| ||| ||| ||| |||
274 GAACGAGAGGAGACCATGCAAGCCT...GAACGACCGCTGGCCTCTT 320
   ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
29 gProGlyAlaPro.ThrSerLeuGlnThrGluProGlnAlaSerIleArg 45
   ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
321 ACCTGGACAGAGTCAGAGCTGGAGACCGAGACCGAGGCTGGAGAGC 370
   ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
46 GlnSerGlnGluProGluAspLeuArgProGluIleArg..... 59
   :: ::||| ::||| ||| ||| ||| ||| ||| ||| |||
371 AAAATCGGGAGCACTTGGAGAGAGAGGGACCCAGGTCAGAGACTGGAG 420
   ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
60 .....IleAlaGlnGluLeuArgArgIleGlyAspGluPheA 72
   ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
421 CCATTACTCAAGATCATCGAGGACCTGAGG..... 451
72 snGluThrTyThrArgArgValPheAlaAsnAsp..... 83
   ::::: ||| ||| ||| ||| ||| ||| |||
452 .....GCTCAGATCTTCGCAATAACTGTGCACAATGCCCG 487
84 TyrArgGluAlaGluAspHis.ProGlnMetValIleLeuGlnLeuA 100
   ::||| ::||| ::||| ||| ||| ||| ||| ||| ||| |||
488 CATCGTTCTGCAGATGACCATGCC...GTCTTGCTGCTGATGACTTAG 534
100 rgPheIlePheArgLeuValTrp 107
   :: ::||| ||| ||| ||| ||| ||| |||
535 AGTCAAGATATGAGACAGAGCTGG 557
```


OM of: US-09-508-832-4 to: GenEmbl.* out_format : pfs

Date: Dec 11, 2001 1:45 AM

About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:

-MODE=framer-p2n.model -DEV=xlp
-Q/cn2.1/USPTO.spool/US09508832/runat_10122001_110349_29549/app_query.fasta_1.620
-DB=GenEmbl -QFMT=fastap -SUFFIX=rge -GAPOP=12.000 -GAPEXT=4.000
-MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000 -OGAPOP=4.500
-OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -DELOP=6.000
-FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DOCLIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-MAXLEN=200000000 -USPR=US09508832 @CGN1_1_0 -NCPU=6 -ICPU=3
-LONGLOG -NO_XLPXY -WAIT -THREADS=1

Search information block:

Query: US-09-508-832-4

Query length: 140

Database: GenEmbl.*

Database sequences: 1472140

Database length: 341344837

Search time (sec): 2485.920000

score.list:

Sequence	Strd Orig	ZScore	EScore	Len	Documentation
gb_pat:AX031281	+	742.00	1004.53	1.1e-47	422 ! AX031281 Sequence 3 from Patent
gb_pat:AX031307	+	742.00	1004.53	1.1e-47	422 ! AX031307 Sequence 3 from Patent
gb_ro:AF032460	+	742.00	1004.53	1.1e-47	423 ! AF032460 Mus musculus BimL mRNA
gb_ro:AF136927	+	727.00	984.38	1.5e-46	423 ! AF136927 Rattus norvegicus Bcl-1
gb_pat:AX031283	+	704.00	951.16	1.1e-44	590 ! AX031283 Sequence 5 from Patent
gb_pat:AX031309	+	704.00	951.16	1.1e-44	590 ! AX031309 Sequence 5 from Patent
gb_ro:AF032459	+	704.00	951.15	1.1e-44	591 ! AF032459 Mus musculus BimEL mRNA
gb_ro:AF065433	+	689.00	931.02	1.4e-43	591 ! AF065433 Rattus norvegicus Bcl-1
gb_pat:AX031285	+	629.00	852.92	3.1e-39	416 ! AX031285 Sequence 7 from Patent
gb_pat:AX031311	+	629.00	852.92	3.1e-39	416 ! AX031311 Sequence 7 from Patent
gb_pr:AF032458	+	629.00	852.91	3.1e-39	417 ! AF032458 Homo sapiens BimL mRNA
gb_pat:AX031287	+	589.00	796.70	4.2e-36	596 ! AX031287 Sequence 9 from Patent
gb_un:AX031313	+	589.00	796.69	4.2e-36	596 ! AX031313 Sequence 9 from Patent
gb_pr:AF032457	+	589.00	796.69	4.2e-36	597 ! AF032457 Homo sapiens BimEL mRNA
gb_pat:AX031279	+	549.00	747.10	2.4e-33	332 ! AX031279 Sequence 1 from Patent
gb_un:AX031305	+	549.00	747.10	2.4e-33	332 ! AX031305 Sequence 1 from Patent
gb_ro:AF032461	+	549.00	747.08	2.5e-33	333 ! AF032461 Mus musculus BimS mRNA
gb_ro:AF05432	+	531.00	722.91	5.4e-32	333 ! AF05432 Rattus norvegicus Bcl-1
gb_ro:AF065431	+	488.00	666.35	7.7e-29	282 ! AF065431 Rattus norvegicus Bcl-1
gb_htg:AC013332	-	337.00	418.31	5.0e-15	180569 ! AC013332 Homo sapiens chrom
gb_htg:AC013332	-	337.00	418.31	5.0e-15	180569 ! AC013332 Homo sapiens chrom
gb_htg:AC046192	-	132.00	144.39	9.13	150035 ! AC046192 Homo sapiens chrom
gb_htg:AC046192	-	128.00	139.02	18.19	150035 ! AC046192 Homo sapiens chrom
gb_ba:STMWHIB12X	+	101.50	127.85	76.12	4615 ! L22864 Streptomyces aureofaci
gb_pl:AF003023	+	100.50	102.97	1.9e+03	132470 ! AP003023 Oryza sativa genom
gb_htg:AP003245	-	100.50	101.62	2.2e+03	160468 ! AP003245 Oryza sativa genom
gb_htg:AC024740	-	100.00	100.16	2.7e+03	179538 ! AC024740 Homo sapiens chrom
gb_htg:AC026803	-	100.00	98.38	3.3e+03	231450 ! AC026803 Homo sapiens chrom
gb_htg:AL390837	+	99.50	108.31	933.72	51090 ! AL390837 Homo sapiens chrom
gb_htg:AC092821	+	99.50	107.68	1.0e+03	55899 ! AC092821 Homo sapiens chrom
gb_htg:AL592487	-	99.50	100.52	2.5e+03	155183 ! AL592487 Homo sapiens chrom
gb_htg:AL513016	-	99.50	98.64	3.2e+03	202922 ! AL513016 Homo sapiens chrom
gb_pr:AF136916	+	99.00	99.13	3.0e+03	171849 ! AC010616 Homo sapiens chrom
gb_ro:AC019153	+	98.50	97.57	3.7e+03	195068 ! AC019153 Mus musculus chrom
gb_pr:AC008403	+	98.00	97.08	3.9e+03	190075 ! AC008403 Homo sapiens chrom
gb_in:EFVAR23A	+	96.50	110.11	740.85	22243 ! L40609 Plasmodium falciparum
gb_htg:AC010327	+	96.50	96.79	4.1e+03	148679 ! AC010327 Homo sapiens chrom
gb_pr:AF166330	+	95.00	113.77	463.51	9909 ! AF166330 Homo sapiens stratum
gb_htg:AC011483	+	95.00	96.94	4.0e+03	109124 ! AC011483 Homo sapiens chrom
gb_htg:AC027602	+	95.00	92.11	7.5e+03	217346 ! AC027602 Homo sapiens chrom
gb_pr:AF243527	+	95.00	91.72	7.8e+03	230000 ! AF243527 Homo sapiens serin

gb_htg:AC020922 + 94.50 94.80 5.3e+03 134693 ! AC020922 Homo sapiens chr
gb_htg:AC024486 - 94.50 93.56 6.2e+03 160737 ! AC024486 Homo sapiens chr
gb_htg:AC014673 - 94.00 105.72 1.3e+03 25789 ! AC014673 Drosophila melano
gb_in:AC008189 - 94.00 91.77 7.8e+03 188359 ! AC008189 Drosophila melan

seq_name: gb_pat:AX031281

seq_documentation_block:

LOCUS AX031281 422 bp DNA PAT 20-SEP-2000

DEFINITION Sequence 3 from Patent WO9914321.

ACCESSION AX031281

VERSION AX031281.1 GI:10278612

KEYWORDS

SOURCE

unidentified.

unidentified.

unclassified.

REFERENCE 1 (bases 1 to 422)

AUTHORS O'Reilly, L., Puthalakath, H., Adams, J., O'Connor, L., Cory, S.,

Huang, D., C. and Strasser, A.

Novel therapeutic molecules

Patent: WO 9914321-A 3 25-MAR-1999;

INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY

LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY

SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

FEATURES

Location/Qualifiers

1..422

/organism="unidentified"

/db_xref="taxon:32644"

1..>420

/note="unnamed protein product"

/codon_start=1

/protein_id="CAC09654.1"

/db_xref="GI:10278613"

/translation="MAKQPSDVSECDREGQLQPAERPPQLRPGAPTSLOTPEQDRS

PAPMSCDKSTQTPSPPCOAFNHVLSAMASIROSEPDLRLPEIRIAQELRRIGDEFN

ETVTRVFANDYREADHPQMVILQLRFFLRVRRH"

BASE COUNT 112 a 116 c 109 g 85 t

ORIGIN

alignment_scores:

Quality: 742.00 Length: 140

Ratio: 5.300 Gaps: 0

Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-4 x AX031281

Align seg 1/1 to: AX031281 from: 1 to: 422

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlygl 17
|||||

1 ATGGCCAAGCAACCTTCTGATGTTCTAGTCTGAGTGTGACAGAGAGTGG 50
|||||

17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||

51 ACAATTGAGCGCTGCTGAGAGCGCTCCAGCTCAGGCTGGGGCCCTA 100
|||||

34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||

101 CCTCCTACAGACAAACCGAAGACAGAGCGCCGACCCATGAGTTGT 150
|||||

51 AspLysSerThrGlnThrProSerProCysGlnAlaPheAsnHisHy 67
|||||

151 GACAGAGTCAACACAAACCCCAAGTCTCTTCCAGAGCTTCAACCACTA 200
|||||

67 rIeuSerAlaMetAlaSerIleArgGlnSerGlnGluProGluAspL 84
|||||

201 TCTCAGTCAATGGTCTCCATACGACAGTCTCAGGAGGAACCTGAAGATC 250
|||||

84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||

251 TCGCGCCGAGATACGGATTCACAGGAGTCTCGCGCGGATCGGAGACG 300
|||||

101 PheAsnGluThrTyrThrArgValPheAlaAsnAspTyrArgGluAl 117
 |||||
 301 TTCAACGAAACTTACACAGGAGGTTTGGCAATGATTACCGGAGGC 350
 |||||
 117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
 |||||
 351 TGAAGACCCCTCAATGGTTATCTTACAACTGTTACGCTTTATCTTCC 400
 |||||
 134 rGluValTyrArgHis 140
 |||||
 401 GTCTGGTATGCAAGGCAT 420

seq_name: gb_un:AX031307

seq_documentation_block:
 LOCUS AX031307 422 bp DNA UNA 20-SEP-2000
 DEFINITION Sequence 3 from Patent WO9914321.
 ACCESSION AX031307
 VERSION AX031307.1 GI:10278635

KEYWORDS
 SOURCE unidentified.
 ORGANISM unidentified
 unclassified.

REFERENCE 1 (bases 1 to 422)
 AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.

TITLE Novel therapeutic molecules
 JOURNAL INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
 LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
 SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)

FEATURES

Location/Qualifiers
 1..422
 /organism="unidentified"
 /db_xref="taxon:32644"

CDS
 1..>420
 /note="unnamed protein product"

/codon_start=1

/protein_id="CAC09659.1"

/db_xref="GI:10278636"

/translation="MAKQPSDVSECDREGLOPAERPPOLRPGAPTSLQTEPDQRS
 PAPMSCDKSTQTSPPCQAPNHYLSANASIQSOEEDLRLPEIRIAQLRIGRIGDEFN
 ETYTRRVFANDYREAEDHPQVLIQLLRIFRLVWRRH"

BASE COUNT

112 a 116 c 109 g 85 t

alignment_scores:

Quality: 742.00 Length: 140
 Ratio: 5.300 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-4 x AX031307 ..

Align seg 1/1 to: AX031307 from: 1 to: 422

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
 |||||
 1 AVGCCCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACAGAGAAGCTGG 50
 |||||
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
 |||||
 51 ACAATTGCAGCTGCTGAGAGGCTCTCCAGCTCAGCGCTGGGGCCCTA 100
 |||||
 34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
 |||||
 101 CTCCCTACAGACAGAACCGCAGACAGAGGCGCGCCCATGAGTTGT 150
 |||||
 51 AspLysSerThrGlnThrProSerProCysGlnAlaPheAsnHisTy 67
 |||||
 151 GACAAGTCAACACAAACCCCAAGTCTCTCTTGGCAGGCGCTTCAACCACTA 200
 |||||

67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluProGluAspL 84
 |||||
 201 TCTCACTGCAATGGCTTCCATAGCAGCTCTCAGGAGGACCTGAAGATC 250
 |||||
 84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
 |||||
 251 TGGCCCGGAGATACGGATTGCACAGGAGCTGCGCGGATCGGAGACGAG 300
 |||||
 101 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 117
 |||||
 301 TTCAACGAAACTTACAAAGGAGGTTTGGCAATGATTACCGCGGAGGC 350
 |||||
 117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
 |||||
 351 TGAAGACCCCTCAATGGTTATCTTACAACTGTTACGCTTTATCTTCC 400
 |||||
 134 rGluValTyrArgHis 140
 |||||
 401 GTCTGGTATGCAAGGCAT 420

seq_name: gb_ro:AF032460

seq_documentation_block:
 LOCUS AF032460 423 bp mRNA ROD 19-FEB-1998
 DEFINITION Mus musculus BimL mRNA, complete cds.
 ACCESSION AF032460
 VERSION AF032460.1 GI:2895501

KEYWORDS house mouse.

SOURCE Mus musculus

ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

REFERENCE 1 (bases 1 to 423)

AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,

Cory,S. and Huang,D.C.

TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis

JOURNAL EMBO J. 17 (2), 384-395 (1998)

MEDLINE 98094360

PUBMED 9430630

REFERENCE 2 (bases 1 to 423)

AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,

Cory,S. and Huang,D.C.S.

TITLE Direct Submission

JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &

Eliza Hall Institute of Medical Research, PO Royal Melbourne

Hospital, Parkville, Victoria 3050, Australia

FEATURES

Location/Qualifiers

1..423

/organism="Mus musculus"

/db_xref="taxon:10090"

1..423

/note="pro-apoptotic BH3-containing Bcl-2 family member"

/codon_start=1

/product="BimL"

/protein_id="AAC40030.1"

/db_xref="GI:2895502"

/translation="MAKQPSDVSECDREGLOPAERPPOLRPGAPTSLQTEPDQRS
 PAPMSCDKSTQTSPPCQAPNHYLSANASIQSOEEDLRLPEIRIAQLRIGRIGDEFN
 ETYTRRVFANDYREAEDHPQVLIQLLRIFRLVWRRH"

BASE COUNT 113 a 116 c 109 g 85 t

ORIGIN

alignment_scores:

Quality: 742.00 Length: 140
 Ratio: 5.300 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-4 x AF032460 ..

Align seg 1/1 to: AF032460 from: 1 to: 423

```
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyc1 17
|||||
1 ATGGCCAAAGCAACCTTCGATGTAAGTCTGAGTGTGACAGAGAAGGTGG 50
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTGCTGAGAGCCCTCCAGCTAGGCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGCAACCGCAAGACAGAGCGCGCACCCATGAGTTGT 150
|||||
51 aspLysSerThrGlnThrProSerProCysGlnAlaPheAsnHisty 67
|||||
151 GACAAGTCAACACAACCCCAAGTCTCTTGGCCAGGCGCTTCAACCATTA 200
|||||
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluProGluAspL 84
|||||
201 TCTCAGTCAATGGCTTCCATACGACAGCTCTCAGGAGNACCTGAAGATC 250
|||||
84 euArgProGluLeuArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
251 TCGCGCCGAGATACGATTGACAGGAGCTGCGCGGATCGGAGACGAG 300
|||||
101 PheAsnGluThrTyThrArgArgValPheAlaAsnAspTyrArgGluAl 117
|||||
301 TTCAACGAACTTACACAGAGGAGGTGTTGCAATGATTTACCGGAGGC 350
|||||
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
351 TGAAGACCACTCCAAATGGTTATCTTACACTGTACGCTTATCTTCTCC 400
|||||
134 rgLeuValTrpArgHis 140
|||||
401 GTCTGGTATGGAGAAGGCAT 420
|||||
```

seq_name: gb_ro:AF136927

```
seq_documentation_block:
LOCUS AF136927 423 bp mRNA ROD 21-APR-1999
DEFINITION Rattus norvegicus Bcl-2 related apoptotic gene product BimL (bimL)
mRNA, complete cds.
ACCESSION AF136927
VERSION AF136927.1 GI:4590514
KEYWORDS Norway rat.
SOURCE Rattus norvegicus
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 423)
AUTHORS Chen,D., Simon,R.P. and Chen,J.
TITLE Cloning of rat bimL and bimL, and their differential expression in
ischemia and normal rat brain
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 423)
AUTHORS Chen,D., Simon,R.P. and Chen,J.
TITLE Direct Submission
JOURNAL Submitted (24-MAR-1999) Department of Neurology, BST, S-526,
Pittsburgh University Medical School, 3500 Terrace Street,
Pittsburgh, PA 15213, USA
```

```
FEATURES
source
1..423
/organism="Rattus norvegicus"
/db_xref="taxon:10116"
gene
1..423
/codon_start=1
/codon_end=423
/codon_start=1
/product="Bcl-2 related apoptotic gene product BimL"
/protein_id="AAD26594.1"
```

```
/db_xref="GI:4590515"
/translation="MAKQPSDVNSCEDREGQLQPAERPPQLRPAPGAPTSLOTESQDRS
PAMSCDKSTQTPSPQCAFNFHLSAMASQSEEDPEIRIAQELRRITGDEFN
ETTYRRAFANDYREAEHPQMVILQLLRFELVWRRH"
BASE COUNT 116 a 112 g 82 t
ORIGIN
```

alignment_scores:
Quality: 727.00 Length: 140
Ratio: 5.230 Gaps: 0
Percent Similarity: 99.286 Percent Identity: 97.857

alignment_block:
US-09-508-832-4 x AF136927 ..

Align seg 1/1 to: AF136927 from: 1 to: 423

```
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyc1 17
|||||
1 ATGGCCAAAGCAACCTTCGATGTAAGTCTGAGTGTGACAGAGAAGGTGG 50
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTGCTGAGAGCCCTCCAGCTAGGCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGCAATCGCAAGACAGAGCGCGCACCCATGAGTTGT 150
|||||
51 aspLysSerThrGlnThrProSerProCysGlnAlaPheAsnHisty 67
|||||
151 GACAAGTCAACACAACCCCAAGTCTCTTGGCCAGGCGCTTCAACCATTA 200
|||||
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluProGluAspL 84
|||||
201 TCTTAGCCATGGCTTCCATAGGACAGCTCTCAGGAGNACCTGAAGATC 250
|||||
84 euArgProGluLeuArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
251 TCGCGCCGAGATACGATTGACAGGAGCTGCGGAGGATCGGAGACGAG 300
|||||
101 PheAsnGluThrTyThrArgArgValPheAlaAsnAspTyrArgGluAl 117
|||||
301 TTCAATGAGACTTACACAGAGGAGGCGTGTGCAACGATTTACCGAGAGC 350
|||||
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
351 GGAAGACCACTCCAAATGGTTATCTTACACTGTACGATTCATCTTCC 400
|||||
134 rgLeuValTrpArgHis 140
|||||
401 GTCTGGTATGGAGAAGGCAT 420
|||||
```

seq_name: gb_pat:AX031283

```
seq_documentation_block:
LOCUS AX031283 590 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 5 from Patent WO9914321.
ACCESSION AX031283
VERSION AX031283.1 GI:10278614
KEYWORDS
```

```
SOURCE unidentified.
ORGANISM unidentified
REFERENCE 1 (bases 1 to 590)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL Patent: WO 9914321-A 5 25-MAR-1999;
INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
```

```
FEATURES
  Source
    Location/Qualifiers
      1..590
        /organism="unidentified"
        /db_xref="taxon:32644"
      1..>587
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="CAC09655.1"
        /translation="MAKQPSDVSSCDREGGQLOPAERPPQLRPGAPTSLOTPEQGNP
        DGEGRCPHSGPQGLAPASPFPATRSPLFIFVRRSSLLSRSSGYSFSDTRSPA
        PMSCDKSTQTPSPCOAFNHVLSAMASIROSEPEDELPEIRIAQLERLRRIGDEFNET
        YTRRVFANDYREADHPQWVILQLLRFELRWRR"
      137 a 178 c 150 g 125 t
BASE COUNT
ORIGIN
alignment_scores:
  Quality: 704.00 Length: 196
  Ratio: 5.029 Gaps: 1
  Percent Similarity: 71.429 Percent Identity: 71.429
Percent Similarity: 71.429 Percent Identity: 71.429
alignment_block:
  US-09-508-832-4 x AX031283 ..
  Align seg 1/1 to: AX031283 from: 1 to: 590
    1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
      |||||
    1 ATGCCCAAGCAACCTTCTGATGTAAGTTCGTAGTGTGACAGAGAAGTGG 50
      |||||
    17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
      |||||
    51 ACAATTGCAGCTGCTCAGAGGCTCCAGCTCAGGCTCAGGCTGGGGCCCTA 100
      |||||
    34 hrSerLeuGlnThrGluProGln..... 41
      |||||
    101 CCTCCCTACAGACAGAACCCGCAAGGTAATCCCGACGGCGAAGGGACCGC 150
      |||||
    41 ..... 41
    151 TGCCCCCAGCGACCTCAGGGCCCGCTGGCCCCCAGCGCCCTGG 200
      |||||
    41 ..... 41
    201 CCCTTTTGCTACCAGATCCCACTTTTTCATCTTTGTGAGAAGATCTTCTC 250
      |||||
    42 ..... AspArgSer 44
      |||||
    251 TGCTGTCCCGTCTCCAGTGGGTATTTCTTTTGTGACAGACAGAGGAGC 300
      |||||
    45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 61
      |||||
    301 CCGGCACCATGATGTTGTGACAGTCAACACAAACCCCAAGTCTCTCTTG 350
      |||||
    61 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 78
      |||||
    351 CCAGGCTTCAACCACTATCTCAGTGCATGCTTCCATACGACAGTCTC 400
      |||||
    78 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 94
      |||||
    401 AGGAGGAACCTGAAGATCTCGGCCGAGATACGGATTGACAGAGGAGCTG 450
      |||||
    95 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 111
      |||||
    451 CGGGGATCGAGACGAGTTCACAGAACTTACAGAGAGGGGTGTTC 500
      |||||
    111 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 128
      |||||
    501 AAATGATTACCGGAGGCTGAAGACCAACCCCTCAATGGTTATCTTACAAC 550
      |||||
    128 euLeuArgPheIlePheArgLeuValTrpArgArgHis 140
      |||||
```

```
551 TGTACGCTTTACTTCCGCTCTGCTATGGAGAGGCAT 588
seq_name: gb_un:AX031309
seq_documentation_block:
  LOCUS AX031309 590 bp DNA UNA 20-SEP-2000
  DEFINITION Sequence 5 from Patent WO9914321.
  ACCESSION AX031309
  VERSION AX031309.1 GI:10278637
  KEYWORDS
  SOURCE
  ORGANISM
    unidentified.
    unclassified.
  REFERENCE
    1 (bases 1 to 590)
      O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
      Huang,D.C. and Strasser,A.
      Novel therapeutic molecules
      Patent: WO 9914321-A 25-MAR-1999;
      INST MEDICAL W & E HALL (AU); PUTHALAKATH HAMSA (AU); REILLY
      LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
      SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
  FEATURES
    Location/Qualifiers
      1..590
        /organism="unidentified"
        /db_xref="taxon:32644"
      1..>587
        /note="unnamed protein product"
        /codon_start=1
        /protein_id="CAC09660.1"
        /db_xref="GI:10278638"
        /translation="MAKQPSDVSSCDREGGQLOPAERPPQLRPGAPTSLOTPEQGNP
        DGEGRCPHSGPQGLAPASPFPATRSPLFIFVRRSSLLSRSSGYSFSDTRSPA
        PMSCDKSTQTPSPCOAFNHVLSAMASIROSEPEDELPEIRIAQLERLRRIGDEFNET
        YTRRVFANDYREADHPQWVILQLLRFELRWRR"
      137 a 178 c 150 g 125 t
BASE COUNT
ORIGIN
alignment_scores:
  Quality: 704.00 Length: 196
  Ratio: 5.029 Gaps: 1
  Percent Similarity: 71.429 Percent Identity: 71.429
alignment_block:
  US-09-508-832-4 x AX031309 ..
  Align seg 1/1 to: AX031309 from: 1 to: 590
    1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
      |||||
    1 ATGCCCAAGCAACCTTCTGATGTAAGTTCGTAGTGTGACAGAGAAGTGG 50
      |||||
    17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
      |||||
    51 ACAATTGCAGCTGCTCAGAGGCTCCAGCTCAGGCTCAGGCTGGGGCCCTA 100
      |||||
    34 hrSerLeuGlnThrGluProGln..... 41
      |||||
    101 CCTCCCTACAGACAGAACCCGCAAGGTAATCCCGACGGCGAAGGGACCGC 150
      |||||
    41 ..... 41
    151 TGCCCCCAGCGACCTCAGGGCCCGCTGGCCCCCAGCGCCCTGG 200
      |||||
    41 ..... 41
    201 CCCTTTTGCTACCAGATCCCACTTTTTCATCTTTGTGAGAAGATCTTCTC 250
      |||||
    42 ..... AspArgSer 44
      |||||
    251 TGCTGTCCCGTCTCCAGTGGGTATTTCTTTTGTGACAGACAGAGGAGC 300
      |||||
    45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 61
      |||||
```

```

|||||
301 CCGGACCACCATGAGTTGTGACAAAGTACACAAACCCCAAGTCCCTGTG 350
61 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 78
|||||
351 CCAGGCGCTTCAACCACTATCTCAGTGCAATGGCTCCATACGACAGTCTC 400
78 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 94
|||||
401 AGGAGAAACCTGAAGATCTGCGCCGGAGATACGAGTTCACAGGAGCTG 450
95 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgValPheAl 111
|||||
451 CGCGCGATCGGAGACGAGTTCAACGAACACTTACACAAAGAGGTGTTGC 500
111 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 128
|||||
501 AAATGATTACCGGAGGCTGAAGACCACTCAAAATGTTATCTTACAAC 550
128 euLeuArgPheIlePheArgLeuValTrpArgArgHis 140
551 TGTACGCTTTATCTTCGCTCTGGTATGGAGAAGGCAT 588

```

seq_name: gb_ro:AF032459

```

seq_documentation_block:
LOCUS AF032459 591 bp mRNA ROD 19-FEB-1998
DEFINITION Mus musculus BimEL mRNA, complete cds.
ACCESSION AF032459
VERSION AF032459.1 GI:2895499
KEYWORDS house mouse.
SOURCE
ORGANISM
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 591)
O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.
Bim: a novel member of the Bcl-2 family that promotes apoptosis
EMBO J. 17 (2), 384-395 (1998)
98094360
PUBMED 9430630
2 (bases 1 to 591)
O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.S.
Direct Submission
Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia
Location/Qualifiers
1..591
/organism="Mus musculus"
/db_xref="taxon:10090"
1..591
/note="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimEL"
/protein_id="AAC40029.1"
/db_xref="GI:2895500"
/translatability="MAKOPSDVSECDREGGOLQPAERPPQLRGAPTSLOTPOGNP
DGEGDRCPHSPGQPLAPPASPGFPATPSPLFIVRRSSLLSSSSGYSFSDIDRSPA
PMSCDKSTQTPSPCCQAFNHYLSAMASIROQEEPEDLRPEIRIAQLRLRIGDFNET
YTRFVANDYREADHPQWVLIQLLRIFLVWRHH"
BASE COUNT 138 a 178 c 150 g 125 t
ORIGIN

```

alignment_scores:
 Quality: 704.00 Length: 196
 Ratio: 5.029 Gaps: 1
 Percent Similarity: 71.429 Percent Identity: 71.429

alignment_block:

```

US-09-508-832-4 x AF032459 ..
Align seg 1/1 to: AF032459 from: 1 to: 591
1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyGcl 17
|||||
1 ATGGCCAAGCAACCTTCGTAGTGTAAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTGCTGAGAGGSCCTCCCGAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGln..... 41
101 COTCCCTACAGACAGACGCCCAAGGTAATCCCGACGGCGAAGGGACGCG 150
41..... 41
151 TCCCGCCACGGCAGCCCTCAGGGCCCGCTGGCCCCACCGGCCAGCCCTGG 200
41..... 41
201 CCGTTTGTCTACAGATCCCGACCTTTTCATCTTTGTGAGAAGATCTTCTC 250
42.....AspArgSer 44
251 TGCTCTCCCGGCTCCAGTGGGTATTTCTCTTTTGACACAGACAGGAGC 300
45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 61
|||||
301 CCGGCACCCATGAGTTGTGACAAGTCAACACAAACCCCAAGTCTCTCTG 350
61 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 78
|||||
351 CCAGGCGCTTCAACCACTATCTCAGTGCAATGGCTCCATACGACAGTCTC 400
78 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 94
|||||
401 AGGAGAAACCTGAAGATCTGCGCCGGAGATACGAGTTCACAGGAGCTG 450
95 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgValPheAl 111
|||||
451 CGCGCGATCGGAGACGAGTTCAACGAACACTTACACAAAGAGGTGTTGC 500
111 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 128
|||||
501 AAATGATTACCGGAGGCTGAAGACCACTCAAAATGTTATCTTACAAC 550
128 euLeuArgPheIlePheArgLeuValTrpArgArgHis 140
551 TGTACGCTTTATCTTCGCTCTGGTATGGAGAAGGCAT 588

```

seq_name: gb_ro:AF065433

```

seq_documentation_block:
LOCUS AF065433 591 bp mRNA ROD 11-MAR-1999
DEFINITION Rattus norvegicus Bcl-2 related ovarian death gene product BOD-L
mRNA, complete cds.
ACCESSION AF065433
VERSION AF065433.1 GI:3228569
KEYWORDS Norway rat.
SOURCE Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.
1 (bases 1 to 591)
Hsu,S.Y., Lin,P. and Hsueh,A.J.
BOD (Bcl-2-related ovarian death gene) is an ovarian BH3
domain-containing proapoptotic Bcl-2 protein capable of
dimerization with diverse antiapoptotic Bcl-2 members
Mol. Endocrinol. 12 (9), 1432-1440 (1998)
98400436
JOURNAL MEDLINE

```

REFERENCE 2 (bases 1 to 591)
 AUTHORS Hsu,S.Y. and Hsueh,A.J.W.
 TITLE Direct Submission
 JOURNAL Submitted (15-MAY-1998) GYM/OB, Stanford University, MSOB S385,
 Stanford, CA 94305, USA

FEATURES
 source
 1..591
 /organism="Rattus norvegicus"
 /db_xref="taxon:10116"
 1..591
 /codon_start=1
 /product="Bcl-2 related ovarian death gene product BOD-L"
 /protein_id="AAC23595.1"
 /db_xref="GI:3228570"
 /translation="MAKQPSDVNSSECDREGGQLQPAERPPQLRPGAPTSLQTESQGNP
 DGEGRCPHGSPQGLPAPSPGPPATRSPLIFIVRRSSLLSRSSGYSFSDTRSPA
 PMSCDKSTQTPSPPCQAFNHYSAMASIRQSEEPEDLRPEIRIAQELRRIGDENET
 YTRRAFANDYREADEHPQWVILQLRFLRWRRH"

BASE COUNT 139 a 177 c 153 g 122 t
 ORIGIN

alignment_scores:
 Quality: 689.00 Length: 196
 Ratio: 4.957 Gaps: 1
 Percent Similarity: 70.918 Percent Identity: 69.898

alignment_block:

US-09-508-832-4 x AF065433 ..

Align seg 1/1 to: AF065433 from: 1 to: 591

```

.1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGCCCAAGCAACCTTCTGATGTAATCTCTGAGTGTACACAGAGAGTGG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCCTGCTGAGAGGCTCCCGAGCTCAGGCCTGGGGCCCTA 100

34 hrSerLeuGlnThrGluProGln..... 41
|||||

101 CCTCCCTACAGACAGATCCGAGTAATCCCGAGCGGAGGAGCCGC 150

41 ..... 41

151 TGCCCCCAGCGCAGCCCTCAGGCGCGCTGCGCCCGCAGCGCCCTGG 200

41 ..... 41

201 TCCTTTTGCTACCAGATCCCGCACTTTTTCATCTTTGTGAGAAGATCTCTC 250

42 ..... AspArgSer 44
|||||

251 TGCTGTCCCGGTCTCCAGTGGGTATTCTCTTTTGACACAGACAGAGC 300

45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProC 61
|||||

301 CCGGCACCCATGATGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 350

61 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 78
|||||

351 CCAGGCTTCAACCATATCTCATGTCATATGGCTTCCATAAGGCGATCTC 400

78 lnGluGlnProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 94
|||||

401 AGGAGNACCTGAAGATCTCGGCCCGCAGAGATACGGATCGCACAGAGCTG 450

95 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 111
|||||

451 CGCGCGATCGGACAGAGTTCAATGACACTTACACAGGAGGCGGCTTTCG 500

111 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 128

```

```

|||||
501 AAACGATTACCGAGCGGAGAGACACCGCAATGGTTATCTTACAC 550

123 euLeuArgPheIlePheArgLeuValTirpArgArgHis 140
|||||

551 TGTACGATTCACTTCCGCTCTGGTCTGGGAGAGGCAC 588

```

seq_name: gb_pat:AX031285

seq_documentation_block:
 LOCUS AX031285 416 bp DNA PAT 20-SEP-2000
 DEFINITION Sequence 7 from Patent WO9814321.
 ACCESSION AX031285
 VERSION AX031285.1 GI:10278616
 KEYWORDS
 ORGANISM
 SOURCE
 unidentified.
 unclassified.

REFERENCE 1 (bases 1 to 416)

AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.
 TITLE Novel therapeutic molecules
 JOURNAL Patent: WO 9814321-A 7 25-MAR-1999:
 INST MEDICAL W & E HALL (AU); PUTHALAKATH HAMSA (AU); REILLY
 LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
 SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)

FEATURES
 source
 1..416
 /organism="unidentified"
 /db_xref="taxon:32644"
 1..>414
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC09656.1"
 /db_xref="GI:10278617"
 /translation="MAKQPSDVNSSECDREGGQLQPAERPPQLRPGAPTSLQTEPODRS
 PAPMSCDKSTQTPSPPCQAFNHYSAMASIRQSEEPEDLRPEIRIAQELRRIGDENFAY
 YARRVFLNNYQAADHPRMVILRLRYIVRLVWRMH"

BASE COUNT 113 a 113 c 103 g 87 t
 ORIGIN

alignment_scores:
 Quality: 629.00 Length: 140
 Ratio: 4.876 Gaps: 1
 Percent Similarity: 92.143 Percent Identity: 85.714

alignment_block:

US-09-508-832-4 x AX031285 ..

Align seg 1/1 to: AX031285 from: 1 to: 416

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGCCAAGCAACCTTCTGATGTAAGTTCGTGAGTGTGACCGAGAGGTAG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCCTGCGAGAGGCTCCCGAGCTCAGACCTGGGGCCCTA 100

34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGAGCCACAGAGAGGAGCCAGCCCATGAGTTGT 150

51 AspLysSerThrGlnThrProSerProCysGlnAlaPheAsnHisTyr 67
|||||
151 GACAAATCAACAAACCCCAAGTCTCTCTTGCAGGCTTCAACCACTA 200

67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGluAspL 84
|||||
201 TCTCAGTGAATGGCTTCCATGAGGAGGCT.....GAACCTGCAGATA 244

84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100

```

```

:::|||||
245 TCAGCCAGATATGATGCGCCCAAGAGTTCGGCGGTATCGGACGACG 294
101 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 117
|||||
295 TTAAACGCTTACTATGCAAGGAGGTATTTTGAATAATTACCAAGCAGC 344
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
345 CGAAGACCAACCAAGATGTTTACGACTGTACGTTACATTGTCC 394
134 tGLeuValTrpArgHis 140
|||||
395 GCCTGGTGGAGAATGCAT 414

```

seq_name: gb_un:AX031311

```

seq_documentation_block: 416 bp DNA UNA 20-SEP-2000
LOCUS AX031311
DEFINITION Sequence 7 from Patent WO9914321.
ACCESSION AX031311
VERSION AX031311.1 GI:10278639
KEYWORDS
SOURCE
ORGANISM

```

```

REFERENCE
AUTHORS 1 (bases 1 to 416)
Huang, D.C., Puthalakath, H., Adams, J., O'Connor, L., Cory, S.,
Hu, D.C. and Strasser, A.
TITLE Novel therapeutic molecules
JOURNAL Patent: WO 9914321-A 25-MAR-1999;
INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HANSA (AU) ; REILLY
LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

```

```

FEATURES
source 1..416
/organism="unidentified"
/db_xref="taxon:32644"
CDS 1..>414
/notes="unnamed protein product"
/codon_start=1
/db_xref="GI:10278640"
/translation="MAKQPSDVSECDREGRLQPAERPPQLRPGAPTSLOTPEQDRS
PAPMSCDKSTQTPSPQAFNHVLSAMSRQAEADMRPEIWIQAELRTIGDEFNAY
YARRVFLNYYQAEDHPRMVLRLRYIVLRVWMH"
BASE COUNT 113 a 113 c 103 g 87 t
ORIGIN

```

```

alignment_scores:
Quality: 629.00 Length: 140
Ratio: 4.876 Gaps: 1
Percent Similarity: 92.143 Percent Identity: 85.714
alignment_block:
US-09-508-832-4 x AX031311
Align seg 1/1 to: AX031311 from: 1 to: 416

```

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyCl 17
|||||
1 ATGGCAAGCAACACCTCTGATGAAGTCTGAGTGTGACCCGAGAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGACGCTCGGAGAGGCCCTCCAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGCCACAGAGAGGCCAGCCAGCCATGATGTTCT 150
51 AspLysSerThrGlnThrProSerProProCysGlnAlaPheAsnHisTy 67

```

```

|||||
151 GACAATCAACACAAACCCCAAGTCTCTTGCAGGCTTCAACCACTA 200
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGluAspL 84
|||||
201 TCTCAGTCAATGGCTTCATGAGCAGGCT.....GAACCTGCAGATA 244
84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
245 TCGCCCCAGAGATATGATGCGCCCAAGAGTTCGGCGGTATCGGACGAG 294
101 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 117
|||||
295 TTAAACGCTTACTATGCAAGGAGGTATTTTGAATAATTACCAAGCAGC 344
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
345 CGAAGACCAACCAAGATGTTTACGACTGTACGTTACATTGTCC 394
134 tGLeuValTrpArgHis 140
|||||
395 GCCTGGTGGAGAATGCAT 414

```

seq_name: gb_pr:AF032458

```

seq_documentation_block:
LOCUS AF032458 417 bp mRNA PRI 19-FEB-1998
DEFINITION Homo sapiens BimL mRNA, complete cds.
ACCESSION AF032458
VERSION AF032458.1 GI:2895497
KEYWORDS
SOURCE
ORGANISM

```

```

Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
AUTHORS 1 (bases 1 to 417)
O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.
TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis
JOURNAL EMBO J. 17 (2), 384-395 (1998)
MEDLINE 98094360
PUBMED 9430630
REFERENCE
AUTHORS 2 (bases 1 to 417)
O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.S.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia

```

```

FEATURES
source 1..417
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS 1..417
/notes="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimL"
/protein_id="AAC39594.1"
/db_xref="GI:2895498"
/translation="MAKQPSDVSECDREGRLQPAERPPQLRPGAPTSLOTPEQDRS
PAPMSCDKSTQTPSPQAFNHVLSAMSRQAEADMRPEIWIQAELRTIGDEFNAY
YARRVFLNYYQAEDHPRMVLRLRYIVLRVWMH"
BASE COUNT 114 a 113 c 103 g 87 t
ORIGIN

```

```

alignment_scores:
Quality: 629.00 Length: 140
Ratio: 4.876 Gaps: 1
Percent Similarity: 92.143 Percent Identity: 85.714
alignment_block:
US-09-508-832-4 x AF032458

```

Align seg 1/1 to: AF032458 from: 1 to: 417

```
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACCGAGAAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProProGlnLeuLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGCGGAGAGGCTCCCCAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CTTCCTACAGACAGACCCACAGAGGAGCCAGCAGCCCATGAGTTGT 150
51 AspLysSerThrGlnThrProSerProProCysGlnAlaPheAsnHisTy 67
|||||
151 GACAAATCAACAAACCCCAAGTCTCTTCCAGGCTTCAACCACTA 200
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGluAspL 84
|||||
201 TCTCAGTGCATGCTTCCATGAGGAGGCT.....GAACCTGCAGATA 244
84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
245 TGGCCCGAGAGATATGATGCCACAGAGTTCGGCGGTATCGGAGAGAG 294
101 PheAsnGluThrTyrThrArgValPheAlaAsnAspTyrArgGluAl 117
|||||
295 TTTAACGCTTACTATGCAAGGAGGATTTTGAATAATTACCAAGCAGC 344
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
345 CGAAGACCCACCAAGATGTTTCTTACGACTGTACGTTACATTGTCC 394
134 rGluValTrpArgArgHis 140
|||||
395 GCTGTGTGGAGATGCAT 414
```

seq_name: gb_pat:AX031287

```
seq_documentation_block:
LOCUS AX031287 596 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 9 from Patent WO9914321.
ACCESSION AX031287
VERSION AX031287.1 GI:10278618
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL Patent: WO 9914321-A 9 25-MAR-1999;
INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HANSA (AU) ; REILLY
LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
FEATURES
Location/Qualifiers
1..596
/organism="unidentified"
/db_xref="taxon:32644"
1..>594
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09657.1"
/db_xref="GI:10278619"
/translation="MAKQPSVSECDREGQLQPAERPPOLRCAPTSLQTEPQGNP
EGNPGGSDSCPHSGPGLAPPAPGPFAIRSLPIFMRSSLLSSSSGYFSFDTD
RSPAPMDCSTQTPSPCCQAFNHLSAMASMRQAEADRPETWIAQLRRIGDEFN
AYARRVFLNNYQAEIDPRMVRILRLRYIVRLVRMH"
BASE COUNT 145 a 175 c 146 g 130 t
ORIGIN
```

alignment_scores:

Quality: 589.00 Length: 200
Ratio: 4.566 Gaps: 2
Percent Similarity: 64.500 Percent Identity: 60.000

alignment_block:

US-09-508-832-4 x AX031287 ..

Align seg 1/1 to: AX031287 from: 1 to: 596

```
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACCGAGAAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProProGlnLeuLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGCGGAGAGGCTCCCCAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CTTCCTACAGACAGACCCACAGAGTGAATCTCGAAGCAATCAGGAGGT 150
41 ..... 41
151 GAAGGGGAGAGCTGCCCCACAGCGCCTCAGGGCCCGCTGCGCCCAACC 200
41 ..... 41
201 TGGCAGCCCTGGCCCTTTTGTCTACCAGATCCCGCTTTTTCATCTTTATGA 250
41 ..... 41
251 GAAGATCCTCCCTGCTGCTCTCGATCTCCAGTGGGTATTTCTCTTTTGAC 300
42 ... AspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 57
|||||
301 ACAGACAGGAGGCCAGCAGCCATGAGTTGTGACAAATCAACACAAACCCC 350
57 oSerProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 74
|||||
351 AAGTCTCTCTGCGAGCCCTTCAACCACATCTCTCAGTGAATGGCTTCCA 400
74 leArgGlnSerGlnGluProGluAspLeuArgProGluIleArgIle 90
|||||
401 TGAGGCAGGCT.....GAACCTGCAGATATGCGCCAGAGATATGATC 444
91 AlaGlnLeuLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 107
|||||
445 GCCCAAGAGTTGGCGGTATCGGAGAGAGGTTTACGCTTACTATGCAAG 494
107 gArgValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetV 124
|||||
495 GAGGGTATTTTGAATAATTACCAAGCAGCCGAGAGACCCACCAAGTGG 544
124 alIleLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 140
|||||
545 TTATCTTACGACTGTACGTTACGTTACGTTACGTTACGTTACGTTACG 594
```

seq_name: gb_un:AX031313

```
seq_documentation_block:
LOCUS AX031313 596 bp DNA UNA 20-SEP-2000
DEFINITION Sequence 9 from Patent WO9914321.
ACCESSION AX031313
VERSION AX031313.1 GI:10278641
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
```


Huang, D.C. and Strasser, A.
 Novel therapeutic molecules
 Patent: WO 9914321-A 25-MAR-1999;
 INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY
 LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
 SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
 FEATURES
 source
 1..596
 /organism="unidentified"
 /db_xref="taxon:32644"
 CDS
 1..594
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC09662.1"
 /db_xref="GI:10278642"
 /translation="MAKQPSDVSECDREGRLQPAERPPQLRPGAPTSIQTEPQGNP
 EGNHGGDSCHPGSPQGLAPASPFPATRSPLFIEMRSSLLSRSSSGYFSFDT
 RSPAPMSCDKSTQTPSPPCQAFNHLYLSAMASMRQAPADMRPEIWTIAQLRRIGDEFN
 AYYARVFLNNYQAEADHPRMVILRLRLYIVRLVWRMH"
 BASE COUNT 145 a 175 c 146 g 130 t
 ORIGIN
 alignment_scores:
 Quality: 589.00 Length: 200
 Ratio: 4.566 Gaps: 2
 Percent Similarity: 64.500 Percent Identity: 60.000
 alignment_block:
 US-09-508-832-4 x AX031313 ..
 Align seg 1/1 to: AX031313 from: 1 to: 596
 1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
 1 ATGGCAAGCAACCTTCGTGATGTAAGTCTGAGTGTGACCGAGAGGTAG 50
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
 51 ACAATGTGAGCGCTGGGAGAGCGCTCCCGAGCTCAGACCTGGGGCCCTA 100
 34 hrSerLeuGlnThrGluProGln..... 41
 101 CTTCCCTACAGACAGACGACCAAGGTATCTGTGAAGCAATACGGAGGT 150
 41 41
 151 GAAGGGACAGCTGCCCGCCAGCGACGCTCAGGGCCGCTGGCCCCACC 200
 41 41
 201 TGCCAGCGCTGGCCCTTTTGTACAGATCCCGCTTTTCATCTTTATGA 250
 41 41
 251 GAAGATCTCCCTGCTGCTGATCCTCAGTGGGTATTTCTCTTTTGAC 300
 42 ...AspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 57
 301 ACAGACAGAGAGCCAGCACCATGATGTTGTGACAAATCAACACAAACCCC 350
 57 oSerProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 74
 351 AAGTCTCTTGGCAGGCGCTTCAACCACTATCTCAGTGCATGGCTTCCA 400
 74 leArgGlnSerClnGluProGluAspLeuArgProGluIleArgile 90
 401 TGAAGCAGGT.....GAACCTGCAGATATCGCCCGCAGAGATATGGATC 444
 91 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 107
 445 GCCCAAGAGTGGCGGTATGGGAGACCGAGTTTAACGCTTACTATATGCAAG 494

107 gArgValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetV 124
 495 GAGGTATTTTGAATAATACCAAGCAGCGAGAGACCCACCAATGG 544
 124 alIleLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 140
 545 TTAUCTTACGACTGTTACATTGTCGCCCTGGTGTGGAGAAATGCAT 594
 seq_name: gb_pr:AF032457
 seq_documentation_block:
 LOCUS AF032457 597 bp mRNA PRI 19-FEB-1998
 DEFINITION Homo sapiens BimEL mRNA, complete cds.
 ACCESSION AF032457
 VERSION AF032457.1 GI:2895495
 KEYWORDS
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 597)
 AUTHORS O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
 Cory, S. and Huang, D.C.
 TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis
 JOURNAL EMBO J. 17 (2), 384-395 (1998)
 MEDLINE 98094360
 PUBMED 9430630
 REFERENCE 2 (bases 1 to 597)
 AUTHORS O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
 Cory, S. and Huang, D.C.S.
 TITLE Direct Submission
 JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
 Eliza Hall Institute of Medical Research, PO Royal Melbourne
 Hospital, Parkville, Victoria 3050, Australia
 FEATURES
 source
 1..597
 /organism="Homo sapiens"
 /db_xref="taxon:9606"
 CDS
 1..597
 /note="pro-apoptotic BH3-containing Bcl-2 family member"
 /codon_start=1
 /product="BimEL"
 /protein_id="AAC39593.1"
 /db_xref="GI:2895496"
 /translation="MAKQPSDVSECDREGRLQPAERPPQLRPGAPTSIQTEPQGNP
 EGNHGGDSCHPGSPQGLAPASPFPATRSPLFIEMRSSLLSRSSSGYFSFDT
 RSPAPMSCDKSTQTPSPPCQAFNHLYLSAMASMRQAPADMRPEIWTIAQLRRIGDEFN
 AYYARVFLNNYQAEADHPRMVILRLRLYIVRLVWRMH"
 BASE COUNT 146 a 175 c 146 g 130 t
 ORIGIN
 alignment_scores:
 Quality: 589.00 Length: 200
 Ratio: 4.566 Gaps: 2
 Percent Similarity: 64.500 Percent Identity: 60.000
 alignment_block:
 US-09-508-832-4 x AF032457 ..
 Align seg 1/1 to: AF032457 from: 1 to: 597
 1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
 1 ATGGCAAGCAACCTTCGTGATGTAAGTCTGAGTGTGACCGAGAGGTAG 50
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
 51 ACAATGTGAGCGCTGGGAGAGCGCTCCCGAGCTCAGACCTGGGGCCCTA 100
 34 hrSerLeuGlnThrGluProGln..... 41
 101 CTTCCCTACAGACAGACGACCAAGGTATCTGTGAAGCAATACGGAGGT 150

41 41
151 GAAGGGACAGCTGCCCCACGCGCCTCAGGGCCCGCTGGCCCAAC 200
41 41
201 TGCAGCCCTGGCCCTTTCTGCTACCAGATCCCGCTTTTCATCTTATGA 250
41 41
251 GAAGATCCTCCCTGCTGCTCGATCCAGTGGGTATTTCTCTTTTGAC 300
42 ... AspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 57
301 ACACAGAGAGCCAGCAGCCATAGTTGTGACAAATCAACACAAACCC 350
57 oSerProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 74
351 AAGTCTCTCTTGCAGGCCCTTCAACCACTATCTCAGTGCATGCAATGGCTTCCA 400
74 leArgGlnSerGlnGluGluProGluAspLeuArgProGluIleArgIle 90
401 TGAGGCAGGCT GACCTGCAGATATGCCCGCAGAGATATGATC 444
91 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 107
445 GCCCAAGAGTTCGGCGGTATCGGAGACGAGTTTAACGCTTACTATGCAAG 494
107 gArgValPheAlaAspTyrArgGluAlaGluAspHisProGlnMetV 124
495 GAGGATATTTTGAATAATTACACAGCCGAGACCCACACCAAGATGG 544
124 alileLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 140
545 TTATCTTACAGCTGTACGTTACATTGTCGCGCTGTGTGAGGAATGCAT 594

seq_name: gb_pat:AX031279

seq_documentation_block:
LOCUS AX031279 332 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 1 from Patent WO9914321.
ACCESSION AX031279
VERSION AX031279.1 GI:10278610
KEYWORDS
SOURCE unidentified.
ORGANISM unidentified
REFERENCE 1 (bases 1 to 332)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY
LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
FEATURES
source
1..332
/organism="unidentified"
/db_xref="taxon:32644"
CDS
1..>330
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09653.1"
/db_xref="GI:10278611"
/translation="MAKOPSDVSSECDREGGLOPAERPPOLRPGAPTSIQTEPQAST
RQSEEPEDLRPEIRIAQELRRIGNEYITRRVFANDFEADHFQMWILQLRLRI
FRLVRRH"
BASE COUNT 87 a 85 c 91 g 69 t
ORIGIN

alignment_scores:

c .

Quality: 549.00 Length: 140
Ratio: 4.991 Gaps: 1
Percent Similarity: 78.571 Percent Identity: 78.571
alignment_block:
US-09-508-832-4 x AX031279 ..
Align seg 1/1 to: AX031279 from: 1 to: 332
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
1 ATGCCCAAGCAACCTTCTGATGTAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
51 ACAATTTGCAGCTGCTGAGAGGCTCTCCCGAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
101 CCTCCCTACAGACAGAACCCGAA 123
51 AspLysSerThrGlnThrProSerProProCysGlnAlaPheAsnHisty 67
123 123
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGluAspL 84
124GCTTCCATACGACAGTCTCAGGAGGAACCTGAAGATC 160
84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
161 TGGGCGCGGAGATACGGATTGACAGAGAGCTGCGCGGATCGGAGACGAG 210
101 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGluAl 117
211 TTCAACGAAACTTACACAGGAGGGTGTGTTGCAAAATGATTACCGCGAGGC 260
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePhea 134
261 TGAAGACCAACCTCAAAATGTTATCTTACAACCTGTACGCTTTATCTTCC 310
134 rGluValTrpArgArgHis 140
311 GTCTGTATGGAGAGGCAT 330

THIS PAGE BLANK (USPTO)

CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.
 XX
 SQ Sequence 422 BP; 112 A; 116 C; 109 G; 85 T; 0 other;

alignment_scores:
 Quality: 742.00 Length: 140
 Ratio: 5.300 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-4 x AAX24994 ..

Align seg 1/1 to: AAX24994 from: 1 to: 422

```

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
|||||
1 ATGCCAAGCAACCTTCTGTATGTAAGTCTGTGACAGAGAAGGTGG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaPro 34
|||||
51 ACAATTGCACGCTCTCAGAGGCTCCCGACGCTCAGGCTGGGCCCTA 100

34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CTTCCCTACAGACAGAACCCGACAGAGGAGCGCGCACCCATGAGTTG 150

51 AspLysSerThrGlnThrProSerProProCysGlnAlaPheAsnHis 67
|||||
151 GACAGTTCACACAAACCCCAAGTCTCTTGCAGGCGCTTCAACCACTA 200

67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluProGluAspL 84
|||||
201 TCTCAGTGCAATGCTTCCATACAGAGTCTCAGGAGGAACTTGAATC 250

84 euArgProGluIleArgIleAlaGlnLeuArgArgIleGlyAspGlu 100
|||||
251 TGGCGCGGAGATACGATTGACAGAGGCTGCGGCGGATCGGAGACGAG 300

101 PheAsnGluThrThrArgArgValPheAlaAsnAspTyrArgGluAl 117
|||||
301 TTCAAGCAAACTTACACAGAGGGGTGTTCGCAATGATTACCGCGGAGC 350

117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
351 TGAAGACCACTTCAATGGTTATCTTACAACTGTATACGCTTTATCTTC 400

134 rGluValThrArgArgHis 140
|||||
401 GTCTGTATGGAGAGGCAT 420

```

seq_name: /SID82/gcgdata/geneseq/geneseq/NA1999.DAT: AAX24995

seq_documentation_block:

ID AAX24995 standard; cDNA; 590 BP.

XX AC AAX24995;

DT 05-JUL-1999 (first entry)

XX DE Murine Bcl-2 interacting mediator of cell death Bim-EL cDNA.
 XX KW Bim-EL; Bcl-2 interacting mediator of cell death; apoptosis;
 XX cell cycle; mouse; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;

KW isoform; ss.
 XX
 OS Mus musculus.
 XX
 PN W09914321-A1.
 XX
 PD 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-AU00772.
 XX
 PR 24-SEP-1997; 97AU-0009373.
 PR 17-SEP-1997; 97AU-0009263.
 XX
 PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.
 XX
 PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;
 PI Puthalakath H, Strasser A;
 XX
 DR WPI; 1999-244030/20.
 DR P-PSDB; AAW98156.
 XX

New isolated member of the Bcl-2 family, Bim used in, e.g. cancer treatment

Claim 3; Page 96-97; 145pp; English.

The present sequence encodes the extra long form (EL) of murine Bim, or Bcl-2 interacting mediator of cell death (see AAW98156), a novel member of the Bcl-2 family that is capable of inducing cell death (apoptosis) and which acts as a 'death-ligand' for certain members of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the only Bcl-2 homology region which it encompasses is BH3. It is the only BH3-only protein for which splice variants exist. These result in the expression of a variety of isoforms, i.e. Bim-S, Bim-L and Bim-EL (see AAW98154-56). cDNAs encoding these murine Bim isoforms were obtained from a T lymphoma cDNA library using human recombinant Bcl-2 protein. The murine Bim gene has been mapped to chromosome 2 at bands F3-G. Human Bim-L and Bim-EL isoforms have also been identified (see AAW98157-58). Binding the dynein light chain was shown to regulate the pro-apoptotic activity of Bim. Bim-S, the splice variant which does not bind to dynein light chain, is a much more potent killer than either Bim-L or Bim-EL. The invention provides variants (see AAW98159-68) of murine and human Bim-L or Bim-EL that cannot bind, couple or otherwise associate with a dynein light chain. The identification of Bim permits the identification and rational design of a range of products for use in therapy, diagnosis, antibody generation and involving modulation of physiological cell death. These therapeutic molecules may act as either antagonists or agonists of Bim's function and will be useful in cancer, autoimmune or degenerative disease therapy. Increased Bim expression or Bim activity is useful, e.g. for treatment or prophylaxis in conditions such as cancer and deletion of autoreactive lymphocytes in autoimmune disease. Decreased Bim expression of Bim activity is useful in regulating inhibition or prevention of cell death or degeneration such as under cytotoxic conditions during e.g. gamma-irradiation and chemotherapy or during HIV/AIDS or other viral infections, ischemia, myocardial infarction, hypoxia, degenerative diseases or for prolonging the survival of cells being transplanted for treatment of disease. Since Bim is expressed in germ cells, modulating Bim expression or Bim activity is useful, e.g. as a contraceptive or method of sterilization by preventing generation of fertile sperm.

Sequence 590 BP; 137 A; 178 C; 150 G; 125 T; 0 other;

alignment_scores:

Quality: 704.00 Length: 196
 Ratio: 5.029 Gaps: 1
 Percent Similarity: 71.429 Percent Identity: 71.429

alignment_block:

US-09-508-832-4 x AAX24995 ..

Align seg 1/1 to: AAX24995 from: 1 to: 590

```
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlygl 17
|||||
1 ATGGCAAGCAACCTTCTGATGAAGTCTGAGTCTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACATTTGAGCCTGCTGAGAGCCCTCCAGCTCAGGCTGGGGCCCTTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CTTCCCTACAGACACAAACCGCAAGTAATCCGACGGCGAAGGGACGCC 150
|||||
41 ..... 41
151 TGCCCCCAGCGAGCCCTCAGGGCCGCTGCCCCCAGCGCCAGCCCTGG 200
|||||
41 ..... 41
201 CCCTTTTGTACCATGATCCCATCCCTTTTCATCTTTCTGAGAGATCTTCTC 250
|||||
42 .....AspArgSer 44
|||||
251 TGCTGTCCGGTCTCCAGTGGGTATTTCTCTTTTCACACAGCAGGAGC 300
|||||
45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 61
|||||
301 CGCGCACCCTGAGTGTGACAAAGTCAACAAACCCCAAGTCTCTTCTG 350
|||||
61 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 78
|||||
351 CCAGGCTTCAACCACTATCTCAGTGCATGCAATGCTTCCATACAGATCTC 400
|||||
78 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 94
|||||
401 AGGAGAACCTCAAGATCTGCCCGGAGATACGATTCACAGAGAGCTG 450
|||||
95 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgValPheAl 111
|||||
451 CGCGCGATCGGAGAGAGTCAACGAACTTACAAAGGAGGCTGTTTC 500
|||||
111 eAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 128
|||||
501 AAATGATTACCGCGAGGTGAAGACCCCTCAATGTTATCTTATCAAC 550
|||||
128 eLeuArgPheIlePheArgLeuValTyrArgArgHis 140
|||||
551 TGTTCAGCTTATCTTCCTGCTGCTGATGAGAGGCAT 588
|||||
```

seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT: AAX24996

seq_documentation_block:

ID AAX24996 standard; cDNA; 416 BP.

XX AC AAX24996;

XX DT 05-JUL-1999 (first entry)

XX DE Human Bcl-2 interacting mediator of cell death Bim-L cDNA.

XX KW Bim-L; Bcl-2 interacting mediator of cell death; apoptosis;
cell cycle; human; cancer; autoimmune disease;
degenerative disease; therapy; contraceptive; splice variant;
isoform; ss.

XX OS Homo sapiens.

XX PN W09914321-A1.

XX XX

XX PD 25-MAR-1999.

XX XX

PF 17-SEP-1998: 98WO-AU00772.
XX
PR 24-SEP-1997: 97AU-0009373.
PR 17-SEP-1997: 97AU-0009263.
XX
PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.
XX
PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;
PI Puthalakath H, Strasser A;
XX
DR WPI; 1999-244030/20.
DR P-PSDB; AAW98157.
XX
PT New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
PT treatment
XX
PS Claim 7; Page 99-100; 145pp; English.

XX The present sequence encodes the long form (L) of human Bim, or
CC Bcl-2 interacting mediator of cell death (see AAW98157), a novel
CC member of the Bcl-2 family that is capable of inducing cell death
CC (apoptosis) and which acts as a 'death-ligand' for certain members
CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
CC only Bcl-2 homology region which it encompasses is BH3. It is the
CC only BH3-only protein for which splice variants exist. These
CC result in the expression of a variety of isoforms, i.e. Bim-S,
CC Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see
CC AAW98158) were isolated from embryo and liver cDNA libraries using
CC mouse Bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see
CC AAW98154-56) are also provided. The human Bim gene maps to
CC chromosome 2 at bands 2q12-2q13. Binding the dynein light
CC chain was shown to regulate the pro-apoptotic activity of Bim.
CC Bim-S, the splice variant which does not bind to dynein light
CC chain, is a much more potent killer than either Bim-L or Bim-EL.
CC The invention provides variants (see AAW98159-68) of murine and human
CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
CC with a dynein light chain. The identification of Bim permits the
CC identification and rational design of a range of products for use
CC in therapy, diagnosis, antibody generation and involving modulation
CC of physiological cell death. These therapeutic molecules may act
CC as either antagonists or agonists of Bim's function and will be
CC useful in cancer, autoimmune or degenerative disease therapy.
CC Increased Bim expression or Bim activity is useful, e.g. for
CC treatment or prophylaxis in conditions such as cancer and deletion
CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
CC expression of Bim activity is useful in regulating inhibition or
CC prevention of cell death or degeneration such as under cytotoxic
CC conditions during e.g. gamma-irradiation and chemotherapy or during
CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
CC hypoxia, degenerative diseases or for prolonging the survival of
CC cells being transplanted for treatment of disease. Since Bim is
CC expressed in germ cells, modulating Bim expression or Bim activity
CC is useful, e.g. as a contraceptive or method of sterilization by
CC preventing generation of fertile sperm.
XX SQ Sequence 416 BP; 113 A; 113 C; 103 G; 87 T; 0 other;

alignment_scores:

Quality: 629.00 Length: 140
Ratio: 4.876 Gaps: 1
Percent Similarity: 92.143 Percent Identity: 85.714

alignment_block:

US-09-508-832-4 x AAX24996

Align seg 1/1 to: AAX24996 from: 1 to: 416

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlygl 17
|||||
1 ATGGCAAGCAACCTTCTGATGAAGTCTGAGTCTGACAGAGAAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34

```

|||||
51 ACAATTCAGCCTCGGAGAGGCTCCCGAGCTCAGAGCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGCCACAGACAGGAGCCAGCAGCCCATGAGTTGT 150
|||||
51 AsplussSerThrGlnThrProSerProProCysGlnAlaPheAsnHlSty 67
|||||
151 GACAAATCAACACAAACCCCAAGTCTCTTGCAGGCGCTTCACCACTA 200
|||||
67 rLeuSerAlaMetAlaSerLeuArgGlnSerGlnGluProGluAspL 84
|||||
201 TCTCAGTGCATGCTTCCATGAGGAGGCT.....GAACCTGCAGATA 244
|||||
84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
245 TGCGCCAGAGATATGATGCTCCCAAGAGTGGCGGTATCGGAGAGCAG 294
|||||
101 PheAsnGluThrTyrThrArgValPheAlaAsnAspTyrArgGluAl 117
|||||
295 TTTAAACGCTTACTATGCAAGGAGGTTATTTTGAATAATTACCAAGCAGC 344
|||||
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheA 134
|||||
345 CGAAGACCCAGCAATGTTATCTTACGACTGTACGTTACATTGTCC 394
|||||
134 rGluValThrPArgArgHis 140
|||||
395 GCCTGGTGTGGAGATCAT 414

```

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT:AAx24997

seq_documentation_block:

ID AAX24997 standard; cDNA; 596 BP.

XX AC AAX24997;

XX DT 05-JUL-1999 (first entry)

XX DE Human Bcl-2 interacting mediator of cell death Bim-EL cDNA.

XX KW Bim-EL; Bcl-2 interacting mediator of cell death; apoptosis;

XX KW cell cycle; human; cancer; autoimmune disease;

XX KW degenerative disease; therapy; contraceptive; splice variant;

XX KW isoform; ss.

XX OS Homo sapiens.

XX PN WO9914321-Al.

XX PD 25-MAR-1999.

XX PF 17-SEP-1998; 98WO-AU00772.

XX PR 24-SEP-1997; 97AU-0009373.

XX PR 17-SEP-1997; 97AU-0009263.

XX PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.

XX PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;

XX PI Puthalakath H, Strasser A;

XX DR WPI; 1999-244030/20.

XX DR P-PSDB; AAW98158.

XX PT New isolated member of the Bcl-2 family, Bim used in, e.g. cancer

XX PT treatment

XX PS Claim 7; Page 101-102; 145pp; English.

XX CC The present sequence encodes the extra long form (EL) of human Bim,

XX CC or Bcl-2 interacting mediator of cell death (see AAW98158), a novel

CC member of the Bcl-2 family that is capable of inducing cell death
 CC (apoptosis) and which acts as a 'death-ligand' for certain members
 CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 CC only Bcl-2 homology region which it encompasses is BH3. It is the
 CC only BH3-only protein for which splice variants exist. These
 CC result in the expression of a variety of isoforms, i.e. Bim-S,
 CC Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see
 CC AAW98158) were isolated from embryo and liver cDNA libraries using
 CC mouse bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see
 CC AAW98154-56) are also provided. The human Bim gene maps to
 CC chromosome 2 at bands 2q12-2q13. Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-68) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC treatment or prophylaxis in conditions such as cancer and deletion
 CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.

XX SQ Sequence 596 BP; 145 A; 175 C; 146 G; 130 T; 0 other;

alignment_scores:

Quality: 589.00 Length: 200

Ratio: 4.566 Gaps: 2

Percent Similarity: 64.500 Percent Identity: 60.000

alignment_block:

US-09-508-832-4 x AAX24997 ..

Align seg 1/1 to: AAX24997 from: 1 to: 596

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTTCTGATGTAAAGTTCTGAGTGTGACCGAGAGGTAG 50
|||||
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGGGAGAGCGCTCCCGAGCTCAGACCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGln..... 41
|||||
101 CCTCCCTACAGACAGAGCCACAGAGTAATCCTGAAGCAATCACGGAGGT 150
|||||
41 ..... 41
151 GAAGGGACAGAGTGCCCCCAGCGAGCCCTCAGGGCCCGCTGGCCCCCACC 200
|||||
41 ..... 41
201 TGCCAGCCCTGGCCCTTTTGTCTACCAGATCCCGCGCTTTTCATCTTTATGA 250
|||||
41 ..... 41
251 GAAGATCCTCCCTGCTGCTCGATCCTCCAGTGGGTATTTCTCTTTTGAC 300
|||||
42 ...AspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 57

```



```

|||||
301 ACAGACAGAGCCAGCACCATGATGTTGACAAATCAACACAAACCCC 350
57 oSerProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 74
|||||
351 AAGTCCTCTTCCAGGCCCTTCAACCACTATCTCAGTGCATGGTCCCA 400
74 leArgGlnSerGlnGluGluProGluAspLeuArgProGluLeuArgIle 90
:|||||:
401 TGAGCAGAGCT.....GAACCTGCAGATATCGCCAGAGATATGGATC 444
91 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 107
|||||
445 GCCCAAGAGTTCGGCGGTATCGGACGAGGATTTACGCTTACTATGCAAG 494
107 gArgValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetV 124
|||||
495 GAGGTATTTTGAATAATTAACCAAGCAGCCGACAGACCCACCAATGG 544
124 alileuGlnLeuLeuArgPheIlePheArgLeuValTrpArgHis 140
545 TTATCTTACGAGTGTACGTTACATGTCTCCGCTGGTGGAGATGCAT 594

```

seq_name: /SIDS2/gcgdata/geneseq/NA1999.DAT:AAx24993

seq_documentation_block:

ID AAX24993 standard; cDNA; 332 BP.

XX AC AAX24993;

XX OS 05-JUL-1999 (first entry)

XX DE Murine Bcl-2 interacting mediator of cell death Bim-S cDNA.

XX KW Bim-S; Bcl-2 interacting mediator of cell death; apoptosis;
 cell cycle; mouse; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;
 KW isoform; ss.

XX OS Mus musculus.

XX PN WO9914321-A1.

XX PD 25-MAR-1999.

XX PF 17-SEP-1998; 98WO-AU00772.

XX PR 24-SEP-1997; 97AU-0009373.

XX PR 17-SEP-1997; 97AU-0009263.

XX PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.

XX PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;

XX PI Puthalakath H, Strasser A;

XX DR WPI; 1999-244030/20.

XX DR P-PSDB; AAW98154.

XX PT New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
 treatment

XX PS Claim 3; Page 92; 145pp; English.

XX CC The present sequence encodes the short form (S) of murine Bim, or
 Bcl-2 interacting mediator of cell death (see AAW98154), a novel
 member of the Bcl-2 family that is capable of inducing cell death
 (apoptosis) and which acts as a 'death-ligand' for certain members
 of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 only Bcl-2 homology region which it encompasses is BH3. It is the
 only BH3-only protein for which splice variants exist. These
 result in the expression of a variety of isoforms, i.e. Bim-S,
 Bim-L and Bim-EL (see AAW98154-56). cDNAs encoding these murine Bim
 isoforms were obtained from a T lymphoma cDNA library using human

CC recombinant Bcl-2 protein. The murine Bim gene has been mapped to
 CC chromosome 2 at bands F3-G. Human Bim-L and Bim-EL isoforms have
 CC also been identified (see AAW98157-58). Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-68) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC treatment or prophylaxis in conditions such as cancer and deletion
 CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.

XX SQ Sequence 332 BP; 87 A; 85 C; 91 G; 69 T; 0 other;

alignment_scores:

Quality: 549.00 Length: 140

Ratio: 4.991 Gaps: 1

Percent Similarity: 78.571 Percent Identity: 78.571

alignment_block:

US-09-508-832-4 x AAX24993 ..

Align seg 1/1 to: AAX24993 from: 1 to: 332

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG 17
|||||
1 ATGGCCAACCAACCTTCTGATGTAGTTCTGAGTGTGACAGAGAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGCTGAGAGGCTCCCGAGCTCAGGCTGGGCCCTTA 100
|||||
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaProMetSerCys 50
|||||
101 CCTCCCTACAGACAGAACCGCAA..... 123
51 AspLysSerThrGlnThrProSerProProCysGlnAlaPheAsnHis 67
123 ..... 123
67 rLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGluAsp 84
|||||
124 .....GCTTCATACGACAGTCTCAGAGAGAACCTGAAGATC 160
|||||
84 euArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAspGlu 100
|||||
161 TCGCGCCGGAGATACGATTGCACAGAGAGCTCGCGGGATCGAGACGAG 210
101 PheAsnGluThrTyrThrArgArgValPheAlaAsnAspTyrArgGlu 117
|||||
211 TTCAACGAAACTTACACAAGAGAGGGTGTTCGCAATGATTACCGCAGGC 260
|||||
117 aGluAspHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePhe 134
|||||
261 TGAAGACCACTTCAATGTTATCTTACAACTGTTACGCTTTATCTTCC 310
134 rgLeuValTrpArgArgHis 140

```



```
5 ProSerAspValSerSerGluCysAspArgGluGlyGlnLeuGlnPr 21
||||| : : : : : : : : : : : : : : : : : : : : : : : :
1409 CCTCAGACCCAGGAGAGCCCAAGCAAGCCCTCCCACTCAGACC 1360
21 oAlaGluArgProGln.....LeuArgp 30
| : : : | |||||
1359 CAAGATCCAGACCCAGCCCTTCTCTTCAACCCCAAGAGTCCAGAC 1310
30 roGlyAlaPro.....ThrSerLeuGlnThrGluPro..... 40
|| ||||| : : : : : : : : : : : : : : : : : : : :
1309 CCCCAGCCCTCTCTCTCAGACCCAGGGGTCCAGACCCAGCCCTCTCTC 1260
41 .....GlnAspArgSerProAlaPrometSerCysAspLysSe 53
|| ||||| : : : : : : : : : : : : : : : : : : : :
1259 CCTCAGACCCAGGGGCCAGATCCCTCTCTCTCTCTCTCTCTCTCTCTCT 1210
53 rThrGlnThrProSerProCysGlnAlaPheAsnHisTyrLeuSerA 70
: : : : : : : : : : : : : : : : : : : : : : : :
1209 AGTCCAGATCCCCAGCC..... 1191
70 laMetAlaSerIleArgGlnSerGlnGluProGluAspLeuArgPro 86
: : : : : : : : : : : : : : : : : : : : : : : :
1190 .....TCCTCTCTCAGACCCAGGGGCCAAGGCCCCAGCCCTCTCTCTCT 1146
87 GluIleArgIleAlaGlnGluLeuArg 95
: : : : : : : : : : : : : : : : : : : : : : : :
1145 CAG.....ACCCAGGAATCCAGA 1128
```

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA1999.DAT:AAZ32020

seq_documentation_block:

ID: AAZ32020 standard; DNA: 38734 BP.

XX *

AC AAZ32020;

XX 10-JAN-2000 (first entry)

XX Human METH1 related EST AL021529.

XX

XX Human; METH1; METH2; anti-angiogenic; metalloprotease thrombospondin;
KW cancer; diagnosis; hyperproliferative disorder; autoimmune disease;
KW angiogenesis inhibitor; abnormal wound healing; inflammation;
KW rheumatoid arthritis; psoriasis; endometrial bleeding disorder;
KW diabetic retinopathy; macula degeneration; haemangioma; detection;
KW arterial-venous malformation; immune deficiency; ss.

XX Homo sapiens.

XX

XX WO9937660-A1.

XX

XX 29-JUL-1999.

XX

XX 22-JAN-1999; 99WO-US01313.

XX

XX 23-JAN-1998; 98US-0072298.

XX 28-AUG-1998; 98US-0098539.

XX

XX (TRUE/) IRUELA-ARISPE L.

XX (HAST/) HASTINGS G A.

XX (RUBE/) RUBEN S M.

XX

XX IrueLa-Arispe L, Hastings GA, Ruben SM;

XX WPI; 1999-590684/50.

XX

XX New isolated metalloprotease thrombospondin polypeptides, useful for
PT treating hyperproliferative disorders, cancers or autoimmune disorders
PT

XX Disclosure; Page 296-321; 457pp; English.

XX

XX AAZ32000 and AAZ32001 encode, and AAY49501 and AAY49502 represent, human
XX metalloprotease thrombospondin (METH) proteins METH1 and METH2
CC

CC respectively. METH1 and METH2 have been found to be potent inhibitors of
CC angiogenesis both in vitro and in vivo. They can be used for treating
CC cancer and other disorders related to angiogenesis including abnormal
CC wound healing, inflammation, rheumatoid arthritis, psoriasis,
CC endometrial bleeding disorders, diabetic retinopathy, some forms of
CC macula degeneration, haemangiomas, and arterial-venous malformations.
CC They may be useful in treating deficiencies or disorders of the immune
CC system, by activating or inhibiting the proliferation, differentiation,
CC or mobilisation (chemotaxis) of immune cells. The etiology of these
CC immune deficiencies or disorders may be genetic, somatic, such as
CC cancer or some autoimmune disorders, acquired (e.g. by chemotherapy or
CC toxins), or infectious. They can also be used to treat inflammatory
CC conditions, both chronic and acute conditions. The products can also be
CC used for detection and diagnosis. AAZ32002 to AAZ32080, and AAY49503 to
CC AAY49511 represent sequences given in the exemplification of the present
CC invention.

XX
SQ Sequence 38734 BP; 6142 A; 13140 C; 13585 G; 5867 T; 0 other;

alignment_scores:

Quality: 90.50 Length: 136

Ratio: 1.437 Gaps: 6

Percent Similarity: 46.324 Percent Identity: 30.147

alignment_block:

US-09-508-832-4 x AAZ32020/rev ..

Align seg 1/1 to reverse of: AAZ32020 from: 1 to: 38734

```
5 ProSerAspValSerSerGluCysAspArgGluGlyGlnLeuGlnPr 21
||||| : : : : : : : : : : : : : : : : : : : :
26579 CCTCGACCGCAACGTGACCTGCTGACGCCGCTACCTCAGCAGCC 26530
21 oAlaGluArgProGlnLeuArgProGly..... 31
: : : : : : : : : : : : : : : : : : : :
26529 GTCTGTGACTCGCTCGACCCCTCGCGCGCGCCGCTCACCAGATGGAGCA 26480
32 .....AlaProThrSerLeuGlnThrGluProGln 41
||||| : : : : : : : : : : : : : : : : : : : :
26479 CCACGTACTCCATGTCCACGGCGCGCAGCAAGC.....ACGGCGCACCA 26436
42 AspArgSerPro.....AlaProMetSerCysAspLysSerThrGl 55
||||| : : : : : : : : : : : : : : : : : : : :
26435 CGAGATCGCGCAGCGCAGCGCGCGCTGATCATGTTCTCTGACACCAAG 26386
55 nThrProSer..... 58
: |||||
26385 CACGCCGTGACAGACTGACCGGGACCTGCTCAACAGCGGGGTACGGGC 26336
59 ..ProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIle 74
||||| : : : : : : : : : : : : : : : : : : : :
26335 CGCGCCCTTGACGGCGCAAGTCCCGCAGCGCGCAGCCGCACTCTGG 26286
75 ArgGlnSerGln.....GluGluProGluAspLeuArgProGluIleAr 89
||||| : : : : : : : : : : : : : : : : : : : :
26285 CGCAGTTCAAGACCGCGCAGCGCTCAGCTGCTGCTGGCGACCAACGTCGG 26236
89 gIleAlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrT 106
||||| : : : : : : : : : : : : : : : : : : : :
26235 GCACCGGAATCCACGTGCGACAACTCGACCTCG.....TCGTCAACGTGCA 26189
106 hrArgArg 108
|||||
26188 CCGCGCGA 26181
seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2001.DAT:AAZ90077
seq_documentation_block:
ID AAC90077 standard; DNA: 38734 BP.
XX
XX AAC90077; ..
XX
```

DT 19-MAR-2001 (first entry)
 DE AL021529 cDNA clone.
 XX
 KW METH; metalloproteinase; thrombospondin; angiogenesis inhibition;
 KW cancer therapy; benign tumour; ocular angiogenic disease;
 KW rheumatoid arthritis; psoriasis; wound healing; endometriosis;
 KW vasculogenesis; granulation; hypertrophic scar; nonunion fracture;
 KW scleroderma, trachoma; vascular adhesion; myocardial angiogenesis;
 KW coronary collateral; cerebral collateral; arteriovenous malformation;
 KW ischaemic limb angiogenesis; Osler-Webber syndrome; wound granulation;
 KW plaque neovascularisation; telangiectasia; haemophilic joint; EST;
 KW angiofibroma; fibromuscular dysplasia; expressed sequence tag;
 KW Crohn's disease; atherosclerosis; birth control; ss.
 XX
 OS Unidentified.
 XX
 XX WO200071577-A1.
 PN
 XX
 PD 30-NOV-2000.
 XX
 XX 25-MAY-2000; 2000WO-US14462.
 PF
 XX 25-MAY-1999; 99US-0318208.
 PR 20-JUL-1999; 99US-0144882.
 PR 10-AUG-1999; 99US-0147823.
 PR 13-AUG-1999; 99US-0373658.
 PR 22-DEC-1999; 99US-0171503.
 PR 22-FEB-2000; 2000US-0183792.
 XX
 PA (HUMA-) HUMAN GENOME SCI INC.
 PA (SMIK) SMITHKLINE BEECHAM CORP.
 PA (BETH-) BETH ISRAEL DEACONESS MEDICAL CENT.
 PA (IRUE/) IRUELA-ARISPE L.
 PA (HAST/) HASTINGS G A.
 PA (RUBEN/) RUBEN S M.
 PA (JONAK/) JONAK Z L.
 PA (TRULLI/) TRULLI S H.
 PA (FORN/) FORNWALD J A.
 PA (TERR/) TERRETT J A.
 XX
 PI IrueLA-Arispe L, Hastings GA, Ruben SM, Jonak ZL, Trulli SH;
 PI Fornwald JA, Terrett JA;
 XX
 XX WPI; 2001-025136/03.
 DR
 XX METH1 and METH2 polynucleotides and encoded polypeptides, used to
 PT inhibit angiogenesis in the treatment of disorders such as cancer,
 PT rheumatoid arthritis and psoriasis -
 XX
 PS Claim 7; Pages 597-622; 769pp; English.
 XX
 CC The present invention relates to human METH1 and METH2, (ME for
 CC metalloproteinase and TH for thrombospondin; see AAB50002 and AAB50003).
 CC The present sequence is an expressed sequence tag (EST) for METH. METH
 CC can be used for inhibiting angiogenesis in an individual, and for
 CC treating cancer, benign tumours, an ocular angiogenic disease,
 CC rheumatoid arthritis, psoriasis, delayed wound healing, endometriosis,
 CC vasculogenesis, granulations, hypertrophic scars, nonunion fractures,
 CC scleroderma, trachoma, vascular adhesions, myocardial angiogenesis,
 CC coronary collaterals, cerebral collaterals, arteriovenous malformations,
 CC ischaemic limb angiogenesis, Osler-Webber syndrome, plaque
 CC neovascularisation, telangiectasia, haemophilic joints, angiofibroma,
 CC fibromuscular dysplasia, wound granulation, Crohn's disease or
 CC atherosclerosis. METH can also be used in birth control. METH can also
 CC be used in diagnostic methods for the prognosis of cancer.
 XX
 SQ Sequence 38734 BP; 6142 A; 13138 C; 13586 G; 5868 T; 0 other;

alignment_scores:
 Quality: 90.50 Length: 136
 Ratio: 1.437 Gaps: 6

Percent Similarity: 46.324 Percent Identity: 30.147
 alignment_block:
 US-09-508-832-4 x AAC90077/rev ..
 .Align seg 1/1 to reverse of: AAC90077 from: 1 to: 38734
 : 5 ProSerAspValSerSerGluCysAspArgGluGlyGlnLeuInPr 21
 : ||||| :
 26579 CCCTGACGCGCAACGTCGACCTGCTGTCGCGGCTACCTCAGCGACCC 26530
 :
 : 21 oAlaGluArgProProGlnLeuArgProGly..... 31
 : ||||| :
 26529 GTGCTGCACTCCGTCGACCCCTCGCGCGCGCGCTCACCACGATGGAGCA 26480
 :
 : 32AlaProThrSerLeuGlnThrGluProGln 41
 : ||||| :
 26479 CCACGTACTCCATGTCACGCGCGCGCCGACCAAGC.....ACGCGGCCACCA 26436
 :
 : 42 AspArgSerPro.....AlaProMetSerCysAspLysSerThrG1 55
 : ||||| :
 26435 CCGAGATCGCGCGACGCGCGCGGTGATCATGTTCTCGACACCAAG 26386
 :
 : 55 nhrProSer..... 58
 : ||||| :
 26385 CACGCGCTGCGACAGACTGACCGGGACCTGCTCAACAGCGGGGTACGGGC 26336
 :
 : 59 ..ProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIle 74
 : ||||| :
 26335 CGCCGCCCTGCGCGCGCAAGTCCCGCGCGCGCGCCGCCACCCGCTCTGG 26286
 :
 : 75 ArgGlnSerGln.....GluGluProGluAspLeuArgProGluIleAr 89
 : ||||| :
 26285 CGCAGTTCAAGACCGGGCGCGCTCACCGTGTGTCGCGACCAACGTCGCG 26236
 :
 : 89 gIleAlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrT 106
 : | :
 26235 GCACGCGGAATCCACGTCGACCAACCTCGACCTCG...TCGTCAACGTCGA 26189
 :
 : 106 hrArgArg 108
 : ||||| :
 26188 CCGCGCGCA 26181
 :
 seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT:AAI21994
 seq_documentation_block:
 ID_AAI21994 standard; DNA; 3331 BP.
 XX
 AC AAI21994;
 XX
 DT 12-OCT-2001 (first entry)
 XX
 DE Probe #11927 for gene expression analysis in human cervical cell sample.
 XX
 KW Probe; human; microarray; gene expression; cervical epithelial cell;
 KW cervical cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200157278-A2.
 XX
 PD 09-AUG-2001.
 XX
 XX 30-JAN-2001; 2001WO-US00670.
 XX
 PR 04-FEB-2000; 2000US-0180312.
 PR 26-MAY-2000; 2000US-0207456.
 PR 30-JUN-2000; 2000US-0608408.
 PR 03-AUG-2000; 2000US-0632366.
 PR 21-SEP-2000; 2000US-0234687.
 PR 27-SEP-2000; 2000US-0236359.
 PR 04-OCT-2000; 2000GB-0024263.
 XX

seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT:AAI47284


```
XX 29-JUL-1999.
PD
XX
XX PF 22-JAN-1999; 99WO-US01313.
XX
XX PR 23-JAN-1998; 98US-0072298.
XX
XX PR 28-AUG-1998; 98US-0098539.
XX
XX (IRUE/) IRUELA-ARISPE L.
PA (HAST/) HASTINGS G A.
PA (RUBE/) RUBEN S M.
XX
XX Iruela-Arispe L, Hastings GA, Ruben SM;
PI
XX
XX WPI: 1999-590684/50.
DR
XX
XX New isolated metalloproteinase thrombospondin polypeptides, useful for
PT treating hyperproliferative disorders, cancers or autoimmune disorders
PT
XX
XX Disclosure: Page 353-359; 457pp; English.
XX
XX AAZ32000 and AAZ32001 encode, and AAY49501 and AAY49502 represent, human
CC metalloproteinase thrombospondin (METH) proteins METH1 and METH2
CC respectively. METH1 and METH2 have been found to be potent inhibitors of
CC angiogenesis both in vitro and in vivo. They can be used for treating
CC cancer and other disorders related to angiogenesis including abnormal
CC wound healing, inflammation, rheumatoid arthritis, psoriasis,
CC endometrial bleeding disorders, diabetic retinopathy, some forms of
CC macula degeneration, haemangiomas, and arterial-venous malformations.
CC They may be useful in treating deficiencies or disorders of the immune
CC system, by activating or inhibiting the proliferation, differentiation,
CC or mobilisation (chemotaxis) of immune cells. The etiology of these
CC immune deficiencies or disorders may be genetic, somatic, such as
CC cancer or some autoimmune disorders, acquired (e.g. by chemotherapy or
CC toxins), or infectious. They can also be used to treat inflammatory
CC conditions, both chronic and acute conditions. The products can also be
CC used for detection and diagnosis. AAZ32002 to AAZ32080, and AAY49503 to
CC AAY49511 represent sequences given in the exemplification of the present
CC invention.
XX
XX SQ Sequence 9810 BP; 1583 A; 3401 C; 3201 G; 1625 T; 0 other;

alignment_scores:
  Quality: 89.00      Length: 114
  Ratio: 1.679        Gaps: 5
  Percent Similarity: 46.491  Percent Identity: 28.947

alignment_block:
US-09-508-832-4 x AAZ32025/rev ..

Align seg 1/1 to reverse of: AAZ32025 from: 1 to: 9810

      4 GlnProSerAspValSerSerGluCysAspArgGluGlyClnLeuG1 20
      ::::  :::  :::  :::  :::  :::  :::  :::  :::  :::
8050 CGCGCCAGAGATCGTCTCGCCAGATCGCCGTAGATTCGGTCAAC 8001

      20 nProAlaGluArgProGlnLeuArgProGlyAlaProThrSerLeuG 37
      ::::  :::  :::  :::  :::  :::  :::  :::  :::  :::
8000 GCAGGCACTCGCGCGGCTCTCTCGCCGCCGCCGCCGCCGCCGCCG 7951

      37 lnThrGluProGlnArgSerProAlaProMetSerCysAspLysSer 53
      :::  :::  :::  :::  :::  :::  :::  :::  :::  :::
7950 CGCGGTCCAGTTCGGATCGTTCGGTCCGACCA..... 7919

      54 ThrGlnThrProSerProCys.GlnAlaPheAsnHisTyrLeuSera 70
      :::  :::  :::  :::  :::  :::  :::  :::  :::  :::
7918 ...CAACGCCCGAGTCGTCGTCGCGAAGCA.....G 7890

      70 laMetAlaSerIleArgGlnSerGlnGluPro..... 81
      :::  :::  :::  :::  :::  :::  :::  :::  :::  :::
7889 TACCGGCACAGAGCCGAGAGACAGACACAGCCCTTCGGCACCGTGC 7840
```


OM of: US-09-508-832-4 to: EST:* out_format : pfs

Date: Dec 11, 2001 1:03 AM

About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:

```
-MODEL=framer_p2n.model -DEV=xlpl
-Q/cn2.1/USPTO_spool/US09508832/runat_10122001_110349_29536/app_query.fasta_1.620
-DB=EST -QFWT=fastap -SUFFIX=rst -GAPOP=12.000 -GAPEXT=4.000
-MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000 -QGAPOP=4.500
-QGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FCGAP=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blotsum62 -TRANS=human40.cdi
-LIST=45 -DOALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-NAXLEN=200000000 -USER=US09508832 -CGN1_L0 -NCPU=6 -ICPU=3
-LONGLOG -NO_XLPHY -WAIT -THREADS=1
```

Search information block:

Query: US-09-508-832-4

Query length: 140

Database: EST:*

Database sequences: 11351937

Database length: 1077921985

Search time (sec): 2629.110000

score_list:

Sequence	Strd	Orig	Zscore	EScore	Len	Documentation
gb_hlc:AK011490	+	675.50	953.68	5.9e-44	1206	AK011490 Mus musculus 10 days
gb_est2:BF621698	+	583.00	824.88	8.8e-37	935	BF621698 602825518F1 NCI CGAP
gb_est2:BF021882	+	525.00	748.90	1.5e-32	452	BF021882 uy59b09.y1 MCI CGAP
gb_est1:AF711169	-	370.00	528.77	2.7e-20	492	AF711169 wt24h12.x1 NCI CGAP
gb_est2:BG173095	+	354.00	503.54	7.0e-19	668	BG173095 602336666F1 NCI CGAP
gb_gss:AZ706148	+	347.00	494.82	2.1e-18	580	AZ706148 RPCI-23-227P3-TV RPCI
gb_est1:AW629314	-	287.00	408.75	1.3e-13	664	AW629314 hi56e02.x1 Soares NFL
gb_est2:BF319454	-	249.00	359.46	7.4e-11	389	BF319454 uy59b09.x1 MCI CGAP
gb_est1:AA629308	+	127.00	184.63	0.4043	501	AA629308 uy59b09.x1 Soares test
gb_est2:BF172831	+	126.00	190.53	0.1895	210	BF172831 PCL5805 Myeloma (PCL)
gb_est1:AA629050	+	123.00	178.96	0.8358	501	AA629050 zu84a06.s1 Soares test
gb_est1:AF209718	+	98.50	143.70	76.99	537	AF209718 AF209718 xenopus laevis
gb_est2:BG649655	+	98.00	145.84	58.52	383	BG649655 RH122_82.D01.b1 A003 R
gb_est2:BG412166	+	98.00	143.28	81.26	519	BG412166 OV2_38.F11.b1 A002 Ova
gb_est1:BE728552	+	95.50	136.55	192.62	758	BE728552 60156205F1 NIH MGC-20
gb_est2:BE903772	+	95.50	135.66	215.77	842	BE903772 60167660F1 NIH MGC-21
gb_est1:BE563554	+	95.50	134.99	235.21	912	BE563554 60133485F1 NIH MGC-39
gb_est2:BE910153	+	95.50	132.29	332.35	1256	BE910153 60150344F1 NIH MGC-7
gb_est1:BE622003	+	95.50	132.19	336.92	1272	BE622003 60144065F1 NIH MGC-7
gb_est1:AL542837	+	95.00	133.99	267.34	944	AL542837 AL542837 LFI FL002 PCL
gb_est1:BE416944	+	94.50	137.06	180.40	603	BE416944 MUG014.H03F990622 ITDC
gb_est2:BG713458	+	94.50	136.80	186.54	622	BG713458 p911n.pk004.15 Normal
gb_est1:BE394838	+	93.50	133.67	278.52	762	BE394838 601312080F1 NIH MGC-44
gb_est2:BE732875	+	93.50	132.56	321.39	870	BE732875 601567809F1 NIH MGC-21
gb_gss:AZ137807	+	93.50	132.25	334.18	902	AZ137807 SP_0180.A2.H09 SPEE St
gb_est2:BE213947	-	93.50	132.02	344.20	927	BE213947 601847413F1 NIH MGC-55
gb_est2:BG913808	+	93.00	132.35	340.14	820	BG913808 602812986F1 NCI CGAP
gb_est2:BG337043	+	93.00	131.56	365.06	900	BG337043 602434310F1 NIH MGC-44
gb_est2:BG699551	+	92.50	134.34	255.66	595	BG699551 602679256F1 NIH MGC-98
gb_est2:BE1394478	+	92.50	133.33	291.11	671	BE1394478 p911n.pk014.m20 Normal
gb_est1:BE394827	+	92.50	132.31	331.60	757	BE394827 601312068F1 NIH MGC-44
gb_est2:BE1260770	+	92.50	132.21	335.87	766	BE1260770 602970728F1 NIH MGC-7
gb_est2:BE799245	+	92.50	131.45	370.57	839	BE799245 601586889F1 NIH MGC-7
gb_gss:CN504440	+	92.50	130.51	418.01	938	AL274281 Tetraodon nigroviridis
gb_est2:BG747433	+	92.50	127.35	626.87	1365	BG747433 602662784F1 NIH MGC-2
gb_est2:BG6990772	-	92.00	139.71	128.33	289	BG6990772 MRI-HT1136-260101-015
gb_est2:BF620177	+	92.00	133.69	277.92	591	BF620177 HVMC0018M031 Hordeu
gb_gss:CN501740	+	92.00	128.67	528.76	1072	AL166063 Tetraodon nigroviridis
gb_est1:AZ414049	+	91.50	133.39	288.79	563	AZ414049 IM0188013F Mouse 10kb
gb_est1:AL507998	+	91.50	131.92	348.50	670	AL507998 AL507998 Hordeum vulg

gb_est2:BG752199 + 91.50 129.13 498.92 934 ! BG752199 602731331F1 NIH_MGC
gb_est2:BF66948 + 91.50 124.51 902.01 1616 ! BF66948 963082E01.y1 C. re
gb_est2:BF727326 + 91.00 132.22 335.69 595 ! BF727326 yf20a03.y1 Human Le
gb_est1:BE366432 - 91.00 131.77 355.23 627 ! BE366432 PIL_33_A12.gl_A002

seq_name: gb_hlc:AK011490

seq_documentation_block:

LOCUS AK011490 1206 bp mRNA HTC 05-JUL-2001
DEFINITION Mus musculus 10 days embryo cDNA, RIKEN full-length enriched
library, clone:2610020M23, full insert sequence.

ACCESSION AK011490.1 GI:12847647

VERSION CAP trapper.

KEYWORDS Mus musculus

SOURCE clone:2610020M23.

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 1206)

AUTHORS Carninci,P. and Hayashizaki,Y.

TITLE High-efficiency full-length cDNA cloning

JOURNAL Methods in enzymology. 303, 19-44 (1999)

MEDLINE 99279253

PUBMED 10349636

REFERENCE 2 (bases 1 to 1206)

AUTHORS Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K.,

Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.

TITLE Normalization and subtraction of cap-trapper-selected cDNAs to

JOURNAL prepare full-length cDNA libraries for rapid discovery of new genes

MEDLINE 20499374

PUBMED 11042159

REFERENCE 3 (bases 1 to 1206)

AUTHORS Shibata,K., Itoh,M., Aizawa,K., Nagaoka,S., Sasaki,N., Carninci,P.,

Konno,H., Akiyama,J., Nishi,K., Kitsuai,T., Tashiro,H., Itoh,M.,

Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A.,

Yamanoto,R., Matsumoto,H., Sakaguchi,S., Ikegami,T., Kashiwagi,K.,

Fujiwaka,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watahiki,M.,

Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsura,S., Kawai,J.,

Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.

TITLE RIKEN integrated sequence analysis (RISA) system-384-format

JOURNAL sequencing pipeline with 384 multicapillary sequencer

MEDLINE 20530913

PUBMED 11076861

REFERENCE 4 (bases 1 to 1206)

AUTHORS The RIKEN Genome Exploration Research Group Phase II Team and the

JOURNAL FANTOM Consortium.

TITLE Functional annotation of a full-length mouse cDNA collection

MEDLINE Nature 409, 685-690 (2001)

PUBMED 11076861

REFERENCE 5 (bases 1 to 1206)

AUTHORS Adachi,J., Aizawa,K., Akahira,S., Akimura,T., Aono,H., Arai,A.,

Arakawa,T., Carninci,P., Fukuda,S., Fukunishi,Y., Furuno,M.,

Handagaki,T., Hara,A., Hayatsu,N., Hiramoto,K., Hiraoka,T., Hori,F.,

Imotani,K., Ishii,Y., Itoh,M., Izawa,M., Kato,H., Kawai,J.,

Kojima,Y., Konno,H., Kouda,M., Koya,S., Kurihara,C., Matsuyama,T.,

Miyazaki,A., Nishi,K., Nomura,K., Numazaki,R., Ohno,M., Okazaki,Y.,

Okido,T., Owa,C., Saito,H., Saito,R., Sakai,C., Sakai,K., Sano,H.,

Sasaki,D., Shibata,K., Shibata,Y., Shinagawa,A., Shiraki,T.,

Sogabe,Y., Tezuka,H., Tagami,M., Tagawa,A., Takahashi,F.,

Tanaka,T., Taji,Y., Toyota,T., Yamamura,T., Yasunishi,A.,

Yoshida,K., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.

TITLE Direct Submission

JOURNAL Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of

Physical and Chemical Research (RIKEN), Laboratory for Genome

Exploration Research Group, RIKEN Genomic Sciences Center (GSC),

RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,

Kanagawa 230-0045, Japan (E-mail:genome-res@sc.riken.go.jp,

URL:http://genome.gsc.riken.go.jp/, Tel:81-45-503-9222,

Fax:81-45-503-9216)

COMMENT Please visit our web site (http://genome.gsc.riken.go.jp/) for

further details.

cDNA library was prepared and sequenced in Mouse Genome Encyclopedia project of Genome Exploration Research Group in Riken Genomic Sciences Center and Genome Science Laboratory in RIKEN. Division of Experimental Animal Research in Riken contributed to prepare mouse tissues. First strand cDNA was primed with a primer [5', GAGAGAGAGAGATCCAGAGCTCTTTTCTTTTCTTTTNN 3'], cDNA was prepared by using trehalose thermo-activated reverse transcriptase and subsequently enriched for full-length by cap-trapper. cDNA went through one round of normalization to Rot = 7.5 and subtraction to Rot = 37.5. Second strand cDNA was prepared with the primer adapter of sequence [5',

GAGAGAGAGATCTCGAGTTAATTAATATCCCGCCCCCCC 3']. cDNA was cleaved with XhoI and SstI. Cloning sites, 5' end: XhoI; 3' end: SstI.

Host: SOLR.

FEATURES

Location/Qualifiers

1..1206
/organism="Mus musculus"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/db_xref="MGD:MGI:1197519"
/db_xref="MGD:MGI:1902115"
/clone="2610020M23"
/clone.lib="RIKEN full-length enriched mouse cDNA library"
/dev_stage="10 days embryo"

BASE COUNT 265 a 339 c 298 g 301 t 3 others
ORIGIN

alignment_scores:

Quality: 675.50 Length: 196
Ratio: 4.895 Gaps: 2
Percent Similarity: 70.408 Percent Identity: 69.898

alignment_block:

US-09-508-832-4 x AK011490 ..

Align seg 1/1 to: AK011490 from: 1 to: 1206

```

1  MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
|||||
220  ATGCCCAAGCAACCTCTGTAGTACGTTCTGTAGTGACAGCGAAGGTGG 269

17  yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
270  ACAATTGCAGCCTGCTGAGAGGCGTCCCGAGCTCAGGCGCCCTCA 319

34  hrSerLeuGlnThrGluPro..... 40
|||||
320  CTTCCCTACAGACAGAACCGCACAGTAAATCCGACGGGGAGGGACCGTG 369

40  ..... 40
370  CCCCCAGCGAGCCCTCAGGGCCCGCTGGCCCCACCGCCAGCCCTGGCC 419

40  ..... 40
420  CTTTTCCTACAGATCCCGACCTTTTCATCTTTGTGAGAAGATCTCTCG 469

41  ..... Gln AsnArgSerPr 45
470  CTGTCCCGGTCTCCAGTGGGTATTTCTCTTTTGACACAGACAGAGGCC 519

45  oAlaProMetSerCysAspLysSerThrGlnThrProSerProCysG 62
|||||
520  GGCACCCATGAGTGTGTGACAAGTCAACACAAACCCCAAGTCTCTCTGCC 569

62  lnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerGln 78
|||||
570  AGGCGCTCAACCACTATCTCAGTGCATGGCTTCCATACGACAGTCTCAG 619

79  GluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeuAr 95
|||||

```

```

620  GAGGAACCTGAAGATCTGCCCGGAGATACGATTGCACAGGAGCTGGC 669

95  gATgllleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAla 112
|||||
670  GCGGATCGGAGAGGAGCTTCAACGAAACTTACACAGAGGGTCTTTGCAA 719

112  snAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnLeu 128
|||||
720  ATGATTACCGCGAGGCTGAGACACCCCTCAATGGTTATCTTACAACATG 769

129  LeuArgPheIlePheArgLeuValTrpArgArgHis 140
|||||
770  TRACGCTTTATCTTCGCTGCTGATGAGAGGCAT 805

```

seq_name: gb_est2:BG921698

seq_documentation_block:

LOCUS BG921698 935 bp mRNA EST 05-JUN-2001
DEFINITION 602825518F1 NCI_CGAP_Mam6 Mus musculus cDNA clone IMAGE:4954300 5',
mRNA sequence.

ACCESSION BG921698

VERSION BG921698.1 GI:14302174

KEYWORDS EST..

SOURCE house mouse.

ORGANISM Mus musculus

REFERENCE 1 (bases 1 to 935)
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgapbs-r@mail.nih.gov

Tissue Procurement: Jeffrey Green M.D.

cDNA Library Preparation: Life Technologies, Inc.

cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: Incyte Genomics, Inc.

Clone distribution: MGC clone distribution information can be

found through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LLAM10915 Row: c column: 05

High quality sequence start: 3

High quality sequence stop: 786.

Location/Qualifiers

1..935

source
/organism="Mus musculus"

/strain="FVB/N"

/db_xref="taxon:10090"

/clone="IMAGE:4954300"

/clone.lib="NCI_CGAP_Mam6"

/sex="female, virgin"

/tissue_type="infiltrating ductal carcinoma"

/dev_stage="5 months"

/lab_host="DH10B"

/note="Organ: mammary; Vector: PCMV-SPORT6; Site_1: SalI;

Site_2: NotI; Cloned unidirectionally. Primer: Oligo dt.

Library constructed by Life Technologies. Investigator

providing samples: Jeffrey Green, M.D., NIH"

BASE COUNT 203 a 283 c 276 g 173 t

ORIGIN

alignment_scores:

Quality: 583.00 Length: 197
Ratio: 4.225 Gaps: 3
Percent Similarity: 70.051 Percent Identity: 68.528

alignment_block:

US-09-508-832-4 x BG921698 ..

Align seg 1/1 to: BG921698 from: 1 to: 935

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17

```

|||||
208 ATGGCCACGACCTTCTGATTAAGTCTGAGTGTGACAGAGAGGTTGG 257
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
258 ACAATTGACGCTGCTGAGAGGCTCCCGACGCTAGGCTGGGGCCCTA 307
|||||
34 hrSerLeuGlnThrGluPro..Gln..... 41
|||||
308 CCTCCCTACAGACAGACCGCAAGTAATCCCGACGGGAGGGACCGC 357
|||||
41 ..... 41
358 TGCCCCCAGCGCATGCCCTCAGGGCCGCTGCCGCCACCGGCCCGCTG 407
|||||
41 ..... 41
408 GCCCTTTTGTACAGATCCGCCACTTTTCATCTTTGTGAGAAGATCTTC 457
|||||
42 ..... AspArgS 44
|||||
458 TCTGCTGCCCGGTCCTCCAGTGGGTATTTCTTTTGACACAGACAGGA 507
|||||
44 exProAlaProMetSerCysAspLysSerThrGlnThrProSerProPro 60
|||||
508 GCCCGGACCCATGAGTGTGACAGTCAACAAAC.CCAAGTCTCTCT 556
|||||
61 CysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnse 77
|||||
557 TGCCAGGCGCTCAACCACTATCTCAGTCAATGGCTTCCATACGACAGTC 606
|||||
-77 rGlnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluL 94
|||||
607 TCAGAGGAGAACCTGAAGATCTCGCCCGGAGATACGGATTGACAGAGG 656
|||||
94 euArgArgIleGlyAspGluPheAsnGluThrTyrArgArgValPhe 110
|||||
657 TCGGGCGGATCGGACAGGATTCACGAAACTTACAGAGGAGGTGTTT 706
|||||
111 AlaAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuG 127
|||||
707 GCAAAATGATTACCGGAGGCTCAAGA.CACCCTCAAATGGTTATCTTACA 755
|||||
127 n..LeuLeuArgPheIlePheArgLeuValTrpArgArg 139
|||||
756 AACGTGTTACGCTTTATCTTCGCTGTGTATGGGGAAA 794

```

seq_name: gb_est2:BF021882

```

seq_documentation_block: 452 bp mRNA 29-DEC-2000
LOCUS BF021882
DEFINITION uv59b09.y1 McCarrey Eddy round spermatid Mus musculus cDNA clone
IMAGE:3663833 5' similar to TR:054918 O54918 BCL2 INTERACTING
MEDIAN OF CELL DEATH ;, mRNA sequence.
ACCESSION BF021882
VERSION BF021882.1 GI:10753214
KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 452)
Marra.M., Hillier.L., Kucaba.T., Martin.J., Beck.C., Wylie.T.,
Underwood.K., Steptoe.M., Theising.B., Allen.M., Bowers.Y., Person
.B., Swaller.T., Gibbons.M., Pape.D., Harvey.N., Schurk.R., Ritter
.E., Kohn.S., Shin.T., Jackson.Y., Cardenas.M., McCann.R.,
Waterston.R. and Wilson.R.
The WashU-NCI Mouse EST Project 1999
Unpublished (1999)
Contact: Marra M/WashU-NCI Mouse EST Project 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800

```

Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:1424601

Seq primer: Primer name ambiguous
High quality sequence stop: 386.

FEATURES

source
1..452
/organism="Mus musculus"
/db_xref="CD-1"
/strain="CD-1"
/clone="IMAGE:3663833"
/clone_lib="McCarrey Eddy round spermatid"
/sex="male"
/tissue_type="round spermatids, pooled from multiple mice"
/dev_stage="60 day"
/lab_host="DH10B (phage-resistant)"
/note="Organ: testis; Vector: pBluescript SK+ (Stratagene
); Site_1: XhoII; Site_2: EcoRI; cDNA oligo dt-primed
[5'-(GA)10-ACTAGTCTCGAGTTTTTTTTTT-3'] and directionally
cloned using 5' linkers 5'-AATTGGCAGCAG-3' and
5'-CTCGTGGC-3'. Size selection of >400bp material gives
average insert size ranging from 1-2 kb. Library was mass
excised (from lambda-unizap-XR) and resulting
single-stranded phagemids were prepped and transformed
into DH10B. Library contains 98.5% recombinants.
References: J. Androl. 20:635-639 and Gene 25:263-269.
Library constructed and donated by J. McCarrey, Ph.D.
(Southwest Foundation for Biomedical Research, Dept. of
Genetics); excision done by E.M. Eddy, Ph.D. (National
Institutes of Health, National Institute of Environmental
Health Sciences). Original lambda-based library is
available through ATCC, catalog #63423."

BASE COUNT 106 a 130 c 112 g 104 t
ORIGIN

alignment_scores:
Quality: 525.00 Length: 99
Ratio: 5.303 Gaps: 0
Percent Similarity: 100.000 Percent Identity: 100.000
alignment_block:
US-09-508-832-4 x BF021882
Align seg 1/1 to: BF021882 from: 1 to: 452

```

42 AspArgSerProAlaProMetSerCysAspLysSerThrGlnThrProSe 58
|||||
121 GACAGAGCGCGGACCCATGATGTTGTGACAAAGTCAACACAAACCCCAAG 170
|||||
58 rProProcysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleA 75
|||||
171 TCCTCTTCCAGGCGCTTCAACCACTATCTCAGTCAATGGCTTCCATAC 220
|||||
75 rGlnSerGlnGluGluProGluAspLeuArgProGluIleArgIleAla 91
|||||
221 GACAGTCTCAGGAGAACCTGAAGATCTCGCCCGGAGATACGATTGCA 270
|||||
92 GlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrArgAr 108
|||||
271 CAGGAGCTCGCGGATCGGAGACGAGTTCACAGAAACTTACACAGGAG 320
|||||
108 gValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetVal 125
|||||
321 GGTGTTTCAATGATTACCGGAGGCTGAAGACCACCTCAATGGTTA 370
|||||
125 leLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 140
|||||
371 TCTTACAACCTGTTACGCTTTATCTTCGCTGTGTATGGAGAGGCAT 417

```

seq_name: gb_est1:AI971169

```

seq_documentation_block:
LOCUS      AI971169          492 bp      mRNA      EST      08-MAR-2000
DEFINITION wr24h12.x1 NCI_CGAP_Pr28 Homo sapiens cDNA clone IMAGE:2488679 3'
            similar to TR:043522 O43522 BML. [1] ;, mRNA sequence.
ACCESSION  AI971169
VERSION    AI971169.1  GI:5767995
KEYWORDS   EST.
SOURCE     human.
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 492)
AUTHORS   NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
            National Cancer Institute, Cancer Genome Anatomy Project (CGAP).
            Tumor Gene Index
            Unpublished (1997)
JOURNAL   Contact: Robert Strausberg, Ph.D.
COMMENT   Email: cgapbs-re@mail.nih.gov
            Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R.
            Emmert-Buck, M.D., Ph.D.
            cDNA Library Prepared by: M. Bento Soares, Ph.D.
            DNA Sequencing by: Washington University Genome Sequencing Center
            Clone distribution: NCI-CGAP clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            www-bio.llnl.gov/bbrp/image/image.html
            Insert length: 712 Std Error: 0.00
            Seq primer: -40UP from Gibco
            High quality sequence stop: 450.
FEATURES             Location/Qualifiers
     source           1..492
                     /organism="Homo sapiens"
                     /db_xref="taxon:9606"
                     /clone="IMAGE:2488679"
                     /clone_lib="NCI_CGAP_Pr28"
                     /sex="male"
                     /dev_stage="adult"
                     /lab_host="DH10B"
                     /note="Organ: prostate; Vector: pT7T3D-Pac (Pharmacia)
                     with a modified polylinker; Plasmid DNA from the
                     normalized library NCI_CGAP_Pr22 was prepared, and ss
                     circles were made in vitro. Following HAP purification,
                     this DNA was used as tracer in a subtractive hybridization
                     reaction. The driver was PCR-amplified cDNAs from a pool
                     of 5,000 clones made from the same library (clonoids
                     985608-986759, 1101192-1101959, and 1217928-1220615).
                     Subtraction by Bento Soares and M. Fatima Bonaldo."
     BASE COUNT      119 a 107 c 130 g 134 t 2 others
     ORIGIN
alignment_scores:
Quality: 370.00      Length: 74
Ratio: 5.211        Gaps: 0
Percent Similarity: 95.946 Percent Identity: 94.595
alignment_block:
us-09-508-832-4 x AI971169/rev ..
Align seg 1/1 to reverse of: AI971169 from: 1 to: 492
1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
425 ATGGCAAGCAACCTTCTGTAGTAAAGTCTCTGAGTGTGACCGAGAAGGTAG 376
17 YGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
375 ACAATTGCACCTCGCGAGAGGCTCCCCAGCTCAGACCTCGGGGCCCTA 326
34 hrSerLeuGlnThrGluProGlnAspArgSerProAlaPrometSerCys 50
325 CCTCCCTACAGACAGAGCCACAGACAGAGAGCCAGCACCACCATGAGTTGT 276

```

```

51 AspLysSerThrGlnThrProSerProCysGlnAlaPheAsnH1sT 67
|||||
275 GACAAATCAACACAAACNNCAAGTCCCTCTGCCAGGCTTCAACCACTA 226

67 rLeuSerAlaMetAlaSerIle 74
|||||
225 TCTCAGTGCATAGTATCATC 204

seq_name: gb_est2:BG173095

seq_documentation_block:
LOCUS      BG173095          668 bp      mRNA      EST      06-FEB-2001
DEFINITION 602336666F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4459720 5',
            mRNA sequence.
ACCESSION  BG173095
VERSION    BG173095.1  GI:12679707
KEYWORDS   EST.
SOURCE     house mouse.
ORGANISM   Mus musculus
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE  1 (bases 1 to 668)
AUTHORS   NIH-MGC http://mgc.nci.nih.gov/.
            National Institutes of Health, Mammalian Gene Collection (MGC)
            Unpublished (1999)
JOURNAL   Contact: Robert Strausberg, Ph.D.
COMMENT   Email: cgapbs-re@mail.nih.gov
            Tissue Procurement: Gilbert Smith, Ph.D.
            cDNA Library Preparation: Life Technologies, Inc.
            DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
            Clone distribution: MGC clone distribution information can be
            found through the I.M.A.G.E. Consortium/LLNL at:
            http://image.llnl.gov
            Plate: LLAM10260 row: c column: 17
            High quality sequence stop: 599.
FEATURES             Location/Qualifiers
     source           1..668
                     /organism="Mus musculus"
                     /strain="FVB/N"
                     /db_xref="taxon:10090"
                     /clone="IMAGE:4459720"
                     /clone_lib="NCI_CGAP_Mam1"
                     /tissue_type="tumor, biopsy sample"
                     /dev_stage="3 months, virgin"
                     /lab_host="DH10B"
                     /note="Organ: mammary; Vector: pCMV-SPORT6; Site_1: Sali;
                     Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT.
                     Library constructed by Life Technologies. Investigator
                     providing samples: Gilbert Smith, NIH"
     BASE COUNT      135 a 235 c 162 g 136 t
     ORIGIN
alignment_scores:
Quality: 354.00      Length: 148
Ratio: 4.265        Gaps: 3
Percent Similarity: 56.081 Percent Identity: 54.054
alignment_block:
us-09-508-832-4 x BG173095 ..
Align seg 1/1 to: BG173095 from: 1 to: 668
1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
223 ATGGCAAGCAACCTTCTGTAGTAAAGTCTCTGAGTGTGACAGAGAAGGTGG 272
17 YGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
273 ACAATTGCACCTCTGAGAGGCTCCCCAGCTCAGGCTCGGGGCCCTA 322

```

```

34 hrSerLeuGlnThrGluPro..... 40
|||||
323 CCTCCTACAGACGACCGCAAGTAATCCGACGGGGAAGGACCTG 372
40 ..... 40
373 CTGCCCCCAGCGACCCCTCAGGGCCGCTTGCCCCCACCAGCCCTG 422
40 ..... 40
423 GCCCTTTTGCTACAGATCCCCCACTTTTCATCTTTGTGAGAAGATCTTC 472
41 .....GlnAsp 42
473 TCTGCTGCTCCCGGTCCTCCAGTGGGTATATCTCTTTTGACACAGCAC 522
43 ArgSerProAlaProMetSerCysAspLysSerThrGlnThrProSerPr 59
|||||
523 AGGACCCGGCACCACATGAGTGTGCAAGTCAACACAAACCCCAAGTCC 572
59 oProCysGlnAlaPheAsnHisTyrLeuSer.AlaMetAlaSerIleArg 75
|||||
573 TCCTTGCCAGGCGCTTCAACCACTATCTCAGTTGCAATGGCTTTTCATACGA 622
76 GlnSer.GlnGluGluProGluAspLeuArgProGluIle 88
|||||
623 CAGTCTCCAGGAGGAACCTGAGGATCTGCGCCCGGAGATC 662
seq_name: gb_gss:A2706148

```

```

seq_documentation_block: 580 bp DNA 24-JAN-2001
LOCUS- A2706148 GSS
DEFINITION RPCI-23-227P3.TV RPCI-23 Mus musculus genomic clone RPCI-23-227P3,
DNA sequence.
ACCESSION A2706148 GI:12433319
VERSION A2706148.1
KEYWORDS GSS.
SOURCE mouse musculus
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 580)
Zhao,S., Nierman,W., Feldblyum,T., Malek,J., Shatsman,S., Akinret
,B., Levins,M., McGann,S., Tsegaye,G., Geer,K., Kroil,M., de Jong,P.
and Fraser,C.M.
Mouse BAC End Sequences from Library RPCI-23
Unpublished (1999)
Other_GSSs: RPCI-23-227P3.TJ
Contact: Shaying Zhao
Department of Eukaryotic Genomics
The Institute for Genomic Research
9712 Medical Center Dr., Rockville, MD 20850, USA
Tel: 301 838 0200
Fax: 301 838 0208
Email: szhao@tigr.org

```

```

Clones are derived from the mouse BAC library RPCI-23. For BAC
library availability, please contact Pieter de Jong
(pdejong@mail.cho.org). Clones may be purchased from BACPAC
Resources (http://www.choi.org/bacpac/orderingframe.htm). BAC end
page: http://www.tigr.org/tldb/bac_ends/mouse/bac_end_intro.html
Plate: 227 row: P column: 3
Seq primer: T7
Class: BAC ends.

```

```

FEATURES
    source
        1..580
            /organism="Mus musculus"
            /strain="C57BL/6J"
            /db_xref="taxon:10090"
            /clone="RPCI-23-227P3"
            /clone_lib="RPCI-23"
            /sex="Female"
            /lab_host="DH10B"
            /note="Organ: Kidney/Brain; Vector: pBACe3.6; Site_1:

```

```

ECORI; Site_2: EcoRI; Female C57BL/6J mouse kidney and/or
brain genomic DNA was isolated and partially digested
with a combination of EcoRI and EcoRI Methylase. Size
selected DNA was cloned into the pBACe3.6 vector at the
EcoRI sites. The ligation products were transformed into
DH10B electrocompetent cells (BRL Life Technologies).
BASE COUNT 138 a 162 c 138 g 142 t
ORIGIN

```

```

alignment_scores:
    Quality: 347.00 Length: 127
    Ratio: 4.887 Gaps: 1
    Percent Similarity: 55.906 Percent Identity: 55.906
alignment_block:
    US-09-508-832-4 x A2706148 ..
    Align seg 1/1 to: A2706148 from: 1 to: 580
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
90 ATGGCCAAGCAACCTCTCTGATGTAGTTCTGAGTGTGACAGAGAGGTGG 139
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
140 ACAATTGACGCTGCTGAGAGGCTCTCCAGCTCAGGCGCTGGGGCCCTA 189
34 hrSerLeuGlnThrGluProGln..... 41
|||||
190 CCTCCTACAGACAGAACCCCAAGTAATCCCGACGGGGAAGGACCGC 239
41 ..... 41
240 TGGCCCCCAGCGACCCCTCAGGCGCGCTGGCCCCCAGCCGACGAGCCTG 289
41 ..... 41
290 CCCTTTTGCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 339
42 .....AspArgSer 44
340 TGCTGTCCCGGTCCTCCAGTGGGTATTTCTTTTTCACACACAGACGAGC 389
45 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 61
|||||
390 CCGGCACCATGAGTGTGACAGTCAACACAAACCCCAAGTCTCTCTTG 439
61 sGlnAlaPheAsnHisTyrLeuSerAlaMet 71
|||||
440 CCAGGCGCTTCAACCACTATCTCAGTGAATG 470
seq_name: gb_est1:AW629314

```

```

seq_documentation_block:
LOCUS- AW629314 664 bp mRNA EST 31-MAR-2000
DEFINITION h156e02.x1 Soares.NFL.T.GBC.S1 Homo sapiens cDNA clone
IMAGE:2976314 3' similar to TR:043522 043522 BML. [1] ; mRNA
sequence.
ACCESSION AW629314
VERSION AW629314.1 GI:7376104
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 664)
NCI-CCGAP http://www.ncbi.nlm.nih.gov/ncicgap.
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
Tumor Gene Index
Unpublished (1997)
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-re@mail.nih.gov

```

This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -40UP from Gibco
High quality sequence stop: 458.

FEATURES	SOURCE
1. <i>General</i>	
2. <i>Specific</i>	
3. <i>Other</i>	
4. <i>Other</i>	
5. <i>Other</i>	
6. <i>Other</i>	
7. <i>Other</i>	
8. <i>Other</i>	
9. <i>Other</i>	
10. <i>Other</i>	
11. <i>Other</i>	
12. <i>Other</i>	
13. <i>Other</i>	
14. <i>Other</i>	
15. <i>Other</i>	
16. <i>Other</i>	
17. <i>Other</i>	
18. <i>Other</i>	
19. <i>Other</i>	
20. <i>Other</i>	
21. <i>Other</i>	
22. <i>Other</i>	
23. <i>Other</i>	
24. <i>Other</i>	
25. <i>Other</i>	
26. <i>Other</i>	
27. <i>Other</i>	
28. <i>Other</i>	
29. <i>Other</i>	
30. <i>Other</i>	
31. <i>Other</i>	
32. <i>Other</i>	
33. <i>Other</i>	
34. <i>Other</i>	
35. <i>Other</i>	
36. <i>Other</i>	
37. <i>Other</i>	
38. <i>Other</i>	
39. <i>Other</i>	
40. <i>Other</i>	
41. <i>Other</i>	
42. <i>Other</i>	
43. <i>Other</i>	
44. <i>Other</i>	
45. <i>Other</i>	
46. <i>Other</i>	
47. <i>Other</i>	
48. <i>Other</i>	
49. <i>Other</i>	
50. <i>Other</i>	
51. <i>Other</i>	
52. <i>Other</i>	
53. <i>Other</i>	
54. <i>Other</i>	
55. <i>Other</i>	
56. <i>Other</i>	
57. <i>Other</i>	
58. <i>Other</i>	
59. <i>Other</i>	
60. <i>Other</i>	
61. <i>Other</i>	
62. <i>Other</i>	
63. <i>Other</i>	
64. <i>Other</i>	
65. <i>Other</i>	
66. <i>Other</i>	
67. <i>Other</i>	
68. <i>Other</i>	
69. <i>Other</i>	
70. <i>Other</i>	
71. <i>Other</i>	
72. <i>Other</i>	
73. <i>Other</i>	
74. <i>Other</i>	
75. <i>Other</i>	
76. <i>Other</i>	
77. <i>Other</i>	
78. <i>Other</i>	
79. <i>Other</i>	
80. <i>Other</i>	
81. <i>Other</i>	
82. <i>Other</i>	
83. <i>Other</i>	
84. <i>Other</i>	
85. <i>Other</i>	
86. <i>Other</i>	
87. <i>Other</i>	
88. <i>Other</i>	
89. <i>Other</i>	
90. <i>Other</i>	
91. <i>Other</i>	
92. <i>Other</i>	
93. <i>Other</i>	
94. <i>Other</i>	
95. <i>Other</i>	
96. <i>Other</i>	
97. <i>Other</i>	
98. <i>Other</i>	
99. <i>Other</i>	
100. <i>Other</i>	

```
1. .664
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2976314"
/clone_lib="Soares_NFL_T"
/lab host="DH10B"
```

/note="organ: pooled; Vector: pT73D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Equal amounts of plasmid DNA from three normalized libraries (fetal lung NBHL19W, testis NHT, and B-cell NCL-IGAP-GCB1) were mixed, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from pools of 5,000 clones made from the same 3 libraries. The pools consisted of I.M.A.G.E. clones 297480-302087, 682632-687239, 726408-728711, and 729097-731399. Subtraction by Bento

BASE COUNT	176 a	131 c	148 g	208 t	1 others
ORIGIN					

alignment_scores:		
Quality:	287.00	Length: 69
Ratio:	4.864	Gaps: 0
Percent Similarity:	85.507	Percent Identity: 78.261

alignment_block:
US-09*508-832-4 x AW629314/rev

Align seg 1/1 to reverse of: AW629314 from: 1 to: 664

3 LysGlnProSerAspValSerSerGluCysAspArgGluGlyGlyGlnLe 19
 . ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| :
 664 AAGCCACCTTTTATGAAGAAGTTTTAGTGTCGCCNGAGAAGGTAGACAAAT 615

[illegible]

36 euGlnThrGluProGlnAspArgSerProAlaProMetSerCysAspLys 52
:::|||||
564 ACAAGCAGAGCCACCAAGACAGGAGCCAGCACCCATGAGTTGTGACAAA 515

53 SerThrGlnThrProSerProCysGlnAlaPheAsnHisTyrLeuSe 69
|||||
514 TCAACACAAACCCCAAGTCCTCCTGCCAGGCCTTCAACCACTATCTCAG 465

69 rAlamet 71
|::|||
464 TGTAAATG 458

seq_name: qb_est2:BF319454

seq_documentation_block:			
LOCUS	BF319454	389 bp	EST
DEFINITION	uy59b09.x1 McCarrey Eddy round spermatid Mus musculus cDNA clone IMAGE:3663833 3' similar to TR:054918 O54918 BC12 INTERACTING MEDIATOR OF CELL DEATH ;, mRNA sequence.		

ACCESSION	BF319454
VERSION	BF319454.1
	GI:11268195

KEYWORDS EST.
SOURCE house mouse.
ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus
1 (bases 1 to 389)
REFERENCE
AUTHORS
Marra M., Hillier L., Kucaba T., Martin J., Beck C., Wylie T.

Underwood, K., Steptoe, M., Theising, B., Allen, M., Bowers, Y., Person, B., Swaller, T., Gibbons, M., Pape, D., Harvey, N., Schurk, R., Ritter, E., Kohn, S., Shin, T., Jackson, Y., Cardenas, M., McCann, R., Weston, R., and Willson, R.

TITLE	JOURNAL	COMMENT
1. The Role of the Teacher in the Classroom	Journal of Educational Research	1980, Vol. 83, No. 1, pp. 1-10
2. The Impact of Technology on Education	Journal of Educational Technology	1981, Vol. 5, No. 2, pp. 11-20
3. The Importance of Parental Involvement	Journal of Educational Psychology	1982, Vol. 74, No. 3, pp. 21-30
4. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	1983, Vol. 86, No. 4, pp. 31-40
5. The Role of the School in the Community	Journal of Educational Research	1984, Vol. 87, No. 5, pp. 41-50
6. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	1985, Vol. 88, No. 6, pp. 51-60
7. The Role of the Teacher in the Classroom	Journal of Educational Research	1986, Vol. 89, No. 7, pp. 61-70
8. The Impact of Technology on Education	Journal of Educational Technology	1987, Vol. 11, No. 3, pp. 71-80
9. The Importance of Parental Involvement	Journal of Educational Psychology	1988, Vol. 80, No. 4, pp. 81-90
10. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	1989, Vol. 92, No. 5, pp. 91-100
11. The Role of the School in the Community	Journal of Educational Research	1990, Vol. 93, No. 6, pp. 101-110
12. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	1991, Vol. 94, No. 7, pp. 111-120
13. The Role of the Teacher in the Classroom	Journal of Educational Research	1992, Vol. 95, No. 8, pp. 121-130
14. The Impact of Technology on Education	Journal of Educational Technology	1993, Vol. 17, No. 4, pp. 151-160
15. The Importance of Parental Involvement	Journal of Educational Psychology	1994, Vol. 86, No. 5, pp. 161-170
16. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	1995, Vol. 98, No. 6, pp. 171-180
17. The Role of the School in the Community	Journal of Educational Research	1996, Vol. 99, No. 7, pp. 181-190
18. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	1997, Vol. 100, No. 8, pp. 191-200
19. The Role of the Teacher in the Classroom	Journal of Educational Research	1998, Vol. 101, No. 9, pp. 201-210
20. The Impact of Technology on Education	Journal of Educational Technology	1999, Vol. 23, No. 5, pp. 211-220
21. The Importance of Parental Involvement	Journal of Educational Psychology	2000, Vol. 92, No. 6, pp. 221-230
22. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2001, Vol. 104, No. 7, pp. 231-240
23. The Role of the School in the Community	Journal of Educational Research	2002, Vol. 105, No. 8, pp. 241-250
24. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2003, Vol. 106, No. 9, pp. 251-260
25. The Role of the Teacher in the Classroom	Journal of Educational Research	2004, Vol. 107, No. 10, pp. 261-270
26. The Impact of Technology on Education	Journal of Educational Technology	2005, Vol. 29, No. 6, pp. 271-280
27. The Importance of Parental Involvement	Journal of Educational Psychology	2006, Vol. 98, No. 7, pp. 281-290
28. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2007, Vol. 110, No. 8, pp. 291-300
29. The Role of the School in the Community	Journal of Educational Research	2008, Vol. 111, No. 9, pp. 301-310
30. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2009, Vol. 112, No. 10, pp. 311-320
31. The Role of the Teacher in the Classroom	Journal of Educational Research	2010, Vol. 113, No. 11, pp. 321-330
32. The Impact of Technology on Education	Journal of Educational Technology	2011, Vol. 35, No. 7, pp. 331-340
33. The Importance of Parental Involvement	Journal of Educational Psychology	2012, Vol. 104, No. 8, pp. 341-350
34. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2013, Vol. 116, No. 9, pp. 351-360
35. The Role of the School in the Community	Journal of Educational Research	2014, Vol. 117, No. 10, pp. 361-370
36. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2015, Vol. 118, No. 11, pp. 371-380
37. The Role of the Teacher in the Classroom	Journal of Educational Research	2016, Vol. 119, No. 12, pp. 381-390
38. The Impact of Technology on Education	Journal of Educational Technology	2017, Vol. 41, No. 8, pp. 391-400
39. The Importance of Parental Involvement	Journal of Educational Psychology	2018, Vol. 110, No. 9, pp. 401-410
40. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2019, Vol. 122, No. 10, pp. 411-420
41. The Role of the School in the Community	Journal of Educational Research	2020, Vol. 123, No. 11, pp. 421-430
42. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2021, Vol. 124, No. 12, pp. 431-440
43. The Role of the Teacher in the Classroom	Journal of Educational Research	2022, Vol. 125, No. 1, pp. 441-450
44. The Impact of Technology on Education	Journal of Educational Technology	2023, Vol. 47, No. 1, pp. 451-460
45. The Importance of Parental Involvement	Journal of Educational Psychology	2024, Vol. 116, No. 2, pp. 461-470
46. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2025, Vol. 128, No. 3, pp. 471-480
47. The Role of the School in the Community	Journal of Educational Research	2026, Vol. 129, No. 4, pp. 481-490
48. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2027, Vol. 130, No. 5, pp. 491-500
49. The Role of the Teacher in the Classroom	Journal of Educational Research	2028, Vol. 131, No. 6, pp. 501-510
50. The Impact of Technology on Education	Journal of Educational Technology	2029, Vol. 51, No. 7, pp. 511-520
51. The Importance of Parental Involvement	Journal of Educational Psychology	2030, Vol. 122, No. 8, pp. 521-530
52. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2031, Vol. 134, No. 9, pp. 531-540
53. The Role of the School in the Community	Journal of Educational Research	2032, Vol. 135, No. 10, pp. 541-550
54. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2033, Vol. 136, No. 11, pp. 551-560
55. The Role of the Teacher in the Classroom	Journal of Educational Research	2034, Vol. 137, No. 12, pp. 561-570
56. The Impact of Technology on Education	Journal of Educational Technology	2035, Vol. 53, No. 1, pp. 571-580
57. The Importance of Parental Involvement	Journal of Educational Psychology	2036, Vol. 128, No. 2, pp. 581-590
58. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	2037, Vol. 140, No. 3, pp. 591-600
59. The Role of the School in the Community	Journal of Educational Research	2038, Vol. 141, No. 4, pp. 601-610
60. The Impact of Teacher Education on Student Achievement	Journal of Educational Research	2039, Vol. 142, No. 5, pp. 611-620
61. The Role of the Teacher in the Classroom	Journal of Educational Research	2040, Vol. 143, No. 6, pp. 621-630
62. The Impact of Technology on Education		

Other_ESTS: uy59b09.y1
Contact: Marra M/WashU-NCI Mouse EST Project 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LINL
IMAGE Consortium (info@image.llnl.gov) for further
MGI:14242601

FEATURES

source

```

Location/Qualifiers
1. .389
/organism="Mus musculus"
/strain="CD-1"
/db_xref="taxon:10090"
/clone="IMAGE:3663833"
/clone_lib="McCarrey Edd
/sex="male"

```

/sex = male
/tissue_type = "round spermatsids, pooled from multiple mice"
/dev_stage = "60 day"
/lab_host = "DH10B (phage-resistant)"
/note = "organ: testis; Vector: pBluescript SK+ (Stratagene)"
); Site_1: XhoII; Site_2: EcoRI; cdna oligo dt-primed
[5'-(GAY)10-ACTAGTCTCGAGTGGTTTTTTTT-3'] and directionall
cloned using 5' linkers 5'-AATTCGACGACGAG-3' and
5'-CTCTGCGCG-3'. Size selection of >400bp material gives
average insert size ranging from 1-2 kb. Library was mass
excised (from lambda-unizap-XR) and resulting
single-stranded phagemids were prepped and transformed
into DH10B. Library contains 98.5% recombinants.
References: J. Androl. 20:635-639 and Gene 25:263-269.
Library constructed and donated by J. McCarrey, Ph.D.
(Southwest Foundation for Biomedical Research, Dept. of
Genetics); excision done by E.M. Eddy, Ph.D. (National
Institutes of Health, National Institute of Environmental
Health Sciences). Original lambda-based library is
available through ATCC, catalog #63423."

104 c 89 g 96 t

```
alignment_scores:
```

Quality:	249.00	Length:	53
Ratio:	4.882	Gaps:	1
Percent Similarity:	96.226	Percent Identity:	94.340

alignment_block:

US-09-508-832-4 x BF319454/rev

Align seg 1/1 to reverse of: BF319454 from: 1 to: 389

```

89 ArgIleAlaGlnGluLeuArgArgIleGly AspGluPheAsnGluThrT 105
   :::::|||||
389 CGATTTCACAGGAACCTCGGGGGATCGAGACGAGTTCAACAGAAACTT 340
   |||||
105 YrTrArqAcqValPheAlaAsnAspTyrArqGluAlaGluAspHisPro 121
   |||||
339 ACACAGGAGGGTGTTCCAAATGATTACC GGAGGCTCAGACCACCCCT 290
   |||||
122 GlnMetValIleLeuGlnLeuLeuArgPheIlePheArgLeuValTrpAr 138
   |||||
289 CAAATGGTTATCTTAACAACCTGTACGCCTTATCTCCGCTCGTATGGAG 240
   |||||
138 gArgHis 140
239 AAGGCAT 233

```


seq_name: gb_est1:AA629308

seq_documentation_block: 501 bp mRNA EST 16-OCT-1997
 LOCUS AA629308
 DEFINITION zu84q06.s1 Soares_testis_NHT Homo sapiens cDNA clone IMAGE:744730
 3', mRNA sequence.

ACCESSION AA629308
 VERSION AA629308.1 GI:2541695
 KEYWORDS EST.
 SOURCE human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS 1 (bases 1 to 501)
 Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
 Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin
 J., Moore, B., Schellenger, K., Steptoe, M., Tan, F., Theising, B.,
 White, Y., Wylie, T., Waterston, R. and Wilson, R.

TITLE

WashU-NCI human EST Project

JOURNAL

Unpublished (1997)

COMMENT

Contact: wilson rk
 Washington University School of Medicine
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
 Tel: 314 286 1800
 Fax: 314 286 1810
 Email: est@watson.wustl.edu

This clone is available royalty-free through LLNL; contact the
 IMAGE Consortium (info@image.llnl.gov) for further information.

Seq primer: -40m13 fwd. ET from Amersham

High quality sequence stop: 471.

FEATURES

source

1..501

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:744730"

/clone_lib="Soares_testis_NHT"

/sex="male"

/lab_host="DH10B"

/note="Vector: pT73D-Pac (Pharmacia) with a modified
 polylinker. Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
 was prepared from mRNA obtained from Clontech Laboratories
 , inc., and primed with a Not I - oligo(dT) primer [5',
 TGTTACCAATGAAGTGGAGCGGCCCAATTTTTTTTTTTTTTTT 3'].

Double-stranded cDNA was ligated to Eco RI adaptors
 (Pharmacia), digested with Not I and cloned into the Not I
 and Eco RI sites of the modified pT73 vector. Library
 went through one round of normalization to Cot5, and was
 constructed by Bento Soares and M. Fatima Bonaldo."

155 a 112 c 97 g 137 t

BASE COUNT

ORIGIN

alignment_scores:

Quality: 127.00 Length: 32
 Ratio: 4.536 Gaps: 0
 Percent Similarity: 87.500 Percent Identity: 71.875

alignment_block:

US-09-508-832-4 x AA629308/rev ..

Align seg 1/1 to reverse of: AA629308 from: 1 to: 501

109 ValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetVal11 125

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

501 GTATTTTTCATAATACCAACAGCCGAGACACACACAGATGGTTAT 452

125 eLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 140

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

451 CTTACGACTGTTTACCTTACATTTGTCGGCTGGTGGAGATGCAT 406

seq_name: gb_est2:BF172831

seq_documentation_block:

LOCUS BF172831 210 bp mRNA EST 23-MAR-2001
 DEFINITION PCL5805 Myeloma (PCL) cDNA library Homo sapiens cDNA, mRNA
 sequence.

ACCESSION BF172831

VERSION BF172831.1 GI:13439045

KEYWORDS EST.

SOURCE human.

ORGANISM

Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE

AUTHORS 1 (bases 1 to 210)

Claudio, O.O., Tang, H., Khan, E.M., Voralia, M., Li, Z., Cukerman, E.,

Francisco-Pabalan, O., Liew, C.C. and Stewart, A.K.

The transcriptional phenotype of myeloma cells

Unpublished (2000)

Contact: A. Keith Stewart, M.D.

Oncology Research

University Health Network

610 University Ave., 5-126, Toronto, Ontario, M5G 2M9, Canada

Tel: (416) 946-4639

Fax: (416) 946-6546

Email: k.stewart@utoronto.ca

PCR Primers

FORWARD: 5'-GCCAAGCTCGAATTAACCTCCTACTAAAGG-3'

BACKWARD: 5'-CCAGTGAATTTAATACGACTCTACTATAGGCG-3'

Seq primer: 5'-GAAATTAACCTCCTACTAAAGG-3'.

Location/Qualifiers

1..210

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone_lib="Myeloma (PCL) cDNA library"

/sex="male"

/tissue_type="Blood"

/cell_type="myeloma"

/dev_stage="Plasma cell leukemia"

/note="Vector: Lambda Zap Express; Site_1: EcoRI; Site_2:

XhoI; mRNA was purified from plasma cell leukemia

patient's peripheral blood containing >95% myeloma. An

oligo d(T)18 primer containing XhoI restriction site was

used to prime first strand synthesis using M-MLV reverse

transcriptase. To protect the cDNAs from XhoI digestion in

subsequent cloning step, the nucleotide analogue

5-methyl-dCTP was added to the nucleotide mixture and

la-32P[dATP was added to monitor the quantity and quality

of first strand synthesis. After second-strand synthesis

and blunting of cDNA termini, EcoRI adapters were ligated

, followed by kinase treatment and digestion with XhoI.

The cDNAs were then size-fractionated using Sephacryl

S-500 column and then ligated into EcoRI and XhoI digested

Lambda Zap Express vector. The ligation product was

packaged using Gigapack II packaging extract. The library

had primary titre of approx. 1x10⁶. Clones from the

primary library were randomly selected for single pass

sequencing."

BASE COUNT 49 a 40 c 57 g 59 t 5 others

ORIGIN

alignment_scores:

Quality: 126.00 Length: 39
 Ratio: 3.818 Gaps: 2
 Percent Similarity: 84.615 Percent Identity: 76.923

alignment_block:

US-09-508-832-4 x BF172831 ..

Align seg 1/1 to: BF172831 from: 1 to: 210

72 AlaSerIleArgGlnSerGlnGluProGluAspLeuArgProGlu11 88

||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

95 GCTTCATGAGGAGTCT.....GAACCTGCAGATATGCGCCAGAGAT 138


```

seq_name: gb_est2:BG412166

seq_documentation_block:
LOCUS      BG412166          519 bp      mRNA          13-MAR-2001
DEFINITION OX2_38_F11.b1_A002 Ovary 2 (OV2) Sorghum bicolor cDNA, mRNA
ACCESSION  BG412166
VERSION    .
KEYWORDS   EST.
SOURCE     BG412166.1  GI:13317719
            sorghum.
ORGANISM   Sorghum bicolor
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACC
            clade; Panicoideae; Andropogoneae; Sorghum.
REFERENCE  1 (bases 1 to 519)
            Cordonnier-Pratt,M.-M., Gingle,A., Marsala,C., Sudman,M. and Pratt
            ,L.H.
TITLE      An EST database from Sorghum: ovaries of varying immature stages
JOURNAL    Unpublished (2000)
COMMENT    Contact: Cordonnier-Pratt MM
            Department of Botany
            The University of Georgia
            Plant Sciences Building, Rm. 2502, Athens, GA 30602-7271, USA
            Tel: 706 542 1860
            Fax: 706 542 1805
            Email: mmpratt@uga.edu

```

email: mmpratt@uga.edu
Seq primer: JEN REV
High quality sequence stop: 517
POLYA-No.

FEATURES

Location/Qualifiers	source
1..519	
/organism="Sorghum bicolor"	
/db_xref="taxon:4558"	
/clone_lib="Ovary 2 (OV2)"	
/note="Organ: Mix of ovaries of varying immature stages from 8-week-old plants; Vector: pBluescript II from Lambda"	

BASE COUNT	ORIGIN	
95 a	178 c	84 t

Notes: Organ: Mix of ovaries of varying immature stages from 8-week-old plants; Vector: pBluescript II from Lambda zap II; Site_1: XhoI; Site_2: EcoRI; The library was made from poly-A RNA in the cloning vector lambda zap II. Clones to be sequenced were prepared by mass excision.

```

alignment_scores:      Length: 99
                        Quality: 98.00
                        Ratio: 1.815
                        Gaps: 5
                        Percent Similarity: 54.545
                        Percent Identity: 34.343

```

```

alignment_block:
US-09-508-832-4 x BG412166  ..
Align seg 1/1 to: BG412166 from: 1 to: 519

2 AlaLysGlnProSerAspValSerSerGluCysAspArgGlu..... 15
  :::::::::::::: :::::::::::::::
48 TCGAAACAGCCGCCCT.....GGTCGGAATGTCTAGAGCCTCCGGCC 91

16 .....GlyGlyGlnLeuGlnProAlaGlu..ArgProGlnLeuArg 29
  :::: :::: :::: :::: ::::
92 GGGCCTAGGGTTCCCGATGGGCGCCGAGGAGCGGCGCTGCTGGAGA 141

30 Pro...GlyAlaProThrSerLeuGlnThrGluProGlnAspArgSerPr 45
  ||| |||::: |||::: ::::: |||::: |||
142 CCACTGGGAACCTCCACGACAAGTTCAGCGACGCCATCCACGCCCTCTCC 191

45 oAlaPrometSerCysAspLysSerThrGlnThrPro.....S 58
  ||||| ||||| ||||| |||||
192 CGGGCCCACTTCTCTGGCGCCGTCCGGCGCGCGCCTCCCGCGCGGACAA 241

58 erProProCysGlnAlaPheAAsnHisTyrLeuSerAlaMetAlaSerIle 74
  ||||| ||||| ::::: |||||
242 GCCGCGCGCGGCGCTCGTGTACGTCAAGGCGGGGGTCTGGCGCTCGGCG 291

```


THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

OM of: US-09-508-832-6 to: GenEmbl:* out_format : pfs
Date: Dec 11, 2001 1:45 AM
About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:
-MODEL=framer_p2n.model -DEV=xlpl
-O=/cgn2.1/USPTO_spool/US09508833/runat_10122001_110349_29549/app_query.fasta_1.620
-DB=GenEmbl -QFMT=fastap -SUFFIX=rge -GAPOP=12.000 -CAPEXT=4.000
-MINMATCH=0.100 -LOOPCL=0.000 -LOOPEXT=0.000 -OGAPOP=4.500
-OGAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FGAPEXT=7.000 -YGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blosum62 -TRANS=human40.cdi
-LIST=45 -DLOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-MAXLEN=200000000 -USER=US09508832_@CWL_1_0 -NCPU=6 -ICPU=3
-LONGLOG -NO_XLPXY -WAIT -THREADS=1

Search information block:
Query: US-09-508-832-6
Query length: 196
Database: GenEmbl:*
Database sequences: 1472140
Database length: -341344837
Search time (sec): 2485.920000

score_list:

Sequence	Strd Orig	zScore	EScore	Len	Documentation
gb_pat:AX031283	+ 1046.00	1072.64	1.8e-51	590	AX031283 Sequence 5 from Patent
gb_un:AX031309	+ 1046.00	1072.64	1.8e-51	590	AX031309 Sequence 5 from Patent
gb_ro:AF065433	+ 1031.00	1057.44	1.3e-50	591	AF065433 Rattus norvegicus Bcl
gb_pat:AX031287	+ 908.00	932.83	1.1e-43	596	AX031287 Sequence 9 from Patent
gb_un:AX031313	+ 908.00	932.83	1.1e-43	596	AX031313 Sequence 9 from Patent
gb_pr:AF032457	+ 908.00	932.82	1.1e-43	597	AF032457 Homo sapiens BimEL mRN
gb_pat:AX031281	+ 704.00	728.38	2.7e-32	422	AX031281 Sequence 3 from Patent
gb_un:AX031307	+ 704.00	728.38	2.7e-32	422	AX031307 Sequence 3 from Patent
gb_to:AF136927	+ 689.00	713.18	1.9e-31	423	AF136927 Rattus norvegicus Bcl
gb_btg:AC013332	+ 656.00	642.39	1.7e-27	180569	AC013332 Homo sapiens chrom
gb_pat:AX031285	+ 591.00	614.04	6.3e-26	416	AX031285 Sequence 7 from Patent
gb_un:AX031311	+ 591.00	614.04	6.3e-26	416	AX031311 Sequence 7 from Patent
gb_pr:AF032458	+ 591.00	614.03	6.3e-26	417	AF032458 Homo sapiens BimL mRN
gb_btg:AC013279	+ 521.00	544.55	4.7e-22	332	AX031279 Sequence 1 from Patent
gb_un:AX031305	+ 521.00	544.55	4.7e-22	332	AX031305 Sequence 1 from Patent
gb_to:AF032461	+ 521.00	544.53	4.7e-22	333	AF032461 Mus musculus BimS mRN
gb_ro:AF065432	+ 503.00	526.30	4.9e-21	333	AF065432 Rattus norvegicus Bcl
gb_btg:AC013331	+ 488.00	512.14	3.0e-20	282	AF065431 Rattus norvegicus Bcl
gb_btg:AC013332	+ 137.00	116.83	3.13-12	180569	AC013332 Homo sapiens chrom
gb_btg:AC046192	+ 132.00	112.91	5.17-68	150035	AC046192 Homo sapiens chrom
gb_btg:AC046192	+ 128.00	108.86	870.33	150035	AC046192 Homo sapiens chrom
gb_pat:AX167575	+ 123.50	129.68	60.23	2454	AX167575 Sequence 75 from Pat
gb_pr:AC010519	+ 123.50	111.50	620.37	46740	AC010519 Homo sapiens chrom
gb_btg:AC024055	+ 123.50	103.40	1.8e+03	173690	AC024055 Homo sapiens chrom
gb_btg:AC093324	+ 123.50	102.71	1.9e+03	194241	AC093324 Homo sapiens chrom
gb_ba:SCBA1A6	+ 122.50	110.64	692.62	45590	AL589708 Streptomyces coelic
gb_pr:U82668	+ 120.50	104.76	1.5e+03	85132	U82668 Homo sapiens shox gene
gb_ba:SCBA6	+ 119.00	109.32	820.08	37445	AL031013 Streptomyces coelic
gb_btg:AC020922	+ 119.00	100.41	2.6e+03	134693	AC020922 Homo sapiens chrom
gb_ba:SCH10	+ 118.50	124.74	1.13-47	2405	AK027614 Homo sapiens cDNA FL
gb_btg:AC020922	+ 117.50	119.71	216.42	4615	L22864 Streptomyces aureofaci
gb_pr:AC005095	+ 117.50	99.60	2.9e+03	119397	AC005095 Homo sapiens BAC cl
gb_btg:AC027602	+ 117.00	95.43	4.9e+03	217346	AC027602 Homo sapiens chrom
gb_btg:AC040922	+ 116.50	96.11	4.5e+03	179372	AC040922 Homo sapiens chrom
gb_ba:AB044076	+ 116.00	117.82	275.56	4896	AB044076 Myxococcus xanthus mc
gb_om:RABCCB111	+ 116.00	115.02	394.85	7713	D14157 Rabbit mRNA for rabbit
gb_btg:AC019122	+ 116.00	94.70	5.3e+03	207636	AC019122 Homo sapiens chrom
gb_pr:AC008403	+ 115.50	94.74	5.3e+03	190075	AC008403 Homo sapiens chrom

gb_pr:AF283769 + 114.50 121.97 161.92 1955 ! AF283769 Homo sapiens clone
gb_pr:HSMB01714 - 114.50 120.89 185.98 2329 ! AL136746 Homo sapiens mRNA;
gb_pr:AF220542 - 114.50 109.23 829.49 15405 ! AF220542 Homo sapiens FCN
gb_pr:AP002815 + 114.50 94.25 5.7e+03 174484 ! AP002815 Homo sapiens gen

seq_name: gb_pat:AX031283

seq_documentation_block:
LOCUS AX031283 590 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 5 from Patent WO9914321.

ACCESSION AX031283

VERSION AX031283.1 GI:10278614

KEYWORDS unidentifed.

SOURCE unidentifed.

ORGANISM unclassified.

REFERENCE 1 (bases 1 to 590)

AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,

Huang,D.C. and Strasser,A.

TITLE Novel therapeutic molecules

JOURNAL INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY

LORRRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY

SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

FEATURES Location/Qualifiers

Source 1..590

1..>587

/db_xref="taxon:32644"

/note="unnamed protein product"

/codon_start=1

/protein_id="CAC09655.1"

/db_xref="GI:10278615"

/translat="MAKOPSDVSDECDREGQLOQAPRRPQLRGAPTSLOTEPOGNP

DGEDRCPHSGPOGPPAPSPGPEATRSPLFIEVRESSLISRSSSCYFSDRDRSPA

YMSCDSTQTPSPPCQAFNHLYLMMASIROSEPEDLRFEIRIAQLRIGDFNET

PMRVRVANDREDDHPHVLQQLRFLRFLVRRR"

BASE COUNT 137 a 178 c 150 g 125 t

ORIGIN

alignment_scores:

Quality: 1046.00 Length: 196

Ratio: 5.337 Gaps: 0

Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-6 x AX031283 ..

Align seg 1/1 to: AX031283 from: 1 to: 590

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17

1 ATGGCCAGCAACACCTTCGTGATGTAAGTCTGAGTGTGACAGAGAGGTGG 50

17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34

51 ACAATTGCAGCTGTGTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTTA 100

34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50

101 COTCCTCAGACAGAACCGCAAGGTAATCCGCGGCGGGAAGGGACCGC 150

51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67

151 TCCCTCCCGCGGAGGCTCAGGCGGCTGCGCCCGCCCGCCCGCCCGCTGG 200

67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84

201 CCGTTTGTCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 250

84 euLeuSerArgSerSerSerGlyTyTyPheSerPheAspThrAspArgSer 100

```

251 TGCTGTCCTCCGCTCTCCAGTGGGTATTTCTCTTTTGACACAGACGAGC 300
101 ProLaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
    CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 350
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
351 CCAGGCGCTTCAACACCATATCTCAGTGCATAGGCTTCCATACGACAGTCTC 400
134 lnGluLupProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
401 AGGAGGAACCTGAAGATCTCGCCCGGAGATACGGATTGCACAGGAGCTG 450
151 ArgArgIleGlyAspGluPheAsnGluThrTyrArgArgValPheAl 167
451 CGCGGATCGGAGAGGAGTTCACGAAACCTACACAGAGGAGGTGTTGC 500
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
501 AAATGATTACCGGAGGCTGAAGACCAACCTCAATGGTTATCTTACAC 550
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
551 TGTACCTTTACTTCCGCTCTCGTGTGATGGAGAGGCAT 588

```

seq_name: gb_un:AX031309

```

seq_documentation_block:
LOCUS AX031309 590 bp DNA UNA 20-SEP-2000
DEFINITION Sequence 5 from Patent WO9914321.
ACCESSION AX031309
VERSION AX031309.1 GI:10278637
KEYWORDS
SOURCE
ORGANISM
unidentified.
unclassified.
REFERENCE
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
TITLE Novel therapeutic molecules
JOURNAL INST MEDICAL W & E HALLS (AU); PUTHALAKATH HANSA (AU); REILLY
LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
FEATURES
Location/Qualifiers
1..590
/organism="unidentified"
/db_xref="taxon:32644"
CDS
1..>587
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09660.1"
/db_xref="GI:10278638"
/translation="MAKOPSDVSECDREGGLOPAERPPOLRPGAPTSLQTEPQGNP
DGEDRCPHGPSQGLAPSPGFPATRPPLFIVRRSSLSRSSGFSFDTDRSPA
PYMCDKSTQTPSPQAFNHYLSAMASIQSEEPEDLRPEIRIAQLERRIGDEFNET
YRRVFANDYREADHPQWILQLRIFRLVWRR"
BASE COUNT 137 a 178 c 150 g 125 t
ORIGIN

```

alignment_scores:
 Quality: 1046.00 Length: 196
 Ratio: 5.337 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-6 x AX031309 ..

Align seq 1/1 to: AX031309 from: 1 to: 590

1 MetAlaLysGlnProSerAspValSerSerGluCysArgGluGlyG1 17

```

1 ATGCCCAAGCAACCTTCTGATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 YGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
    CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 100
51 ACAATTGCACCTGCTGAGAGGCTCTCCCAAGTCAAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
    CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 150
101 CCTCCCTACAGACAGAACCGCAAGGTAATCCCGAGCGCGGAAGGGACCGC 150
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
    TGGCCCGACCGGAGCTCTCAGGCGCCGCTGGCCCAACCCGCGCAGCCCTGG 200
151 TGGCCCGACCGGAGCTCTCAGGCGCCGCTGGCCCAACCCGCGCAGCCCTGG 200
67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
    CCCTTTTGTCTACAGATCCCACTTTTTCATCTTTGTGAGAAGATCTTCTC 250
201 CCCTTTTGTCTACAGATCCCACTTTTTCATCTTTGTGAGAAGATCTTCTC 250
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
    TGCTGTCCCGGCTCTCCAGTGGGTATTTCTCTTTTGACACAGACAGGAGC 300
251 TGCTGTCCCGGCTCTCCAGTGGGTATTTCTCTTTTGACACAGACAGGAGC 300
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
    CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 350
301 CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 350
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
    CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 400
351 CCGGACCCCATGAGTTGTGACAAAGTCAACACAAACCCCAAGTCTCTCTG 400
134 lnGluLupProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
    AGGAGGAACCTGAAGATCTCGCCCGGAGATACGGATTGCACAGGAGCTG 450
401 AGGAGGAACCTGAAGATCTCGCCCGGAGATACGGATTGCACAGGAGCTG 450
151 ArgArgIleGlyAspGluPheAsnGluThrTyrArgArgValPheAl 167
    CGCGGATCGGAGAGGAGTTCACGAAACCTACACAGAGGAGGTGTTGC 500
451 CGCGGATCGGAGAGGAGTTCACGAAACCTACACAGAGGAGGTGTTGC 500
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
    AAATGATTACCGGAGGCTGAAGACCAACCTCAATGGTTATCTTACAC 550
501 AAATGATTACCGGAGGCTGAAGACCAACCTCAATGGTTATCTTACAC 550
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
    TGTACCTTTACTTCCGCTCTCGTGTGATGGAGAGGCAT 588
551 TGTACCTTTACTTCCGCTCTCGTGTGATGGAGAGGCAT 588

```

seq_name: gb_ro:AF032459

seq_documentation_block:

```

LOCUS AF032459 591 bp mRNA ROD 19-FEB-1998
DEFINITION Mus musculus BimEL mRNA, complete cds.
ACCESSION AF032459
VERSION AF032459.1 GI:2895499
KEYWORDS
SOURCE house mouse.
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.

```

1 (bases 1 to 591)

O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,

Cory,S. and Huang,D.C.

Bim: a novel member of the Bcl-2 family that promotes apoptosis

EMBO J. 17 (2), 384-395 (1998)

98094360

9430630

2 (bases 1 to 591)

O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,

Cory,S. and Huang,D.C.S.

Direct Submission

Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &

Eliza Hall Institute of Medical Research, PO Royal Melbourne

Hospital, Parkville, Victoria 3050, Australia

TITLE

JOURNAL

551 TGTACGCTTTATCTTCCTGCTGATGGAGAGCAT 588
 seq_name: gb_ro:AF065433
 seq_documentation_block: 591 bp mRNA ROD 11-MAR-1999
 LOCUS AF065433 Rattus norvegicus Bcl-2 related ovarian death gene product BOD-L
 DEFINITION mRNA, complete cds.
 ACCESSION AF065433 GI:3228569
 VERSION AF065433.1
 KEYWORDS Norway rat.
 SOURCE Rattus norvegicus
 ORGANISM Rattus norvegicus
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
 Rattus.
 REFERENCE 1 (bases 1 to 591)
 AUTHORS Hsu,S.Y., Lin,P. and Hsueh,A.J.
 TITLE BOD (Bcl-2-related ovarian death gene) is an ovarian BH3
 domain-containing proapoptotic Bcl-2 protein capable of
 dimerization with diverse antiapoptotic Bcl-2 members
 JOURNAL Mol. Endocrinol. 12 (9), 1432-1440 (1998)
 MEDLINE 98400436
 REFERENCE 2 (bases 1 to 591)
 AUTHORS Hsu,S.Y. and Hsueh,A.J.W.
 TITLE Direct Submission
 JOURNAL Submitted (15-MAY-1998) GYN/OB, Stanford University, MSOB S385,
 Stanford, CA 94305, USA
 FEATURES
 source
 1..591
 /organism="Rattus norvegicus"
 /db_xref="taxon:10116"
 CDS
 1..591
 /codon_start=1
 /product="Bcl-2 related ovarian death gene product BOD-L"
 /protein_id="AAC23595.1"
 /db_xref="GI:3228570"
 /translation="MAKOPSDVNSECDREGQLOPARRPQLRPGAPTSIQTSPQGNP
 DGEGRCPHSGPQGLPAPPSPGPFATRSPLIFVRRSSLLSRSSCYFSFDDTRSPA
 PMSCDKSTQTSFPCQAFNHLYSAMASIRSQSEEDLRFPIRAQLRIGDEFNET
 YTRRAFANDYREADHPQMVILQLLRFILVRRH"
 BASE COUNT 139 a 177 c 153 g 122 t
 ORIGIN
 alignment_scores:
 Quality: 1031.00 Length: 196
 Ratio: 5.287 Gaps: 0
 Percent Similarity: 99.490 Percent Identity: 98.469
 alignment_block:
 US-09-508-832-6 x AF065433 ..
 Align, seg 1/1 to: AF065433 from: 1 to: 591
 1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG 17
 1 ATGCCCAAGCAACCTCTGATGATAATTCGAGTGTGACAGAGAGGTGG 50
 17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
 51 ACAATTGCAGCCTCTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTTA 100
 34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
 101 CCTCCCTACAGACAGATCGCAAGTAATCCCGACGCGGAAGGGACCGC 150
 51 CysProHisGlySerProGlnGlyProLeuAlaProAlaSerProG 67
 151 TGCCCCCAGCGAGCCCTCAGGGCCGCTGGCCCCACCGCCAGCCCTGG 200
 67 yProPheAlaThrArgSerProLeuPheIlePheValArgSerSerL 84
 201 CCCCTTTGCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 250
 84 euLeuSerArgSerSerSerGlyTyPheSerPheAspThrAspArgSer 100
 251 TGCCTGCTCCCGTCTCCAGTGGGTATTTCCTTTTGACACAGACAGGAGC 300
 101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
 301 CCGCACCCCATGAGTGTGACAGTCAACACAAACCCCAAGTCCCTCTTG 350
 117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
 351 CCAGCCCTTCAACCACTATCTCAGTGCATAGGCTCCATACGACACTCTC 400
 134 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
 401 AGGAGGAACCTGAAGATCTCGCCCGGAGATACGGATTGCACAGGAGCTG 450
 151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
 451 CGGCGGATCGAGACGAGTTCACAGAACTTACACAAAGGAGGCTGTTTCG 500
 167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
 501 AAATGATTACCGGAGGCTCAACACCACTCCCTCAATATGGTTATCTTACAAC 550
 184 euLeuArgPheIlePheArgLeuValTrpArgArgHis 196

```

|||||
201 TCCTTTGCTACAGATCCCACTTTTCATCTTTGTGAGAAGATCTTCTC 250
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
|||||
251 TGCTGTCCCGGTCTCCAGTGGGTATTTCTTTTGACACAGACAGAGC 300
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
|||||
301 CCGCACCCCATGAGTTGTGACAGTCAACACAAACCCCAAGTCTCTCTG 350
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
|||||
351 CCAGGCTTCAACCAATATCTCAGTGCATGCTTCCATAGGCAAGTCTC 400
134 lnGluGluProGluAspLeuArgProGluIleAlaGlnGluLeu 150
|||||
401 AGGAGGAACCTGAAGATCTCGCCCGACAGATACGGATCGACAGGAGCTG 450
151 ArgArgIleGlyaspGluPheAsnGluThrTyrThrArgArgValPheAl 167
|||||
451 CGCGGATCCGACAGAGTTCATGAGCTTACACGAGGAGGGGCTTTCG 500
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
|||||
501 AAACGATTACCGAGAGCGGAGACACACCCGCAATGGTTATCTTACAAC 550
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
|||||
551 TGTATGATTCACTTCCGCTGCTGCGAGAGGAC 588

```

seq_name: gb_pat:AX031287

```

seq_documentation_block:
LOCUS AX031287 596 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 9 from Patent WO9914321.
ACCESSION AX031287
VERSION AX031287.1 GI:10278618
KEYWORDS
SOURCE
ORGANISM
unidentified.
unclassified.
REFERENCE
1 (bases 1 to 596)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
Novel therapeutic molecules
PATENT: WO 9914321-A 9 25-MAR-1999;
INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
FEATURES
Location/Qualifiers
1..596
/organism="unidentified"
/db_xref="taxon:32644"
CDS
1..>594
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09657.1"
/db_xref="GI:10278618"
/translation="MAKOPSDVSSCEDREGLOAPRPOLRCPAPTSLOTPEQGNP
EGNKGEDSCPHSPQGLAPPSPGFATRSPLFIFMRSSLLSRSSSGYFSDTD
RSPAPMCDKSTQTPSPPCQAFNHLSAMRQAEPMRPEIWIQAEIQLRRIGDEFN
AYARRVFNLYQAEADHPRMVILRLRYIVRLVRMH"
BASE COUNT 145 a 175 c 146 g 130 t
ORIGIN

```

alignment_scores:

Quality: 908.00 Length: 200
Ratio: 4.935 Gaps: 2
Percent Similarity: 92.000 Percent Identity: 86.500

alignment_block:

```

US-09-508-832-6 x AX031287 ..
Align seq 1/1 to: AX031287 from: 1 to: 596
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1 ATGGCAAGCAACCTCTCTGATGAAGTCTTGAGTGTGACCGAAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTCAGCCCTGCGGAGAGGCTCCCAAGTCAAGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAsp.....Gly 46
|||||
101 CCTCCCTACAGACAGACGCCCAAGGTAATCTGAAGGCAATCACGGAGGT 150
47 GluGlyAspArgCysProHisGlySerProGlnGlnGlyProLeuAlaProPr 63
|||||
151 GAAGGGACAGCTGCCCCACGGCAGCCCTCAGGGCCCGCTGGCCCCACC 200
63 oAlaSerProGlyProPheAlaThrArgSerProLeuPheIlePheValA 80
|||||
201 TGGCAGCCCTGGCCCTTTTCTACAGATCCCGCTTTTCATCTTTATGA 250
80 rgArgSerSerLeuLeuSerArgSerSerSerGlyTyrPheSerPheAsp 96
|||||
251 GAAGATCTCTCCCTGCTGCTCGATCTCCAGTGGGTATTTCTCTTTTGC 300
97 ThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 113
|||||
301 ACAGACAGGAGCCCGACCCCATGAGTTGTGACAAATCAACACAAACCCC 350
113 oSerProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 130
|||||
351 AAGTCTCTCTTGGCAGCCCTCAACCACTATCTCAGTGCATGGCTTCCA 400
130 leArgGlnSerGlnGluGluProGluAspLeuArgProGluIleArgIle 146
|||||
401 TGAGGCGAGGT.....GAACCTGCAGATATGCGCCCGACAGATATGATC 444
147 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 163
|||||
445 GCCACAGAGTGGCGGTATCGGAGAGGAGTTTAAACCTTACTTACTGCAAG 494
163 gatGValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetV 180
|||||
495 GAGGGTATTTTTCATTAATAATTAACCAAGCAGCCGAAGACCACCCAGAAATGG 544
180 alIleLeuGlnLeuLeuArgPheIlePheArgLeuValTyrArgArgHis 196
|||||
545 TTATCTTACGACTGTTACGTTACATTTCCGCTGCTGGTGTGGAGAATGCAT 594
seq_name: gb_un:AX031313
seq_documentation_block:
LOCUS AX031313 596 bp DNA UNA 20-SEP-2000
DEFINITION Sequence 9 from Patent WO9914321.
ACCESSION AX031313
VERSION AX031313.1 GI:10278641
KEYWORDS
SOURCE
ORGANISM
unidentified.
unclassified.
REFERENCE
1 (bases 1 to 596)
AUTHORS O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
Huang,D.C. and Strasser,A.
Novel therapeutic molecules
PATENT: WO 9914321-A 25-MAR-1999;
INST MEDICAL W & E HALL (AU); PUTHALAKATH HANSA (AU); REILLY
LORRAINE O (AU); ADAMS JERRY (AU); CONNOR LIAM O (AU); CORY
SUZANNE (AU); HUANG DAVID C S (AU); STRASSER ANDREAS (AU)
FEATURES
Location/Qualifiers
1..596

```

```
/organism="unidentified"
/db_xref="taxon:32644"
1. >594
/note="unnamed protein product"
/codon_start=1
/protein_id="CAC09662.1"
/db_xref="GI:10278642"
/translation="MAKQPSDVSSCEDREGRLQPAERPPQLRPGAPTSLOTBPQGNP
EGNHGGEGSCPHGSPQGLAPSPGPAFMRSSLLSSSGYFSFDT
RSPAPMSCDKSTQTPPCQAFNHYLSAMASMRQAPADMRPEIWIQAELRRIGDEFN
AYYARVFLNNYQAADHPRMVILRLRYIVRLVWRMH"
BASE COUNT 145 a 175 c 146 g 130 t
ORIGIN

alignment_scores:
  Quality: 908.00 Length: 200
  Ratio: 4.935 Gaps: 2
Percent Similarity: 92.000 Percent Identity: 86.500

alignment_block:
US-09-508-832-6 x AX031313
Align seg 1/1 to: AX031313 from: 1 to: 596
1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyCl 17
|||||
1 ATGGCAAAAGCAACCTTCTGATGTAAGTTCTGAGTGACCGAGAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTCGGAGAGCCCTCCCGAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAsp.....Gly 46
|||||
101 CCTCCCTACAGACAGCCACAAGTAACTCTGAGGCAATCACGAGGT 150
47 GluGlyAspArgCysProHisGlySerProGlnGlyProLeuAlaProPr 63
|||||
151 GAAAGGGACAGCTGCCCGCAGCGCCCTCAGGCGCGCTGGCCGCCACC 200
63 oAlaSerProGlyProPheAlaThrArgSerProLeuPheIlePheValA 80
|||||
201 TGCCAGCCCTGGCCCTTTTGCTACAGATCCCGCTTTTCATCTTTATGA 250
80 rgArgSerSerLeuLeuSerArgSerSerGlyTyrPheSerPheAsp 96
|||||
251 GAAGATCTCCTCGTCTCGATCTCCAGTGGGTATTTCTTTTTCAC 300
97 ThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 113
|||||
301 ACAGACAGAGGCCAGCACCCTAGTGTGTGACAAATCAACACAAACCCC 350
113 oSerProProCysGlnAlaPheAsnHisTyrIleuSerAlaMetAlaSerI 130
|||||
351 AAGTCTCTTGGCAGGCTTCAACCACTATCTCAGTGAATGGTCTCA 400
130 leArgGlnSerGlnGluProGluAspLeuArgProGluIleArgIle 146
|||||
401 TGAGGCAGGT.....GAACCTGCAGATATCGGCCAGAGATATGGATC 444
147 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 163
|||||
445 GCCCAAGAGTTTGGCGGTATCGGAGACGAGTTTAACGCTTACTATGCAAG 494
163 gArgValPheAlaAsnAspTyrArgGluAlaAlaAspHisProGlnMetV 180
|||||
495 GAGGATATTTTGAATAATACCAAGACCGGAGACCAACCCACCAATGG 544
180 alIleLeuGlnLeuLeuArgPheIlePheArgLeuValTyrArgArgHis 196
|||||
545 TTATCTTACGACTGTACGTTACATTGTCGCCCTGGTGTGGAGATGTCAT 594
```

```
seq_name: gb_pr:AF032457
seq_documentation_block:
LOCUS AF032457 597 bp mRNA PRI 19-FEB-1998
DEFINITION Homo sapiens BimEL mRNA, complete cds.
ACCESSION AF032457
VERSION AF032457.1 GI:2895495
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 597)
AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.
TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis
JOURNAL EMBO J. 17 (2), 384-395 (1998)
MEDLINE 98094360
PUBMED 9430830
REFERENCE
2 (bases 1 to 597)
AUTHORS O'Connor,L., Strasser,A., O'Reilly,L.A., Hausmann,G., Adams,J.M.,
Cory,S. and Huang,D.C.S.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia
FEATURES
source
1. 597
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS
1. 597
/note="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimEL"
/protein_id="AAC39593.1"
/db_xref="GI:2895496"
/translation="MAKQPSDVSSCEDREGRLQPAERPPQLRPGAPTSLOTBPQGNP
EGNHGGEGSCPHGSPQGLAPSPGPAFMRSSLLSSSGYFSFDT
RSPAPMSCDKSTQTPPCQAFNHYLSAMASMRQAPADMRPEIWIQAELRRIGDEFN
AYYARVFLNNYQAADHPRMVILRLRYIVRLVWRMH"
BASE COUNT 146 a 175 c 146 g 130 t
ORIGIN

alignment_scores:
  Quality: 908.00 Length: 200
  Ratio: 4.935 Gaps: 2
Percent Similarity: 92.000 Percent Identity: 86.500

alignment_block:
US-09-508-832-6 x AF032457
Align seg 1/1 to: AF032457 from: 1 to: 597
1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyCl 17
|||||
1 ATGGCAAAAGCAACCTTCTGATGTAAGTTCTGAGTGACCGAGAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTCGGAGAGCCCTCCCGAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAsp.....Gly 46
|||||
101 CCTCCCTACAGACAGCCACAAGTAACTCTGAGGCAATCACGAGGT 150
47 GluGlyAspArgCysProHisGlySerProGlnGlyProLeuAlaProPr 63
|||||
151 GAAAGGGACAGCTGCCCGCAGCGCCCTCAGGCGCGCTGGCCGCCACC 200
63 oAlaSerProGlyProPheAlaThrArgSerProLeuPheIlePheValA 80
|||||
201 TGCCAGCCCTGGCCCTTTTGCTACAGATCCCGCTTTTCATCTTTATGA 250
80 rgArgSerSerLeuLeuSerArgSerSerGlyTyrPheSerPheAsp 96
|||||
251 GAAGATCTCCTCGTCTCGATCTCCAGTGGGTATTTCTTTTTCAC 300
97 ThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 113
|||||
301 ACAGACAGAGGCCAGCACCCTAGTGTGTGACAAATCAACACAAACCCC 350
113 oSerProProCysGlnAlaPheAsnHisTyrIleuSerAlaMetAlaSerI 130
|||||
351 AAGTCTCTTGGCAGGCTTCAACCACTATCTCAGTGAATGGTCTCA 400
130 leArgGlnSerGlnGluProGluAspLeuArgProGluIleArgIle 146
|||||
401 TGAGGCAGGT.....GAACCTGCAGATATCGGCCAGAGATATGGATC 444
147 AlaGlnGluLeuArgArgIleGlyAspGluPheAsnGluThrTyrThrAr 163
|||||
445 GCCCAAGAGTTTGGCGGTATCGGAGACGAGTTTAACGCTTACTATGCAAG 494
163 gArgValPheAlaAsnAspTyrArgGluAlaAlaAspHisProGlnMetV 180
|||||
495 GAGGATATTTTGAATAATACCAAGACCGGAGACCAACCCACCAATGG 544
180 alIleLeuGlnLeuLeuArgPheIlePheArgLeuValTyrArgArgHis 196
|||||
545 TTATCTTACGACTGTACGTTACATTGTCGCCCTGGTGTGGAGATGTCAT 594
```

80 rArgSerSerLeuLeuSerArgSerSerSerGlyTyrPheSerPheAsp 96
 |||||
 251 GAAGATCTCTCCCTGCTCTCGATCTCCAGTGGGTATTTCTTTTGAC 300
 |||||
 97 ThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 113
 |||||
 301 ACAGACAGGAGCCAGCCAGCCATGAGTTGACAAATCAACACAAACCCC 350
 |||||
 113 oSerProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerI 130
 |||||
 351 AAGTCTCTCTGCGAGCGCTTCAACCACTATCTCAGTGAATGGCTTCCA 400
 |||||
 130 leArgGlnSerGlnGluGluProGluAspLeuArgProGluIleArgIle 146
 |||||
 401 TGAGGAGGCT.....GAACCTGCAGATATGCCGCCAGATATGATC 444
 |||||
 147 AlaGlnGluLeuArgGlyAspGluPheAsnGluThrTyrThrAr 163
 |||||
 445 GCCCAGAGTTGCGGCTATCGGAGACGAGTTTAAACGCTTACTATCAAG 494
 |||||
 163 gArgValPheAlaAsnAspTyrArgGluAlaGluAspHisProGlnMetV 180
 |||||
 495 GAGGATATTTGAATAATTACCAAGCAGCCGGAAGACCACCAAGATGG 544
 |||||
 180 alileLeuGlnLeuLeuArgPheIlePheArgLeuValTrpArgArgHis 196
 |||||
 545 TTATCTTACGACTGTACGTTACATTCCTCGCTGGTGGAGAAATGCAT 594
 |||||

seq_name: gb_pat:AX031281

seq_documentation_block: 422 bp DNA PAT 20-SEP-2000
 LOCUS AX031281
 DEFINITION Sequence 3 from Patent WO9914321.
 ACCESSION AX031281
 VERSION AX031281.1 GI:10278612
 KEYWORDS
 SOURCE
 ORGANISM
 O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.
 Novel therapeutic molecules
 Patent: WO 9914321-A 3 25-MAR-1999;
 INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY
 LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
 SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
 FEATURES
 Location/Qualifiers
 1..422
 /organism="unidentified"
 /db_xref="taxon:32644"
 1..>420
 /note="unnamed protein product"
 /codon_start=1
 /protein_id="CAC09654.1"
 /db_xref="GI:10278613"
 /translation="MAKQPSDVSECDREGQLQAPRPOLRPGAPTSLQTEPQDRS
 PAPMSCDKSTQTPSPQCAFNYHLSAMASIROEPEDLRPEIRIAQLRLRIGDEFN
 ETTYRFRVFANDYREAEDHPQMVILQLLRIFRLVRRH"
 BASE COUNT 112 a 116 c 109 g 85 t
 ORIGIN

alignment_scores:
 Quality: 704.00 Length: 196
 Ratio: 5.029 Gaps: 1
 Percent Similarity: 71.429 Percent Identity: 71.429

alignment_block:
 US-09-508-832-6 x AX031281 ..
 Align seg 1/1 to: AX031281 from: 1 to: 422

seq_name: gb_un:AX031307
 seq_documentation_block: 422 bp DNA UNA 20-SEP-2000
 LOCUS AX031307
 DEFINITION Sequence 3 from Patent WO9914321.
 ACCESSION AX031307
 VERSION AX031307.1 GI:10278635
 KEYWORDS
 SOURCE
 ORGANISM
 O'Reilly,L., Puthalakath,H., Adams,J., O'Connor,L., Cory,S.,
 Huang,D.C. and Strasser,A.
 Novel therapeutic molecules
 Patent: WO 9914321-A 25-MAR-1999;
 INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; REILLY
 LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY
 SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)
 FEATURES
 Location/Qualifiers
 1..422
 /organism="unidentified"
 /db_xref="taxon:32644"
 1..>420
 CDS

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 |||||
 1 ATGCCCAAGCAACCTTCTGATGTAGTTCCTGAGTGTGACAGAGAAGGTGG 50
 |||||
 17 yGlnLeuGlnProAlaGluArgProProGlnLeuLeuArgProGlyAlaProT 34
 |||||
 51 ACAATTGCGAGCCCTGAGAGCCCTCCCGAGCTCAGGCTGAGGCGGCCCTA 100
 |||||
 34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
 |||||
 101 CCTCCCTACAGACAGAACCCCAA..... 123
 |||||
 51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
 |||||
 123 123
 67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
 |||||
 123 123
 84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
 |||||
 124GACAGGAGC 132
 |||||
 101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
 |||||
 133 CCGGCACCCATGAGTTGTGACAAGTCAACACAAACCCCAAGTCTCCTTG 182
 |||||
 117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
 |||||
 183 CCAGGCGCTTCAACCACTATCTCAGTGAATGGCTTCCATACGACAGTCTC 232
 |||||
 134 lngLluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
 |||||
 233 AGAGGAACCTGAAGATCTGCGCCGAGATACGGATTGCACAGGAGCTG 282
 |||||
 151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
 |||||
 283 CGCGCGATCGGAGCGAGTTCAACGAAACTTACACAAAGGAGGTGTTTGC 332
 |||||
 167 asnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
 |||||
 333 AAATGATTACCGCGAGGCTGAAGACCAACCTCAAAATGGTTATCTTACAAC 382
 |||||
 184 euLeuArgPheIlePheArgLeuValTrpArgArgHis 196
 |||||
 383 TGTTAGCCTTTATCTTCCGCTCGGTATGGAGAGGCAT 420
 |||||

```

/notes="unnamed protein product"
/codon_start=1
/protein_id="CAC09659.1"
/db_xref="GI:10278636"
/translation="MAKQPSDVSECDREGGQLQPAERPPQLRPGAPTSLOTPEQDQRS
PAPMSCDKSTQTPSPPCOAFNHYLSAMASTROSEPDLRPEIRIAQELRRIGDEFN
ETVTRVFANDYREAEHPQMVIOLLRFILVWRHH"
BASE COUNT      112 a  116 c  109 g   85 t
ORIGIN

alignment_scores:
  Quality: 704.00      Length: 196
  Ratio: 5.029        Gaps: 1
Percent Similarity: 71.429 Percent Identity: 71.429

alignment_block:
US-09-508-832-6 x AX031307 ..
Align seg 1/1 to: AX031307 from: 1 to: 422

1  MetaLalysGlnProSerAspValSerGluCysAspArgGluGlycl 17
1  ATGGCCAAAGCAACCTTCTCATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yClnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
1  ACAATTGCAGCCTGCTGAGAGGCCTCCCGAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
101 CCTCCTCAGACAGAACCGCAA.....123
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProGl 67
123 .....123
67 yPropheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
123 .....123
84 euLeuSerArgSerSerGlyTyrPheSerPheAspThrAspArgSer 100
124 .....GACAGGAGC 132

seq_name: gb_ro:AF032460
seq_documentation_block:
LOCUS      AF032460      423 bp      mRNA      ROD      19-FEB-1998

Mus musculus BimL mRNA, complete cds.
AF032460 GI:2895501
house mouse.
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.
Bim: a novel member of the Bcl-2 family that promotes apoptosis
EMBO J. 17 (2), 384-395 (1998)
98094360
PUBMED
9430630
REFERENCE
2 (bases 1 to 423)
O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.S.
Direct Submission
Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia
Location/Qualifiers
1..423
/organism="Mus musculus"
/db_xref="taxon:10090"
1..423
/notes="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimL"
/protein_id="AAC40030.1"
/db_xref="GI:2895502"
/translation="MAKQPSDVSECDREGGQLQPAERPPQLRPGAPTSLOTPEQDQRS
PAPMSCDKSTQTPSPPCOAFNHYLSAMASTROSEPDLRPEIRIAQELRRIGDEFN
ETVTRVFANDYREAEHPQMVIOLLRFILVWRHH"
BASE COUNT      113 a  116 c  109 g   85 t
ORIGIN

alignment_scores:
  Quality: 704.00      Length: 196
  Ratio: 5.029        Gaps: 1
Percent Similarity: 71.429 Percent Identity: 71.429

alignment_block:
US-09-508-832-6 x AF032460 ..
Align seg 1/1 to: AF032460 from: 1 to: 423

1  MetaLalysGlnProSerAspValSerGluCysAspArgGluGlycl 17
1  ATGGCCAAAGCAACCTTCTCATGTAAGTTCTGAGTGTGACAGAGAAGGTGG 50
17 yClnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
1  ACAATTGCAGCCTGCTGAGAGGCCTCCCGAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
101 CCTCCTCAGACAGAACCGCAA.....123
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProGl 67
123 .....123
67 yPropheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
123 .....123
84 euLeuSerArgSerSerGlyTyrPheSerPheAspThrAspArgSer 100
124 .....GACAGGAGC 132

seq_name: gb_ro:AF032460
seq_documentation_block:
LOCUS      AF032460      423 bp      mRNA      ROD      19-FEB-1998

```

```

101 ProAlaPrometSerCysAspLysSerThrGlnThrProSerProProCy 117
133 CCGCACCATCTAGTTGTGACAGTCAACAAACCCCAAGTCTCTCTT 182
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
183 CCAGGCTTCAACCACTATCTCAAGTGTGCAATGGCTTCCATACGAGTCTC 232
134 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
233 AGGAGGAACCTGAGATCTGCGCCGAGATACGATTGCACAGGAGCTG 282
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
283 CGCGGATCGAGAGAGGATTCACAGAACTTACACAAAGAGGGTGTGTTGC 332
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
333 AATGATTACCGGAGGCTGAAGACCACTCAATGGTTATCTTACAAC 382
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
383 TGTACGCTTATCTCTCGTCTGGTATGAGAGGCAT 420

```

seq_name: gb_ro:AF136927

```

seq_documentation_block:
LOCUS AF136927 423 bp mRNA ROD 21-APR-1999
DEFINITION Rattus norvegicus Bcl-2 related apoptotic gene product BimL (bimL)
mRNA, complete cds.
ACCESSION AF136927
VERSION AF136927.1 GI:4590514
KEYWORDS
SOURCE Norway rat.
ORGANISM Rattus norvegicus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sclurognathi; Muridae; Murinae;
Rattus.
REFERENCE 1 (bases 1 to 423)
AUTHORS Chen,D., Simon,R.P. and Chen,J.
TITLE Cloning of rat bimL and bimL, and their differential expression in
ischemia and normal rat brain
JOURNAL unpublished
REFERENCE 2 (bases 1 to 423)
AUTHORS Chen,D., Simon,R.P. and Chen,J.
TITLE Direct Submission
JOURNAL Submitted (24-MAR-1999) Department of Neurology, BST, S-526,
Pittsburgh University Medical School, 3500 Terrace Street,
Pittsburgh, PA 15213, USA
FEATURES
source
1..423
/organism="Rattus norvegicus"
/db_xref="taxon:10116"
gene 1..423
/ene="bimL"
CDS 1..423
/codon_start=1
/product="Bcl-2 related apoptotic gene product BimL"
/protein_id="BAD26594.1"
/db_xref="GI:4590515"
/translation="MAKQPSDVNSECDREGGQLOPAERPPQLRPGAPTSLOTESQDRS
FAPMSKSTPTSPQCAFNFHLSAMASIRSQEPEDLPEIRIAQLRRIGDEFN
ETVTRAPANDYRAEDHPQMVLQLLFIPLVRRH"
BASE COUNT 116 a 113 c 112 g 82 t
ORIGIN

```

alignment_scores:
Quality: 689.00 Length: 196
Ratio: 4.957 Gaps: 1
Percent Similarity: 70.918 Percent Identity: 69.898

alignment_block:

US-09-508-832-6 x AF136927 ..

Align seg 1/1 to: AF136927 from: 1 to: 423

```

1 MetalAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
1 ATGCCAAGCAACCTTCTGATGTAATTCAGTGTGACAGAGAAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
51 ACAATTGCAGCCTGCTGAGAGGCTCCCCAGCTCAGGCCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
101 CCTCCCTACAGACAGATCGCAA..... 123
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
123 ..... 123
67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerL 84
123 ..... 123
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
124 .....GACAGGAGC 132
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
133 CCGGCACCCATGATGTTGTGACAACTCAACACAAACCCCAAGTCTCTCTT 182
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
183 CCAGGCTTCAACCACTATCTTACGCAATGGCTTCCATACGAGTCTC 232
134 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
233 AGGAGGAACCTGAAGATCTGCGCCGAGATACGATCGCACAGGAGCTG 282
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
263 CGGAGGATCGGAGACAGTTCATAGACTTACACGAGGAGGCGTTCG 332
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
333 AACAGATTACCGAGCGGGAAGACCAACCCCAATGGTTATCTTACAAC 382
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
383 TGTACGATTATCTCTCGTCTGGTATGAGAGGCAT 420

```

seq_name: gb_htg:AC013332

```

seq_documentation_block:
LOCUS AC013332 180569 bp DNA HTG 16-MAR-2000
DEFINITION Homo sapiens chromosome 2 clone RP11-438K19 map 2, WORKING DRAFT
SEQUENCE, 6 unordered pieces.
ACCESSION AC013332
VERSION AC013332.4 GI:7248987
KEYWORDS HTG; HTGS_PHASE1; HTGS_DRAFT.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 180569)
AUTHORS Birren,B., Linton,L., Nusbaum,C. and Lander,E.
TITLE Homo sapiens chromosome 2, clone RP11-438K19
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 180569)
AUTHORS Birren,B., Linton,L., Nusbaum,C., Lander,E., Allen,N., Anderson,M.,
Baldwin,J., Barna,N., Beckerly,R., Boguslavsky,L., Boukhgalter,B.,

```

Brown, A., Castle, A., Colangelo, M., Collins, S., Collymore, A., Cooke, P., DeArallano, K., Dewar, K., Domino, M., Donegan, L., Doyle, M., Ferreira, P., Fitzhugh, W., Forrest, C., Funke, R., Gage, D., Galagan, J., Gardyna, S., Grant, G., Hagos, B., Hartford, A., Horton, L., Howland, J. C., Johnson, R., Jones, C., Kann, L., Karatas, A., Klein, J., Lehoczy, J., Lieu, C., Locke, K., Macdonald, P., Marquis, N., McEwan, P., McGurk, A., McKernan, K., McDonald, P., Meldrim, J., Morrow, J., Naylor, J., Norman, C. H., O'Connor, T., O'Donnell, P., Peterson, K., Pollara, V., Riley, R., Roy, A., Santos, R., Severy, P., Stange-Thomann, N., Stojanovic, N., Subramanian, A., Talamas, J., Tesfaye, S., Tirrell, A., Vassiliev, H., Vo, A., Wheeler, J., Wu, X., Wyman, D., Ye, W. J., Zimmer, A. and Zody, M.

TITLE

JOURNAL

COMMENT

Submitted (06-NOV-1999) Whitehead Institute/MIT Center for Genome Research, 320 Charles Street, Cambridge, MA 02141, USA
On Mar 16, 2000 this sequence version replaced gi:6478985.
All repeats were identified using RepeatMasker:
Smit, A.F.A. & Green, P. (1996-1997)
<http://ftp.genome.washington.edu/RM/RepeatMasker.html>

----- Genome Center

Center: Whitehead Institute/ MIT Center for Genome Research

Center code: WIBR

Web site: <http://www-seq.wi.mit.edu>

Contact: sequence_submissions@genome.wi.mit.edu

----- Project Information

Center project name: L3811

Center clone name: 438_K_19

----- Summary Statistics

Sequencing vector: M13; M77815; 100% of reads

Chemistry: Dye-terminator Big Dye; 100% of reads

Assembly program: Phrap; version 0.960731

Consensus quality: 136049 bases at least Q40

Consensus quality: 172735 bases at least Q30

Consensus quality: 178014 bases at least Q20

Insert size: 175000; agarose-fp

Quality coverage: 180069; sum-of-contigs

Quality coverage: 4.7 in Q20 bases; agarose-fp

Quality coverage: 4.6 in Q20 bases; sum-of-contigs

* NOTE: This is a 'working draft' sequence. It currently consists of 6 contigs. The true order of the pieces is not known and their order in this sequence record is arbitrary. Gaps between the contigs are represented as runs of N, but the exact sizes of the gaps are unknown. This record will be updated with the finished sequence as soon as it is available and the accession number will be preserved.

* 1 2165: contig of 2165 bp in length
* 2166 2265: gap of 100 bp
* 2266 12624: contig of 10359 bp in length
* 12625 12724: gap of 100 bp
* 12725 27927: contig of 15203 bp in length
* 27928 28027: gap of 100 bp
* 28028 65158: contig of 37131 bp in length
* 65159 65258: gap of 100 bp
* 65259 107505: contig of 42247 bp in length
* 107506 107605: gap of 100 bp
* 107606 180569: contig of 72964 bp in length.

FEATURES

SOURCE

1. 180569
/organism="Homo sapiens"
/db_xref="taxon:9606"
/chromosome="2"
/map="2"
/clone="RP11-438K19"
/clone_lib="RPC1-11 Human Male BAC"
1. 2165
/note="assembly_fragment"
2266. 12624
/note="assembly_fragment"
clone_end:SP6
vector_side:right"
12725. 27927

misc_feature

misc_feature

misc_feature

misc_feature
28028. 65158
/note="assembly_fragment"
misc_feature
65259. 107505
/note="assembly_fragment"
misc_feature
107606. 180569
/note="assembly_fragment"
clone_end:r7
vector_side:right"
BASE COUNT 49889 a 39169 c 39952 g 51056 t 503 others
ORIGIN

alignment_scores:

Quality: 656.00 Length: 131
Ratio: 5.248 Gaps: 1
Percent Similarity: 95.420 Percent Identity: 93.893

alignment_block:

US-09-508-832-6 x AC013332/rev ..

Align seg 1/1 to reverse of: AC013332 from: 1 to: 180569

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyG1 17
|||||
15100 ATGCCAAAGCAACCTTCGTATGTAAGTTCTGAGTGTGACCGAAGGTAG 15051
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
15050 ACAATTGCGAGCTCGGAGAGCGCTCCCGACGTACAGCTGGGGCCCTA 15001
34 hrSerLeuGlnThrGluProGlnGlyAsnProAsp.....Gly 46
|||||
15000 CCTCCTACAGACAGAGCCACCAAGGTAATCTGAAGGCAATCAGCGAGGT 14951
47 GluGlyAspArgCysProHisGlySerProGlnGlyProLeuAlaProPr 63
|||||
14950 GAAGGGGACAGCTGCCCGACGCGCGCTCAGGGCGCGCTGGGCCCCACC 14901
63 oAlaSerProGlyProPheAlaThrArgSerProLeuPheIlePheVala 80
|||||
14900 TGCCAGCGCTGGCCCTTTTGTCTACCATCCCGCTTTTCATCTTATGA 14851
80 rGArgSerSerLeuLeuSerArgSerSerGlyTyrPheSerPheAsp 96
|||||
14850 GAAGATCTCTCCTGCTGCTCGATCTCCAGTGGGTATTTCTCTTTTGAC 14801
97 ThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnThrPr 113
|||||
14800 ACAGACAGAGGCGCCAGCCCATGAGTTGTGACAAATCAACACAAACCCC 14751
113 oSerProProCysGlnAlaPheAsnHisTyrIleuSerAlaMet 127
|||||
14750 AAGTCTCTCTTCCAGGCGCTTCAACCCACTATCTCAGTGCATG 14708

seq_name: gb_pat:AX031285

seq_documentation_block:

LOCUS AX031285 416 bp DNA PAT 20-SEP-2000
DEFINITION Sequence 7 from Patent WO9914321.
ACCESSION AX031285
VERSION AX031285.1 GI:10278616
KEYWORDS
SOURCE
ORGANISM
unidentified.
unclassified.

REFERENCE

1 (bases 1 to 416)

O'Reilly, L., Puthalakath, H., Adams, J., O'Connor, L., Cory, S.,

Huang, D. C. and Strasser, A.

Novel therapeutic molecules

Patent: WO 9914321-A 7 25-MAR-1999;

INST MEDICAL W & E HALL (AU) ; PUTHALAKATH HAMSA (AU) ; RETILLY

LORRAINE O (AU) ; ADAMS JERRY (AU) ; CONNOR LIAM O (AU) ; CORY

JOURNAL

SUZANNE (AU) ; HUANG DAVID C S (AU) ; STRASSER ANDREAS (AU)

```

FEATURES             Location/Qualifiers
     source            1..416
                        /organism="unidentified"
                        /db_xref="taxon:32644"
     CDS               1..>414
                        /note="unnamed protein product"
                        /codon_start=1
                        /protein_id="CAC09656.1"
                        /db_xref="GI:10278617"
                        /translation="MAKQPSDVSECDRECRQLQPAERPQLRPGAPTSLOTSPQDRS
PAMSCDKSTQTSPSCQAENHLSWASMRQEPADMPETWIATQELRRIGDFEFNAI
YARRVELNNYQAAEDHPVMILRLLYIVLVRMH"
BASE COUNT          113 a   113 c   103 g      87 t
ORIGIN

alignment_scores:
    Quality: 591.00           Length: 196
    Ratio: 4.581              Gaps: 2
Percent Similarity: 65.816    Percent Identity: 61.224

alignment_block:
US-09-508-832-6 x AX031285 ..

Align seg 1/1 to: AX031285 from: 1 to: 416

1 MetAlaLysGlnProSerAspValSerGluCysAspArgGluGlyGl 17
|||||
1 ATFGCAAGACCACTTCGTAGTGAAGTTCTGAGTGACCAGAGAAGTAG 50
|||||
77 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCTCGGGAGAGGCCTCCCGACTCAGACCTGGGGCCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
101 CCTCCCTACAGACAGGCCACA... 123

51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProGl 67
123 ..... 123

67 yPropheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
123 ..... 123

84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
|||||
124 .....GACAGGAGC 132

101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
|||||
133 CCAGACCCCATGAGTTGTGCAAAATCAACACAAAACCCCAAGTCCTCCTTG 182
|||||
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
|||||
183 CCAGGCCTTCAACCACTATCTCAGTGCAATGGCTTCCATGAGGACGGCT. 231
|||||
134 lnGluLuProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
|||||
232 ....GAACCTGCAGATATGCGCCAGAGATATGGATGCGCCAAGAGTTG 276
|||||
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
|||||
277 CGGCGTATPCGAGACGAGTTAAGCGCTTACTACTGCAAGAGGGGATTTTT 326
|||||
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
|||||
327 GAATAATTACCACGACCGGAAGACCCCACCAAGATGGTTATCTTACGAC 376
|||||
184 euLeuArgPheIlePheArgLeuValTrpArgArgHis 196
|||||

```


133 CCAGCACCATGAGTTGTGACAAATCAACACAAACCCCAAGTCTCCTTG 182
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
183 CCAGGCTTCAACCACTATCTCAGTGAATGCTTCCATGAGGAGGCT. 231
134 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
232GAACCTGCAGATATGCGCCAGAGATATGATCGCCACAGAGTTG 276
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
277 CGCGTATCGGAGAGAGTCTTAACGCTTACTATGCAAGAGGGTATTTT 326
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
327 GAATAATTACCAAGCAGCGGAGAGACCAACCCAGATGTTTATCTTACGAC 376

seq_name: gb_pr:AF032458

seq_documentation_block: 417 bp mRNA PRI 19-FEB-1998
LOCUS AF032458
DEFINITION Homo sapiens BimL mRNA, complete cds.
ACCESSION AF032458
VERSION AF032458.1 GI:2895497
KEYWORDS
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 417)
AUTHORS O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.
TITLE Bim: a novel member of the Bcl-2 family that promotes apoptosis
JOURNAL EMBO J. 17 (2), 384-395 (1998)
MEDLINE 9430630
PUBMED
REFERENCE 2 (bases 1 to 417)
AUTHORS O'Connor, L., Strasser, A., O'Reilly, L.A., Hausmann, G., Adams, J.M.,
Cory, S. and Huang, D.C.S.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-1997) Molecular Genetics of Cancer, The Walter &
Eliza Hall Institute of Medical Research, PO Royal Melbourne
Hospital, Parkville, Victoria 3050, Australia
FEATURES
source Location/Qualifiers
1..417
/organism="Homo sapiens"
/db_xref="taxon:9606"
CDS
1..417
/note="pro-apoptotic BH3-containing Bcl-2 family member"
/codon_start=1
/product="BimL"
/protein_id="AAC39594.1"
/db_xref="GI:2895498"
/translation="MAKQPSDVSECDREGRLQAPERPPLRPGAPTSLOTPEODRS
PAPMSCKSTQTPSPPCQAFNHYLSAMASMKRAEPADMRPEIWIQELRLRIGDEFNAY
YARRFENNYQAEDHPRWVILRLRYIVLWVRMH"

BASE COUNT 114 a 113 c 103 g 87 t
ORIGIN

alignment_scores:
Quality: 591.00 Length: 196
Ratio: 4.581 Gaps: 2
Percent Similarity: 65.816 Percent Identity: 61.224
alignment_block:
US-09-508-832-6 x AF032458.

Align seg 1/1 to: AF032458 from: 1 to: 417
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG 17
1 ATGGCAAGCAACCTTCTGATGTAAGTTCTGAGTGTACCGAGAAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
51 ACAATTGCGAGCTCGGAGAGGCGCTCCCGAGCTCAGACCTGGGCCCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
101 CCTCCCTACACAGACGACCAAA 123
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG 67
123 123
67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
123 123
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
124GACAGGAGC 132
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
133 CCAGCACCATGAGTTGTGACAAATCAACACAAACCCCAAGTCTCCTTG 182
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
183 CCAGGCTTCAACCACTATCTCAGTGAATGCTTCCATGAGGAGGCT. 231
134 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
232GAACCTGCAGATATGCGCCAGAGATATGATCGCCACAGAGTTG 276
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
277 CGCGTATCGGAGAGAGTCTTAACGCTTACTATGCAAGAGGGTATTTT 326
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
327 GAATAATTACCAAGCAGCGGAGAGACCAACCCAGATGTTTATCTTACGAC 376
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
377 TGTACGTTACATTTGTCGCCCTGGTGTGAGAAATGCAT 414

CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by
 CC preventing generation of fertile sperm.
 XX
 SQ Sequence 590 BP; 137 A; 178 C; 150 G; 125 T; 0 other;

alignment_scores:
 Quality: 1046.00 Length: 196
 Ratio: 5.337 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-6 x AAX24995 ..

Align seg 1/1 to: AAX24995 from: 1 to: 590

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
 1 ATGCCCAAGCAACCTTCTGATGTAAAGTCTGTGAGTGTGACAGAGAAGTGG 50
 17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
 51 ACAATTGCAGCCCTCTGAGAGGCTCCCAAGCTCAGGCCCTGGGGCCCTA 100
 34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
 101 CTTCTCTACAGACAGAACCGCAAGTAAATCCGACGCGAAGGGGACCGC 150
 51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
 151 TGCCCCCAGCGAGCCCTCAGGCGCCGCTGGCCCCCAGCGCCAGCCCTGG 200
 67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerSerL 84
 201 CCCTTTTGTCTACCAAGATCCCACTTTTCACTTTGTGAGAAGATCTCTC 250
 84 euleuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
 251 TGTGTGTCGGGTCTCCAGTGGGTATTCTCTTTTGACACAGACAGGAGC 300
 101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
 301 CCGCACCCATGAGTGTGTGACAAGTCAACACAACCCCAAGTCCCTCTTG 350
 117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
 351 CCAGGCTTCAACCACTATCTCAGTCAATGGCTTCCATACGACAGTCTC 400
 134 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
 401 AGAGGAAACCTGAAGATCTCGCGCCGAGATACGGATTGCACAGAGGCTG 450
 151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
 451 CGCGGATCCGACAGAGTTCAACAGAACTTACAAAGGAGGGTGTTCG 500
 167 aSnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
 501 AAATGATTACCGGAGGCTGAAGACCAACCCTCAATGGTTATCTTACAAC 550
 184 euleuArgPheIlePheArgLeuValTrpArgHis 196
 551 TGTACGCTTATCTTCCGCTCGTGTGGTAGAAGGCAT 588

seq_name: /SID52/gcgdata/geneseq/geneseqn/NA1999.DAT: AAX24997

seq_documentation_block:

XX ID AAX24997 standard; cDNA; 596 BP.
 AC AAX24997;
 XX
 DT 05-JUL-1999 (first entry)
 DE Human Bcl-2 interacting mediator of cell death Bim-EL cDNA.
 KW Bim-EL; Bcl-2 interacting mediator of cell death; apoptosis;
 KW cell cycle; human; cancer; autoimmune disease;
 KW degenerative disease; therapy; contraceptive; splice variant;
 KW isoform; ss;
 XX
 OS Homo sapiens.
 XX
 PN W09914321-A1;
 XX
 PD 25-MAR-1999.
 XX
 PF 17-SEP-1998; 98WO-AU00772.
 XX
 PR 24-SEP-1997; 97AU-0009373.
 PR 17-SEP-1997; 97AU-0009263.
 XX
 PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.
 XX
 PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;
 PI Puthalakath H, Strasser A;
 XX
 DR WPI; 1999-244030/20.
 DR P-PSDB; AAW98158.
 XX
 PT New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
 PT treatment
 XX
 PS Claim 7; Page 101-102; 145pp; English.
 XX
 CC The present sequence encodes the extra long form (EL) of human Bim,
 CC or Bcl-2 interacting mediator of cell death (see AAW98158), a novel
 CC member of the Bcl-2 family that is capable of inducing cell death
 CC (apoptosis) and which acts as a 'death-ligand' for certain members
 CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
 CC only Bcl-2 homology region which it encompasses is BH3. It is the
 CC only BH3-only protein for which splice variants exist. These
 CC result in the expression of a variety of isoforms, i.e. Bim-S,
 CC Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see
 CC AAW98158) were isolated from embryo and liver cDNA libraries using
 CC mouse Bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see
 CC AAW98154-56) are also provided. The human Bim gene maps to
 CC chromosome 2 at bands 2q12-2q13. Binding the dynein light
 CC chain was shown to regulate the pro-apoptotic activity of Bim.
 CC Bim-S, the splice variant which does not bind to dynein light
 CC chain, is a much more potent killer than either Bim-L or Bim-EL.
 CC The invention provides variants (see AAW98159-88) of murine and human
 CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
 CC with a dynein light chain. The identification of Bim permits the
 CC identification and rational design of a range of products for use
 CC in therapy, diagnosis, antibody generation and involving modulation
 CC of physiological cell death. These therapeutic molecules may act
 CC as either antagonists or agonists of Bim's function and will be
 CC useful in cancer, autoimmune or degenerative disease therapy.
 CC Increased Bim expression or Bim activity is useful, e.g. for
 CC treatment or prophylaxis in conditions such as cancer and deletion
 CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
 CC expression of Bim activity is useful in regulating inhibition or
 CC prevention of cell death or degeneration such as under cytotoxic
 CC conditions during e.g. gamma-irradiation and chemotherapy or during
 CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
 CC hypoxia, degenerative diseases or for prolonging the survival of
 CC cells being transplanted for treatment of disease. Since Bim is
 CC expressed in germ cells, modulating Bim expression or Bim activity
 CC is useful, e.g. as a contraceptive or method of sterilization by

DE Murine Bcl-2 interacting mediator of cell death Bim-L cDNA.

Sequence 422

Ratio: 5.029

Sequence 422 BP; 112 A; 116 C; 109 G; 85 T; 0 other;

```

Length: 196
Gaps: 1

```

```

Percent Similarity: 71.429   Percent Identity: 71.429
alignment_block:
US-09-508-832-6 x AAX24994   ..
Align seg 1/1 to: AAX24994   from: 1 to: 422

1  MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
1  ATGGCCAAAGCAACCTTCTGATGTAAGTTCGTAGTGTGCACAGAAGGTGG 50
|||||
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGGCTCTCAGAGGCTCCAGCTCAGGCTGGGGCCCTA 100
|||||
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
101 CCTCCCTACAGACAGAACCCGAA..... 123
|||||
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
|||||
123 ..... 123
|||||
67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerL 84
|||||
123 ..... 123
|||||
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
|||||
124 .....GACAGGAGC 132
|||||
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
|||||
133 CCGGCAACCATGAGTGTGTGACAGTCAACCAACCAACCCCAAGTCTCTTG 182
|||||
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
|||||
183 CCAGGCTTCAACCCACATCTCAGTGCAATGGCTTCCATACGACAGCTCTC 232
|||||
134 lnGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
|||||
233 AGSAGGAACCTGAAGATCTCGCCCGGAGATACGGATTTGCACAGAGAGCTG 282
|||||
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
|||||
283 CGGCGGATTCGGAGACGAGTTCAACGAAACTTACACAGGAGGGGTGTTGC 332
|||||
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
|||||
333 AAATGATTACCGGAGGCTCAGACACCACCCTCAATGGTTATCTTACAAC 382
|||||
184 euLeuArgPheIlePheArgLeuValTrpArgArgHis 196
|||||
383 TGTTCACCTTTATCTTCGGTCTGTATGAGAGAGGAT 420
|||||

```

seq_name: /SIDS2/qcadata/qeneseq/qeneseqn/NA1999.DAT: AAX24996

seq_documentation_block:
ID AAX24996 standard: cDNA: 416 BP.

XX	AAX24996; -	
XX	AC	
XX	XX	
DT	XX	
XX	05-JUL-1999 (first entry)	
XX	XX	
DE	Human Bcl-2 interacting mediator of cell death Bim-L cDNA.	
XX	XX	
KW	Bim-L; Bcl-2 interacting mediator of cell death; apoptosis;	
KW	cell cycle; human; cancer; autoimmune disease;	
KW	degenerative disease; therapy; contraceptive; splice variant;	
KW	isoform; ss.	
XX	XX	
OS	Homo sapiens.	
XX	XX	

PN	W09914321-AL.	
XX		
PD	25-MAR-1999.	
XX		
PF	17-SEP-1998; 98WO-AU00772.	
XX		
PR	24-SEP-1997; 97AU-0009373.	
PR	17-SEP-1997; 97AU-0009263.	
XX		
PA	(HALL-) HALL INST MEDICAL RES WALTER & ELIZA.	
XX		
PI	Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;	
PI	Puthalakath H, Strasser A;	
XX		
XX	WPI; 1999-244030/20.	
DR	P-PSDB; AAW98157.	
XX		
PT	New isolated member of the Bcl-2 family, Bim used in, e.g. cancer	
PT	treatment	
XX		
PS	Claim 7; Page 99-100; 145pp; English.	
XX		
CC	The present sequence encodes the long form (L) of human Bim, or	
CC	Bcl-2 interacting mediator of cell death (see AAW98157), a novel	
CC	member of the Bcl-2 family that is capable of inducing cell death	
CC	(apoptosis) and which acts as a 'death-ligand' for certain members	
CC	of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the	
CC	only Bcl-2 homology region which it encompasses is BH3. It is the	
CC	only BH3-only protein for which splice variants exist. These	
CC	result in the expression of a variety of isoforms, i.e. Bim-S,	
CC	Bim-L and Bim-EL. cDNAs encoding human Bim-L and Bim-EL (see	
CC	AAW98158) were isolated from embryo and liver cDNA libraries using	
CC	mouse Bim cDNA. Murine Bim-S, Bim-L and Bim-EL isoforms (see	
CC	AAW98154-56) are also provided. The human Bim gene maps to	
CC	chromosome 2 at bands 2q12-q13. Binding the dynein light	
CC	chain was shown to regulate the pro-apoptotic activity of Bim.	
CC	Bim-S, the splice variant which does not bind to dynein light	
CC	chain, is a much more potent killer than either Bim-L or Bim-EL.	
CC	The invention provides variants (see AAW98159-68) of murine and human	
CC	Bim-L or Bim-EL that cannot bind, couple or otherwise associate	
CC	with a dynein light chain. The identification of Bim permits the	
CC	identification and rational design of a range of products for use	
CC	in therapy, diagnosis, antibody generation and involving modulation	
CC	of physiological cell death. These therapeutic molecules may act	
CC	as either antagonists or agonists of Bim's function and will be	
CC	useful in cancer, autoimmune or degenerative disease therapy.	
CC	Increased Bim expression or Bim activity is useful, e.g. for	
CC	treatment or prophylaxis in conditions such as cancer and deletion	
CC	of autoreactive lymphocytes in autoimmune disease. Decreased Bim	
CC	expression of Bim activity is useful in regulating inhibition or	
CC	prevention of cell death or degeneration such as under cytotoxic	
CC	conditions during e.g. gamma-irradiation and chemotherapy or during	
CC	HIV/AIDS or other viral infections, ischemia, myocardial infarction,	
CC	hypoxia, degenerative diseases or for prolonging the survival of	
CC	cells being transplanted for treatment of disease. Since Bim is	
CC	expressed in germ cells, modulating Bim expression or Bim activity	
CC	is useful, e.g. as a contraceptive or method of sterilization by	
CC	preventing generation of fertile sperm.	
XX		
SQ	Sequence 416 BP; 113 A; 113 C; 103 G; 87 T; 0 other;	

alignment_scores:		
Quality:	591.00	Length: 196
Ratio:	4.581	Gaps: 2
Percent Similarity:	65.816	Percent Identity: 61.224

alignment_block:

US-09-508-832-6 'X AAX24996

Align seq 1/1 to: AAX24996 from: 1 to: 416

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyGly 17

```

|||||
1 ATGGCAAGCAACCTCTGTAGTAAAGTTCTGAGTGTGACCGAGAGGTAG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGGGAGAGGCCTCCACAGCTCAGACCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
101 CCTCCCTCAGACAGAGCCACAA..... 123
51 CysProHisGlySerProGlnGlyProLeuAlaProAlaSerProG1 67
123 ..... 123
67 yProPheAlaThrArgSerProLeuPheIlePheValArgSerSerL 84
123 ..... 123
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
|||||
124 .....GACAGGAGC 132
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
|||||
133 CCAGCACCCTCAACCACTATCTCAGTGCATTCAGTCCATGAGGAGGCT. 182
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
|||||
183 CCAGCCCTTCAACCACTATCTCAGTGCATTCAGTCCATGAGGAGGCT. 231
134 InGluGluProGluAspLeuArgProGluIleArgIleAlaGlnGluLeu 150
|||||
232 .....GAACCTGCAGATATGCGCCAGAGATATGATCGCCCAAGAGTTG 276
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
|||||
277 CGGCGTATCGGAGACGAGTTTAAACGCTTACTATGCAAGGAGGGTATTTT 326
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
|||||
327 GAATAATTTACCAAGCAGCGGAGACCCACCAAGATGTTATCTTACGCAC 376
184 euLeuArgPheIlePheArgLeuValTyrArgArgHis 196
|||||
377 TGTTCAGTTACATTGTCGCGCTGGTGGAGAAATGCAT 414
seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA1999.DAT:AAx24993
seq_documentation_block:
ID AAX24993 standard; cDNA; 332 BP.
XX AC AAX24993;
XX AC AAX24993;
XX DT 05-JUL-1999 (first entry)
XX DE Murine Bcl-2 interacting mediator of cell death Bim-S cDNA.
XX DE Bim-S; Bcl-2 interacting mediator of cell death; apoptosis;
KW cell cycle; mouse; cancer; autoimmune disease;
KW degenerative disease; therapy; contraceptive; splice variant;
KW isoform; ss.
XX OS Mus musculus.
XX PN W09914321-A1.
XX XX 25-MAR-1999.
XX XX 17-SEP-1998; 98WO-AU00772.
XX XX 24-SEP-1997; 97AU-0009373.
XX PR 17-SEP-1997; 97AU-0009263.

```

```

XX PA (HALL-) HALL INST MEDICAL RES WALTER & ELIZA.
XX PI Adams J, Cory S, Huang DCS, O'Connor L, O'Reilly L;
XX PI Puthalakath H, Strasser A;
XX DR WPI; 1999-244030/20.
XX DR P-PSDB; AAW98154.
XX PT New isolated member of the Bcl-2 family, Bim used in, e.g. cancer
XX PT treatment
XX PS Claim 3; Page 92; 145pp; English.
XX CC The present sequence encodes the short form (S) of murine Bim, or
XX CC Bcl-2 interacting mediator of cell death (see AAW98154), a novel
XX CC member of the Bcl-2 family that is capable of inducing cell death
XX CC (apoptosis) and which acts as a 'death-ligand' for certain members
XX CC of the pro-survival Bcl-2 family. Bim is a BH3-only protein, as the
XX CC only BH3-only region which it encompasses is BH3. It is the
XX CC only BH3-only protein for which splice variants exist. These
XX CC result in the expression of a variety of isoforms, i.e. Bim-S,
XX CC Bim-L and Bim-EL (see AAW98154-56). cDNAs encoding these murine Bim
XX CC isoforms were obtained from a T lymphoma cDNA library using human
XX CC recombinant Bcl-2 protein. The murine Bim gene has been mapped to
XX CC chromosome 2 at bands F3-G. Human Bim-L and Bim-EL isoforms have
XX CC also been identified (see AAW98157-58). Binding the dynein light
XX CC chain was shown to regulate the pro-apoptotic activity of Bim.
XX CC Bim-S, the splice variant which does not bind to dynein light
XX CC chain, is a much more potent killer than either Bim-L or Bim-EL.
XX CC The invention provides variants (see AAW98159-68) of murine and human
XX CC Bim-L or Bim-EL that cannot bind, couple or otherwise associate
XX CC with a dynein light chain. The identification of Bim permits the
XX CC identification and rational design of a range of products for use
XX CC in therapy, diagnosis, antibody generation and involving modulation
XX CC of physiological cell death. These therapeutic molecules may act
XX CC as either antagonists or agonists of Bim's function and will be
XX CC useful in cancer, autoimmune or degenerative disease therapy.
XX CC Increased Bim expression or Bim activity is useful, e.g. for
XX CC treatment of prophylaxis in conditions such as cancer and deletion
XX CC of autoreactive lymphocytes in autoimmune disease. Decreased Bim
XX CC expression of Bim activity is useful in regulating inhibition or
XX CC prevention of cell death or degeneration such as under cytotoxic
XX CC conditions during e.g. gamma-irradiation and chemotherapy or during
XX CC HIV/AIDS or other viral infections, ischemia, myocardial infarction,
XX CC hypoxia, degenerative diseases or for prolonging the survival of
XX CC cells being transplanted for treatment of disease. Since Bim is
XX CC expressed in germ cells, modulating Bim expression or Bim activity
XX CC is useful, e.g. as a contraceptive or method of sterilization by
XX CC preventing generation of fertile sperm.
XX SQ Sequence 332 BP; 87 A; 85 C; 91 G; 69 T; 0 other;

```

```

alignment_scores:
  Quality: 521.00      Length: 196
  Ratio: 4.736        Gaps: 1
  Percent Similarity: 56.122 Percent Identity: 56.122
alignment_block:
  US-09-508-832-6 x AAX24993
Align seg 1/1 to: AAX24993 from: 1 to: 332
1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyCl 17
|||||
1 ATGGCAAGCAACCTCTGTAGTAAAGTTCTGAGTGTGACAGAGAGGTGG 50
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProT 34
|||||
51 ACAATTGCAGCCTGCTGAGAGGCCTCCACAGCTCAGGCTGGGGCCCTA 100
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50

```

```

|||||
101 CCTCCTTACAGACAGACCGCAA..... 123
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
123 ..... 123
67 yProPheAlaThrArgSerProLeuPheIlePheValArgSerSerL 84
123 ..... 123
84 euleuSerArgSerSerGlyTyrPheSerPheAspThrAspArgSer 100
123 ..... 123
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
123 ..... 123
117 sGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGlnSerG 134
124 .....GCTTCATACGACAGTCTC 142
134 lncGluGluProGluAspLeuArgProGluIleArgIleAlaGlnLeu 150
143 AGGAGGAACCTGAAGATCTCGCCCGGAGATACGGATTGCACAGGAGCTG 192
151 ArgArgIleGlyAspGluPheAsnGluThrTyrThrArgArgValPheAl 167
193 CGCGCGATCGGACAGCTTCAACGAACTTACACAGGAGGCTGTTGC 242
167 aAsnAspTyrArgGluAlaGluAspHisProGlnMetValIleLeuGlnL 184
243 AAATGATTACCGGAGGCTGAAGACCAACCTCAATGGTTATCTTACAAC 292
184 euleuArgPheIlePheArgLeuValTrpArgHis 196
293 TGTATCGCTTATCTTCGGTCTGGTATGAGGAAGGCAT 330

seq_name: /SID52/gcgdata/geneseq/geneseq/NA1998.DAT:AAV35620
seq_documentation_block:
ID AAV35620 standard; DNA; 32367 BP.
XX
AC AAV35620;
XX
DT 07-SEP-1998 (first entry)
XX
DE Human SHOX (short stature homeobox containing gene) gene sequence.
XX
KW Homeobox domain; human growth gene; growth regulation; growth defect;
KW turner's syndrome; short stature homeobox containing gene; SHOXa;
KW SHOX; bone disease; osteoporosis; calcium regulation; short stature;
KW transcription factor A; ss.
XX
OS Homo sapiens.
XX
PN WO9814568-Al.
XX
PD 09-APR-1998.
XX
PF 29-SEP-1997; 97WO-EP05355.
XX
PR 16-JAN-1997; 97EP-0100583.
PR 01-OCT-1996; 96US-0027633.
XX
PA (RAPP/) RAPPOLD-HOERBRAND G.
XX
PI Rao E, Rappold-hoerbrand G;
XX
DR WPI; 1998-271719/24.
XX
PT New human growth genes - used to develop products for the diagnosis

```

```

PT and treatment of human growth defects such as short stature, e.g.
PT Turner's syndrome
XX
XX Claim 19; Pages 51-67; 84pp; English.
XX
CC This is the human SHOX gene sequence containing the PAR1 region. The
CC gene region corresponding to short stature has been identified as a
CC region of approximately 500 kb in the PAR1 region of the X and Y
CC chromosomes. Three genes in this region have been identified as
CC candidates for the short stature gene. These genes were designated SHOX
CC (also referred to as SHOX93 or HOX93), pET92 and SHOT (SHOX-like homeobox
CC gene on chromosome three). The SHOX gene has two separate splicing sites
CC resulting in two variations SHOXa and SHOXb. The specification provides
CC sequences of SHOX (short stature homeobox-containing) genes SHOX ET92,
CC SHOXa, SHOXb, SHOT and exons of the SHOX genes as shown in AAV35610 to
CC AAV35621 and protein sequences of the human growth protein transcription
CC factor SHOXa, SHOXb and SHOT as shown AAV60573 to AAV60575. The novel
CC genes are responsible for human growth. Defects in the genes can cause
CC short stature, e.g. Turner's syndrome. The products can be used to
CC develop agents for the treatment of short stature or other human growth
CC disorders. The products can also be used for providing a mitogenic effect
CC on cells, e.g. for the treatment of bone diseases such as osteoporosis
CC and diseases involved with disturbance in the bone calcium regulation.
XX
SQ Sequence 32367 BP; 7627 A; 8130 C; 8564 G; 8043 T; 3 other;

```

alignment_scores:

```

Quality: 120.50      Length: 159
Ratio: 1.470         Gaps: 11
Percent Similarity: 51.572 Percent Identity: 33.962

```

alignment_block:

```

US-09-508-832-6 x AAV35620/rev

```

```

Align .seg 1/1 to reverse of: AAV35620 from: 1 to: 32367
5 ProSerAspValSerSerGluCysAspArgGluGlyGlnLeuGlnPr 21
14059 CCCAGCCTCTCCCGAGGACACAGATCCCAAGGCTCTCCAGGACAC 14010
21 oAlaGluArgProGlnLeuArgProGlyAlaProThrSerLeuGlnT 38
14009 AGGT.....CCCCAAGCCTCTCCCGGACACCA..... 13982
38 hrGluProGlnGlyAsnProAspGlyGluGlyAspArgCysProHisGly 54
13981 ..GGTCCCCAAGCCTCTCCCGGTCACTAGT.....CCCCAAGGC 13943
55 SerProGln.....GlyProLeuAlaProProAlaSerProGlyProPh 69
13942 ACTCCGAGACACAGGTCCCGAAGCTCTCCAAGGTCAACAGGTCCCA 13893
69 eAla.....ThrArgSerProLeuPheIlePheValArgArgS 82
13892 AGGCTCTCCCGAGGACACAGGTCCCAAGGCTCTCCCGGTCAACAGGT 13843
82 erSerLeuLeuSerArg...SerSerGlyTyrPheSerPheAspThr 97
13842 CCCAGGCTCTCCAAGGTCAACAGGTCCCAAGCTCTCTCTGGGACACC 13793
98 .....AspArg.SerProAlaProMetSerCysAspLysS 109
13792 AGGTGTTCAGGCTCTCCCGGACACCAAGTCCCAAGC.....T 13752
109 erThrGlnThrPro.....SerProCysGln 118
13751 CTCGCGGACACAGGTCCCAAGCTCTCCCGGTCAACAGGTCTCCAA 13702
119 AlaPheAsnHisTyrLeuSerAlaMetAlaSerIleArgGln.....Se 133
13701 GCCTCTCCAGGACACAGGTCCCAAGCTCTCCAGGACACACAGGTCC 13652

```


133 rClnGluGluProGluAspLeuArg 141
 ||| :|||:||||| |||
 13651 CCAGCCCTCTCCCGAGGACACGAG 13627

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2001.DAT:AAH17812

seq_documentation_block:

ID AAH17812 standard; cDNA; 2405 BP.

XX AAH17812;

XX 26-JUN-2001 (first entry)

XX Human cDNA sequence SEQ ID NO:17475.

XX Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.

XX Homo sapiens.

XX EP1074617-A2.

XX 07-FEB-2001.

XX 28-JUL-2000; 2000EP-0116126.

XX 29-JUL-1999; 99JP-0248036.

XX 27-AUG-1999; 99JP-0300253.

XX 11-JAN-2000; 2000JP-0118776.

XX 02-MAY-2000; 2000JP-0183767.

XX 09-JUN-2000; 2000JP-0241899.

XX (HELI-) HELIX RES INST.

XX Ota T, Isoqai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

XX Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;

XX WPI; 2001-318749/34.

XX Primer sets for synthesizing polynucleotides, particularly the 5602

XX full-length cDNAs defined in the specification, and for the detection

XX and/or diagnosis of the abnormality of the proteins encoded by the

XX full-length cDNAs -

XX Claim 8; SEQ ID 17475; 2537pp + CD ROM; English.

XX The present invention describes primer sets for synthesizing 5602
 CC full-length cDNAs defined in the specification. Where a primer set
 CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
 CC to the complementary strand of a polynucleotide which comprises one of
 CC the 5602 nucleotide sequences defined in the specification, where the
 CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
 CC of an oligonucleotide comprising a sequence complementary to the
 CC complementary strand of a polynucleotide which comprises a 5'-end
 CC sequence and an oligonucleotide comprising a sequence complementary to a
 CC polynucleotide which comprises a 3'-end sequence, where the
 CC oligonucleotide comprises at least 15 nucleotides, and the combination of
 CC the 5'-end sequence/3'-end sequence is selected from those defined in
 CC the specification. The primer sets can be used in antisense therapy and
 CC in gene therapy. The primers are useful for synthesizing polynucleotides,
 CC particularly full-length cDNAs. The primers are also useful for the
 CC detection and/or diagnosis of the abnormality of the proteins encoded by
 CC the full-length cDNAs. The primers allow obtaining of the full-length
 CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
 CC AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to
 CC AAB95893 represent human amino acid sequences; and AAH13629 to AAH13632
 CC represent oligonucleotides, all of which are used in the exemplification
 CC of the present invention.

XX Sequence 2405 BP; 508 A; 784 C; 739 G; 374 T; 0 other;

alignment_scores:

Quality: 118.50 Length: 198

Ratio: 1.445 Gaps: 5
 Percent Similarity: 41.414 Percent Identity: 24.242

alignment_block:

US-09-508-832-6.x AAH17812 ..

Align seg 1/1 to: AAH17812 from: 1 to: 2405

2 AlAtysGlnProSerAspValSerSerGluCysAspArgGluGlyGlyGly 18
 ||| :|||:||||| |||
 498 GCGCCGAGGCTCTCGACGCGCGGAACGCTGCTTCGCCCTAGGCGCAGT 547
 ||| :|||:||||| |||
 18 nLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProThrS 35
 ||| :|||:||||| |||
 548 GGGCCAGGACTCCACCACGCGCGCGCGCGCTCTCTCGGCC... 593
 ||| :|||:||||| |||
 35 erLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArgCys 51
 ||| :|||:||||| |||
 594CAGAGCCAGGCACCTGGGGGCCAGAGGCACACGCTTCGGGGAG 638
 ||| :|||:||||| |||
 52 ProHisGlySerProGlnGlyProLeu...AlaProProAlaSerProG 67
 ||| :|||:||||| |||
 639 CCGGGTCCGCGCTCTCGCATCTTGTGTGCGCACGCGCGCGCGCGCCGC 688
 ||| :|||:||||| |||
 67 yProPheAlaThrArgSerProLeuPheIlePheValArgSerSerL 84
 :||| -|||
 689 GCCGTACGA..... 698
 84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
 699CCC 701
 101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
 ||| :|||:||||| |||
 702 CCAGCACGCCGAGCGCCCGCGAGTCCACTGTGCGCTCGCGCCCGCCGAC 751
 ||| :|||:||||| |||
 117 sGln.....AlaPheAsnH 122
 :||| :|||:||||| |||
 752 GCGCCCCGGGAAAGTTCCTACTCTGTCATTTTCACACGTAATTTACAATA 801
 ||| :|||:||||| |||
 122 IsTyrLeuSerAlaMetAlaSerIleArgGlnSerGlnGluGluProGlu 138
 :||| :|||:||||| |||
 802 ACCACGAGATTCTCCGCGCTCGCTAGGAACGACGCGCGCGGCGGAGCT 851
 ||| :|||:||||| |||
 139 AspLeuArgProGluIleArgIleAlaGlnGluLeuArgArgIleGlyAs 155
 ||| :|||:||||| |||
 852 GCCGCTCTCCGAGATCAAGCCCTGCAGCAG..... 884
 ||| :|||:||||| |||
 155 pGluPheAsnGluThrTyrThrArgValPheAlaAsnAspTyrArgG 172
 ||| :|||:||||| |||
 885ACCGGAGGCTCTGCGAACGCGCAGGAGC 915
 ||| :|||:||||| |||
 172 luAlaGluAspHisProGlnMetValIleLeuGlnLeuLeuArg 186
 :||| :|||:||||| |||
 916 GGACCGCGGTGCACACCATCAGCGGAGCTTCGAGGCGCTCAGG 959
 ||| :|||:||||| |||

seq_name: /SIDS2/gcgdata/geneseq/geneseqn/NA2000.DAT:AAZ61771

seq_documentation_block:

ID AAZ61771 standard; cDNA; 1421 BP.

XX AAZ61771;

XX 27-MAR-2000 (first entry)

DE cDNA encoding mouse skin cell transmembrane protein, SEQ ID NO:244.
 XX Skin; dermal papilla; keratinocyte; neonatal foreskin fibroblast;
 KW embryonic skin cell; keratinocyte stem cell; transit amplifying cell;
 KW secreted; transmembrane; inflammation; cancer; neurological disease;
 KW angiogenesis; tumour vascularisation; growth disorder;
 KW developmental disorder; skin wound; hair follicle disorder;
 KW anti-inflammatory; cytostatic; neuroprotective; vulnery; ss.

er;
pyed;

ed with
able with
vention
RP), RPGR
RPGR
select
minated
titan
d where
skies,
izers.
15
ant
ng
oe

```

alignment_scores:
  Quality: 110.00      Length: 147
  Ratio: 1.279        Gaps: 6
  Percent Similarity: 58.503  Percent Identity: 27.891

alignment_block:
  US-09-508-832-6 x AAD07131/rev ..

  Align seg 1/1 to reverse of: AAD07131 from: 1 to: 2800

5 ProSerAspValSerSerGluCysAspArgGluGlyGlnLeuGlnPr 21
770 CCTTCTCCACTTCTCTCTCCCTCTCTCTCCACTTCCCTCTCTCTC 721
21 oAaGluArgProProGlnLeuArgProGluAlaProThrSerLeuGlnT 38
770 CTCCACTTCCCTCTCTCTTCCCAATCTGCTCTCTCTCTCTCTCTCC 671
38 hrGluProGlnGlyAsnProAspGlyGlu...GlyAspArgCysProHis 53
670 CCTCCCTTCTCTCTCTCCCTCTCTCTTCCCTCTCTCTCTCTCTCTCC 621
54 GlySerPro.....GlnGlyProLeuAlaProProAla.....SerPr 66
620 AATTCCCTCTCTCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 571
66 oGlyProPheAlaThrArgSerProLeuPheLeuPheValArgArgSer$ 83
570 CTCCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 545
93 hrLeuLeuSerArgSerSerSertGlyTyrPheSerPheAspThrAspArg 99
544 CTCCTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 495
100 Ser.....ProAlaProMetSerCysAspLy 108
494 TCTTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 445
108 sSerThrGlnThrPro...SerProCysGlnAlaPheAsnHisTyrL 124
444 CTCCTCCCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 395
124 euSerAlaMetAlaSerIleArgGlnSerGlnGluPro 137
394 CCTCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCC 354

seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA2001.DAT: AAD07132

seq_documentation_block:
  AAD07132 standard; cDNA; 2803 BP.

  AAD07132;

  06-AUG-2001 (first entry)

  Canine retinitis pigmentosa GTPase regulator (RPGR) mutant
  Dog; X-linked progressive retinal atrophy 2; XLPRA2; genet;
  retinitis pigmentosa GTPase regulator; RPGR; Siberian Husky;
  Miniature Schnauzer; mutant; mutelin; ss.

  Canis familiaris.
  OS Synthetic.
  OS
  XX
  XX
  AC
  AC
  XX
  XX
  DT
  DT
  DE
  DE
  XX
  KW
  KW
  KW
  KW
  XX
  XX
  OS
  OS
  XX
  XX
  Key Location/Qualifiers
  CDS 1..1149
  FT /*tag= a
  FT /product= "Canine retinitis pigmentosa GTPase
  FT regulator mutant"
  FT /note= "CDS does not include start codon"
  FT /partial
  FT mutation (931..932, AGAG)

```


DR P-PSDB; AAB12028.
XX New PR domain peptides comprising amino acid sequences from, for
PT example retinoblastoma-interacting zinc finger, or egl-43 proteins, for
PT regulating gene transcription and controlling cell proliferation and
PT differentiation
XX
XX Example 1; Fig 1; 91pp; English.
XX
CC The present sequence is the rat retinoblastoma (Rb)-interacting zinc
CC finger (RIZ) protein coding sequence. RIZ is a nuclear phosphoprotein
CC that acts as a cell differentiation factor. RIZ can modulate cell growth
CC by binding to Rb protein, which is involved in regulating cell
CC proliferation. In addition, RIZ can act to regulate transcription. RIZ
CC functions to maintain cells in the G1 phase of the cell cycle, by
CC interacting with Rb through the cr2 domain of RIZ. Rat RIZ protein
CC contains a number of GTPase motifs (see AAB12037 to AAB12056 and AAB12099
CC to AAB12104). RIZ protein is a PR domain protein and is present primarily
CC in the cell nucleus. RIZ gene mutations may be implicated in various
CC cancers such as melanoma, neuroblastoma, leukaemia and breast cancer, and
CC so the RIZ gene may be used in gene therapy for these disorders. Since
CC RIZ protein is implicated in cell cycle arrest, inhibition of RIZ
CC activity may be useful in neurodegenerative disorder therapy e.g. for
CC Parkinson's, Huntington's or Alzheimer's disease, paralysis or motor
CC neuron disorders, or cardiac disorder therapy e.g. for heart disease
CC where the ability to induce neural/ cardiac tissue proliferation would be
CC useful.
XX
SQ Sequence 6171 BP; 1683 A; 1645 C; 1524 G; 1319 T; 0 other;

alignment_scores:
Quality: 109.50 Length: 222
Ratio: 1.084 Gaps: 12
Percent Similarity: 45.495 Percent Identity: 24.775
alignment_block:
US-09-508-832-6 x AAB60103 ..
Align seg 1/1 to: AAB60103 from: 1 to: 6171

2 AlaLysGlnProSerAspVal.....SerSerGluCysAspArgGluG1 16
||||:|||||
2941 GCTGAGTCTCCACCTGAGTGTGGCCCTCTCTCACCCCTCTCCAGAC 2990
16 yGlyGlnLeuGlnProAlaGluArgProGlnGlnLeuArgProGlyAlaP 33
:||||:|||||
2991 AGCCTCTTATCTCCGGTTCAGCTGCTCTCTTTAACCCCTCCAGAGC 3040
33 roThrSer.....
||||:|||||
3041 CTTCTTCCCTCCCTCCCTCTCTCTCTGTTAACTGTTGCCACTCCACCA 3090
36LeuGlnThrGluProGlnGlyAsnPro.....AspGlyG1 47
||||| ||| ||| |||
3091 CTTCCCTCTCTTCCACAGCTCTCTCTCTCCACCCCTCTTGTGAGCTC 3140
47 uGlyAspArgCysProHis.....GlySerProG 57
:||||:|||||
3141 CCTCAGCAGTGTCCCTCTCTCTCTCTCAACACCACTGCTCAGTCTCTCT 3190
57 lnglyProLeuAlaProAlaSerProGlyPro..... 68
||||:|||||
3191 TTCCCATTTCTTCCCAACAGTGTCTCTCTCTCTCTCTCTCTCTCTCT 3240
69PheAlaThrArgSerProLeuPheIlePheValArgAr 81
||||:|||||
3241 GTAGAGCCACTTATGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 3272
81 gSerSerLeuLeuSerArgSerSerSerGlyTyrPheSerPheAspThrA 98
||||| |||||||
3273 TCCCCCAACACTTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT 3322

98 spArgSerProAlaProMetSerCysAspLysSerThrGlnThrProSer 114
:: |||||
3323 CT.....TCCTGC.....TCCTCCACCTCCCTCCCTCC 3348
115 ProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIle.. 130
|||||
3349 CCACCC.....CCTCTTTCAGCAGTGTCTCTCTCTCTCTCTCTCT 3380
131ArgG 132
3381 TTCTCTCTGGGACAACTGGAGGCATCTCTGCTGCAGTAACCTTTCAAAC 3430
132 InSerGlnGluGluProGluAspLeuArgProGluIleArgIleAlaGln 148
||||:|||||
3431 AGGAGGAGTTCAGAGTGAAGTCTGAAACCCCAAG.....GAA 3468
149 GluLeuArgArgIleGlyAspGlu.....PheAsnGluThrTyrThrAr 163
|||||
3469 GAGGCCCCACCTGCAGGGGACAGAGTGTGGTCCCAAGAACATTCAGCA 3518
163 gArgValPheAlaAsn 168
:::|
3519 AAACCTTCATTTGCAAT 3534
seq_name: /SIDS2/gcgdata/geneseq/geneseq/NA2000.DAT:AAZ50085
seq_documentation_block:
ID AAZ50085 standard; cDNA; 1249 BP.
XX
AC AAZ50085;
XX
DT 04-MAY-2000 (first entry)
XX
DE Rice serine O-acetyltransferase-1 cDNA clone.
XX
KW Serine O-acetyltransferase: sulphate assimilation; O-acetylserine;
KW rice; clone rlr24.pk0069.all; cysteine formation; marker; probe;
KW plant breeding; transgenic plant; ss.
XX
OS Oryza sativa.
XX
FH Key Location/Qualifiers
FT CDS 119..1030
FT /*tag= a
FT /product= "Rice serine O-acetyltransferase-1"
FT /note= "Derived from the clone rlr24.pk0069.all"
FT /transl_except= (pos:194..196, aa:Val)
XX
PN WO200004167-A2.
XX
PD 27-JAN-2000.
XX
PF 13-JUL-1999; 99WO-US15872.
XX
PR 14-JUL-1998; 98US-0092833.
XX
PA (DUPO) DU PONT DE NEMOURS & CO E I.
XX
PI Falco SC, Allen SM, Maxwell CA;
XX
DR WPI; 2000-182432/16.
DR P-PSDB; AAY44768.
XX
PT New isolated nucleic acid fragment encoding a sulfate assimilation
PT protein in plants, useful as probes to isolate genes encoding
PT homologous proteins from other plant species -
XX
PS Claim 3; Page 35; 44pp; English.
XX
CC The present sequence is a cDNA encoding rice serine O-acetyltransferase,
CC a sulphate assimilation protein. This is obtained from rlr24 cDNA
CC library, clone rlr24.pk0069.all, derived from rice leaf infected with
CC Magaporthe grisea strain 4360-R-62. Serine O-acetyltransferase converts

CC serine to O-acetylserine, that is involved in the formation of cysteine.
CC This sequence is used as a probe to isolate other plant sulphate
CC assimilation proteins, for genetic and physical mapping of related genes
CC and as markers of traits linked to the gene. This is useful for plant
CC breeding. It is also used to create transgenic plants with altered
CC levels of serine O-acetyltransferase, or found in cell types or
CC developmental stages in which they are not normally found.
XX
SQ Sequence 1249 BP; 193 A; 477 C; 361 G; 218 T; 0 other;

alignment_scores:

Quality: 109.00 Length: 191
Ratio: 1.239 Gaps: 8
Percent Similarity: 46.073 Percent Identity: 27.225

alignment_block:

US-09-508-832-6 x AAZ50085 ..

Align seg 1/1 to: AAZ50085 from: 1 to: 1249

```
25 ProProGlnLeuArgPro.....GlyAlaProThrSe 35
|||||:  |||  :|:|:|  ||
378 CCTCCACGCTGCTCTCCAGCTCTCTACGACCTCTCGTGGCTCCCTC 427
35 rLeuGlnThrProGlnGlyAsnProAspGlyGluGlyAspArgCysP 52
| :|:|  |||:|:|  |||:|:|  |
428 GCCGGCGACCCCTCCCGCGCGCTCGTGC.....C 462
52 roHisGlySerProGlnGlyProLeuAlaProAlaSerProGlyPro 68
|| :|:|  |||:|:|  |||  :|:|  |||  |||  |||  |||  |||
463 CGACCTCTCGCGCGGCTCCAGGACCCGCTGGTGGCTTCTCC 512
69 PheAlaThrArgSerProLeuPheIlePheValArgSerSer..... 83
|||:|  :|:|  :|:|  |||  |||
513 ACTGCCTCTCACT.....ACAAGGCTTCTCTGCCATC 547
84 .....LeuLeuSerSerSerSerGlyTyrPheSerPheAspThrA 98
|||||:|  |||:|:|  |||  |||  :|:|
548 CAGGCCACGCGCTCGCGACGCTCTGGCGCGACGCGCGCGCCCT 597
98 sArg.....SerProAlaProMetSerCysAspLysSerThrGln 111
:|:|  |||  |||  |||  |||  |||  |||  |||  |||  |||
598 CGGCTCGCGCTCCAGTCCGCGCTCGCGAGGTGTTGCGCGTCCATCC 647
112 ThrProSerProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAl 128
|||||  |||  :|:|  :|:|  |||
648 ACCCGCGCGCGGATCGGCAAGGGCTCTCTCGACACGCGCACGGGC 697
128 aSerIle.ArgGlnSerGlnGlu..... 136
||||  |||:|:|  |||:|:|  |||:|:|  |||:|:|
698 GTCGTATCGAGAGACCGCGCTATCGGCGACACGTCTCCATCTCTCA 747
137 .....ProGln 138
|||:|
748 CCACGTACGCTGGCGGGACAGCGCCGTGGGCGACCGGCCACCCCA 797
138 uAsp.....LeuArgProGluIleArgIleAlaGlnGluLeuArgArgI 153
:|:|  |||  |||  |||  |||  |||  |||  |||  |||  |||
798 AGATCGCGCGCGCTCTCATTTGGCGCGCGCGACGATCTCTGGCAAT 847
153 leGlyAspGluPheAsnGluThrTyrThrArgValPheAlaAsnAsp 169
|||:|  |||:|  |||:|  |||:|  |||:|  |||:|  |||:|
848 GTCAGGATCGGCCCGCGCGAAGATCGGGCGCGGTCTGTCTCAT 897
170 TyrArgGluAlaGluAspHis 176
|||  |||  |||  |||  |||
898 CGACGTGCGCGCGAGCCAC 918
```


OM of: US-09-508-832-6 to: EST.* out_format : pfs

Date: Dec 11, 2001 1:03 AM

About: Results were produced by the GenCore software, version 4.5,
Copyright (c) 1993-2000 CompuGen Ltd.

Command line parameters:

-MODE=framer_p2n.model -DEV=xlp
-Q/cn2.1/USPTO_spool/US09508832/runat_10122001_110349_29536/app_query.fasta_1.620
-DB=EST -QFMT=fastap -SUFFIX=1st -GAPOP=12.000 -GAPEXT=4.000
-MINMATCH=0.100 -LOOPT=0.000 -LOOPT=0.000 -GAPOP=4.500
-GAPEXT=0.050 -XGAPOP=10.000 -XGAPEXT=0.500 -FGAPOP=6.000
-FGAPOP=7.000 -XGAPOP=10.000 -YGAPEXT=0.500 -DELOP=6.000
-DELEXT=7.000 -START=1 -MATRIX=blosum62 -TRANS=human4.0.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0
-ALIGN=15 -MODE=LOCAL -OUTFMT=pfs -NORM=ext -MINLEN=0
-MAXLEN=200000000 -USPR=US09508832 -CGNL_1_0 -NCPU=6 -ICPU=3
-LONGLOG -NO_XLPXY -WAIT -THREADS=1

Search information block:

Query: US-09-508-832-6
Query length: 196
Database: EST.*
Database sequences: 11351937
Database length: 1077921985
Search time (sec): 2629.110000

score_list:

Sequence	Strd Orig	ZScore	EScore	Len	Documentation
gb_htc:AK011490	+	980.50	1136.71	1206	AK011490 Mus musculus 10 days
gb_est2:BG921698	+	918.00	1066.42	935	BG921698 602825518F1 NCI_CGAP_M
gb_est2:BF021882	+	730.00	854.67	452	BF021882 uy59b09.y1 McCarrey Ed
gb_gss:AZ706148	+	689.00	805.25	580	AZ706148 RPI1-23-227P3 TV RPI1
gb_est2:BG173095	+	606.50	708.68	668	BG173095 602336666F1 NCI_CGAP_M
gb_est1:AF1971169	-	332.00	393.51	492	AF1971169 wr24h12.x1 NCI_CGAP_P
gb_est2:BF319454	-	249.00	299.35	389	BF319454 uy59b09.x1 McCarrey Ed
gb_est1:AW629314	-	249.00	295.11	664	AW629314 hf156602.x1 Soares_NFL
gb_est1:AF209718	-	202.00	242.41	537	AF209718 AF209718 Xenopus laevi
gb_est1:AW48960	+	149.00	190.84	0.1822	AW48960 R24840G.s1 Soares.test
gb_est1:AA629308	+	127.00	156.19	501	AA629308 R24840G.s1 Soares.test
gb_est2:BF172831	+	126.00	161.92	210	BF172831 PCL5805 Myeloma (PCL)
gb_est1:AA629308	-	123.00	151.56	28.09	AA629308 uy84a06.s1 Soares.test
gb_est2:BF259468	+	118.50	142.97	768	BF259468 HVSMEF001P03f Hordeum
gb_htc:BC007683	+	115.00	134.44	252.28	BC007683 Homo sapiens, postemb
gb_est2:BF631591	+	114.50	137.32	174.41	BF631591 HVSMB0016115f Hordeum
gb_est1:BEA08300	+	113.00	138.19	156.12	BEA08300 601302689F1 NIH_MGC_21
gb_est2:BF627834	+	113.00	136.36	197.35	BF627834 HVSMB0005020f Hordeum
gb_est1:AW550178	+	111.50	137.99	160.09	AW550178 L0061B04-3 NIA Mouse H
gb_est1:AV437695	+	111.50	137.85	162.92	AV437695 AV437695 Porphyra yezo
gb_gss:AO744259	+	111.50	133.80	274.11	AO744259 HS_5508.A2.E11.T7A RPC
gb_gss:CN50379K	+	110.50	132.71	315.02	AL231329 Tetraodon nigroviridis
gb_est2:BF6868252	+	110.50	132.80	672.16	BF6868252 963107807.x1 C. reinh
gb_est2:BG997598	+	109.50	136.84	185.42	BG997598 PM0-HT0911-210301-018
gb_est1:BE611648	+	109.50	135.29	223.87	BE611648 AV611648 Bos taurus lu
gb_est2:BG921067	+	109.50	133.37	292.58	BG921067 602825319F1 NCI_CGAP_M
gb_gss:BG394426	+	109.50	132.79	331.68	BG394426 602456946F1 NIH_MGC_1
gb_est2:BT289133	+	108.50	134.17	261.15	BT289133 UI-R-DKO-cfe-h-03-0-UI
gb_est2:BF491700	+	108.50	133.04	301.95	BF491700 AT28505.5prime AT Dros
gb_est2:BF312248	+	108.50	128.16	564.76	BF312248 601898759F1 NIH_MGC_1
gb_est1:AF1368415	+	108.00	130.91	396.88	AF1368415 qy08b11.x1 NCI_CGAP_B
gb_est2:BE807996	+	108.00	127.36	625.94	BE807996 H3060B11-3 NIA Mouse
gb_est2:BE880795	+	108.00	127.29	631.30	BE880795 601493220F1 NIH_MGC_6
gb_est2:BG895004	+	107.50	132.64	317.74	BG895004 355805 MARC 1P1G Sus s
gb_est1:BE313313	+	107.50	129.40	481.91	BE313313 601147639F1 NIH_MGC_13
gb_gss:CN50310C	+	107.50	129.31	487.07	AL446045 Tetraodon nigroviridis
gb_est2:BE619071	+	107.50	129.29	488.79	BE619071 601472685F1 NIH_MGC_68
gb_est2:BG827242	+	107.50	128.04	573.86	BG827242 602749384F1 NIH_MGC_1
gb_est1:AU124084	+	107.00	131.97	346.51	AL24084 AU124084 NT2RM2 Homo s
gb_est1:AJ006538	+	107.00	130.86	399.37	AJ006538 AJ006538 Zea mays earl
gb_est1:AL508424	+	107.00	130.32	417.22	AL508424 AL508424 Hordeum vulg

gb_est2:BF496767 + 106.50 130.79 402.97 619 1 BF496767 AT10677.5prime AT D
gb_est2:BF504432 + 106.50 130.70 407.60 626 1 BF504432 AT05788.5prime AT D
gb_est2:BF498774 + 106.50 130.51 417.54 641 1 BF498774 AT13245.5prime AT D
gb_est2:BF506369 + 106.50 129.79 457.98 702 1 BF506369 AT08819.5prime AT D

seq_name: gb_htc:AK011490

seq_documentation_block:

LOCUS AK011490 1206 bp mRNA HFC 05-JUL-2001
DEFINITION Mus musculus 10 days embryo cDNA, RIKEN full-length enriched library, clone:2610020M23, full insert sequence.

ACCESSION AK011490

VERSION AK011490.1 GI:12847647

KEYWORDS CAP trapper.

SOURCE Mus musculus (strain:C57BL/6J) 10 days embryo cDNA to mRNA,

clone_lib:RIKEN full-length enriched mouse cDNA library

SOURCE clone:2610020M23.

ORGANISM Mus musculus

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 1206)

AUTHORS Carninci,P. and Hayashizaki,Y.

TITLE High-efficiency full-length cDNA cloning

JOURNAL Methods in enzymology. 303, 19-44 (1999)

MEDLINE 99279253

PUBMED 10349636

REFERENCE 2 (bases 1 to 1206)

AUTHORS Carninci,P., Shibata,Y., Hayatsu,N., Sugahara,Y., Shibata,K.,

Itoh,M., Konno,H., Okazaki,Y., Muramatsu,M. and Hayashizaki,Y.

Normalization and subtraction of cap-trapper-selected cDNAs to

prepare full-length cDNA libraries for rapid discovery of new genes

Genome research. 10 (10), 1617-1630 (2000)

JOURNAL 20499374

MEDLINE 11042159

REFERENCE 3 (bases 1 to 1206)

AUTHORS Shibata,K., Itoh,M., Aizawa,K., Nagao,K., Sasaki,N., Carninci,P.,

Konno,H., Akiyama,Y., Nishi,K., Kitsuai,T., Tashiro,H., Itoh,M.,

Sumi,N., Ishii,Y., Nakamura,S., Hazama,M., Nishine,T., Harada,A.,

Yamamoto,R., Matsumoto,H., Sakauchi,S., Ikegami,T., Kashiwagi,K.,

Fujiwaka,S., Inoue,K., Togawa,Y., Izawa,M., Ohara,E., Watahiki,M.,

Yoneda,Y., Ishikawa,T., Ozawa,K., Tanaka,T., Matsuura,S., Kawai,J.,

Okazaki,Y., Muramatsu,M., Inoue,Y., Kira,A. and Hayashizaki,Y.

RIKEN integrated sequence analysis (RISA) system--384-format

sequencing pipeline with 384 multicapillary sequencer

Genome research. 10 (11), 1757-1771 (2000)

JOURNAL 20530913

MEDLINE 11076861

REFERENCE 4 (bases 1 to 1206)

AUTHORS The RIKEN Genome Exploration Research Group Phase II Team and the

FANTOM Consortium.

Functional annotation of a full-length mouse cDNA collection

Nature 409, 685-690 (2001)

JOURNAL 20530913

MEDLINE 11076861

REFERENCE 5 (bases 1 to 1206)

AUTHORS Adachi,J., Aizawa,K., Akahira,S., Akimura,T., Aono,H., Arai,A.,

Arakawa,T., Carninci,P., Fukuda,S., Fukunishi,Y., Furuno,M.,

Hanagaki,T., Hara,A., Hayatsu,N., Hiranoto,K., Hiraoka,T., Hori,F.,

Imotani,K., Ishii,Y., Itoh,M., Izawa,M., Kato,H., Kawai,J.,

Kojima,Y., Konno,H., Kouda,M., Koya,S., Kurihara,C., Matsuyama,T.,

Miyazaki,A., Nishi,K., Nomura,K., Numazaki,R., Ohno,M., Okazaki,Y.,

Okido,T., Owa,C., Saito,H., Saito,R., Sakai,C., Sakai,K., Sano,H.,

Sasaki,D., Shibata,K., Shibata,Y., Shinagawa,A., Shiraki,T.,

Sogabe,Y., Suzuki,H., Tagami,M., Tagawa,A., Takahashi,F.,

Tanaka,T., Tejima,Y., Toya,T., Yamamura,T., Yasunishi,A.,

Yoshida,K., Yoshino,M., Muramatsu,M. and Hayashizaki,Y.

Direct Submission

Submitted (10-JUL-2000) Yoshihide Hayashizaki, The Institute of

Physical and Chemical Research (RIKEN), Laboratory for Genome

Exploration Research Group, RIKEN Genomic Sciences Center (GSC),

RIKEN Yokohama Institute, 1-7-22 Suehiro-cho, Tsurumi-ku, Yokohama,

Kanagawa 230-0045, Japan (E-mail:genome-res@sc.riken.go.jp,

URL:http://genome.gsc.riken.go.jp/, Tel:81-45-503-9222,

Fax:81-45-503-9216)

COMMENT Please visit our web site (<http://genome.gsc.riken.go.jp/>) for


```

|||||
301 AACGAACCTACACAAGAGGCTTTGCAATGATTACCGCAGGCTGA 350
|||||
174 uASpHisProGlnMetValIleLeuGlnLeuLeuArgPheIlePheArgL 191
|||||
351 AGACCACCCTCAATGGTTATCTTACAACTGTTACGGCTTTATCTTCGGTC 400
|||||
191 euValTtpArgArgHis 196
|||||
401 TGGTATGGAGAAGGCAT 417

```

seq_name: gb_gss:AZ706148

seq_documentation_block: 580 bp DNA GSS 24-JAN-2001
 LOCUS AZ706148
 DEFINITION RPCI-23-227P3-TV RPCI-23 Mus musculus genomic clone RPCI-23-227P3,
 DNA sequence.

ACCESSION AZ706148
 VERSION AZ706148
 KEYWORDS GSS.
 SOURCE house mouse.

ORGANISM
 Mus musculus

REFERENCE
 AUTHORS Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 580)
 Zhao, S., Nierman, W., Feldblyum, T., Malek, J., Shatsman, S., Akinret
 , B., Levins, M., McGann, S., Tsegaye, G., Geer, K., Krol, M., de Jong, P.
 and Fraser, C.M.
 Mouse BAC End Sequences from Library RPCI-23

TITLE
 JOURNAL
 COMMENT

Other GSSs: RPCI-23-227P3.TJ
 Contact: Shaying Zhao
 Department of Eukaryotic Genomics
 The Institute for Genomic Research
 9712 Medical Center Dr., Rockville, MD 20850, USA
 Tel: 301 838 0200
 Fax: 301 838 0208
 Email: szhao@tigr.org

Clones are derived from the mouse BAC library RPCI-23. For BAC
 library availability, please contact Pieter de Jong
 (pdejong@mail.cho.org). Clones may be purchased from BACPAC
 Resources (<http://www.choi.org/bacpac/orderingframe.htm>). BAC end
 page: http://www.tigr.org/tdb/bac_ends/mouse/bac_end_intro.html
 Plate: 227 row: P column: 3
 Seq primer: 17
 Class: BAC ends.

FEATURES

Location/Qualifiers
 1..580
 /organism="Mus musculus"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="RPCI-23-227P3"
 /clone_lib="RPCI-23"
 /sex="Female"
 /lab_host="DH10B"
 /note="organ: Kidney/Brain; Vector: pBAC3.6; Site_1:
 EcoRI; Site_2: EcoRI; Female C57BL/6J mouse kidney and/or
 brain genomic DNA was isolated and partially digested
 with a combination of EcoRI and EcoRI methylase. Size
 selected DNA was cloned into the pBAC3.6 vector at the
 EcoRI sites. The ligation products were transformed into
 DH10B electrocompetent cells (BRL Life Technologies)."

BASE COUNT 138 a 162 c 138 g 142 t
 ORIGIN

alignment_scores:

Quality: 589.00 Length: 127
 Ratio: 5.425 Gaps: 0
 Percent Similarity: 100.000 Percent Identity: 100.000

alignment_block:

US-09-508-832-6 x AZ706148

Align seg 1/1 to: AZ706148 from: 1 to: 580

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG 17
|||||
90 ATGCCAAGCAACCTCTCTGATGTAAGTTCTGAGTGTACAGAGAAGGTGG 139
|||||
17 yGlnLeuGlnProAlaGluArgProGlnLeuArgProGlyAlaProt 34
|||||
140 ACAATTGACGCTGCTGAGAGGCTCCAGCTCAGGCTGGGGCCCTA 189
|||||
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
190 CTTCCCTTACAGACAGAACCCGAGGTAATCCGACGCGAAGGGGACCGC 239
|||||
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG 67
|||||
240 TGCCCCCAGCGAGCCCTCAGGGCCCGCTGGCCGCCAGCCGCGCCCTGG 289
|||||
67 yProPheAlaThrArgSerProLeuPheIlePheValArgSerSerL 84
|||||
290 CCCTTTTGGCTACAGATCCCACTTTTTCATCTTTGTGAGAAGATCTTCTC 339
|||||
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
|||||
340 TGTGTGTCCTCCGCTCTCCAGTGGGTATTTCTTTTGACACAGACAGGAGC 389
|||||
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProProCy 117
|||||
390 CCGGCCCATGATGAGTGTGACAAGTCAACACAAACCCCAAGTCTCTCTTG 439
|||||
117 sGlnAlaPheAsnHisTyrLeuSerAlaMet 127
|||||
440 CCAGGGCTTCAACCACTATCTCAGTGCAATG 470

```

seq_name: gb_est2:BG173095

seq_documentation_block:

LOCUS BG173095 668 bp mRNA EST 06-FEB-2001
 DEFINITION 602333666F1 NCI_CGAP_Mam1 Mus musculus cDNA clone IMAGE:4459720 5',
 mRNA sequence.

ACCESSION BG173095

VERSION BG173095.1 GI:12679707

KEYWORDS EST.

SOURCE house mouse.

ORGANISM

Eukaryota; Metazoa; Chordata; Rodentia; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 668)

AUTHORS NIH-MGC <http://mgc.nci.nih.gov/>.

TITLE National Institutes of Health, Mammalian Gene Collection (MGC)

JOURNAL Unpublished (1999)

COMMENT

Contact: Robert Strausberg, Ph.D.
 Email: cgapbs-r@mail.nih.gov

Tissue Procurement: Gilbert Smith, Ph.D.

cDNA Library Preparation: Life Technologies, Inc.

DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)

Cloned through the I.M.A.G.E. Consortium/LLNL at:

http://image.llnl.gov

Plate: LLAM10260 row: c column: 17

High quality sequence stop: 599.

Location/Qualifiers

1..668

source

/organism="Mus musculus"

/strain="FVB/N"

/db_xref="taxon:10090"

/clone="IMAGE:4459720"

/clone_lib="NCI_CGAP_Mam1"

/tissue_type="tumor, biopsy sample"

/dev_stage="3 months, virgin"

/lab_host="DH10B"

/note="Organ: mammary; Vector: pCMV-SPORT6; Site_1: Salt; Site_2: Not; Cloned unidirectionally. Primer: Oligo dr. Library constructed by Life Technologies. Investigator providing samples: Gilbert Smith, NIH"

BASE COUNT 135 a 235 c 162 g 136 t

ORIGIN

alignment_scores:

Quality: 606.50 Length: 150

Ratio: 4.460 Gaps: 6

Percent Similarity: 90.667 Percent Identity: 85.333

alignment_block:

US-09-508-832-6 x BG173095 ..

Align seg 1/1 to: BG173095 from: 1 to: 668

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
223 ATGGCCAAAGCAACCTTCGTAGTGAAGTTCTGAGTGTGACAGAGAGGTGG 272
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
273 ACAATTGAGGCTGCTGAGAGGCTCCCGAGCTCAGGCTGGGGCCCTA 322
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
323 CTCCCTACAGACAGAACCGCAAGGTAATCCGACGGCGGAAGGGACCTG 372
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG 67
|||||
373 CTGGCCCCAGCGGCGCTCAGGCGCCGCTTGGCCCCACCGCGGAGCCCTG 422
67 lyProPheAlaThrArgSer.ProLeuPheIlePheValArgArgSerSe 83
|||||
423 GCCCTTTGCTACAGATCCCGCCACTTTTCATCTTTGTGAGAAGATCTTC 472
83 rLeuLeuSerArgSerSerGlyTyrPheSer....PheAspThrAspA 99
|||||
473 TCTGCTGCCGGTCTCCAGTGGGTATATTCTCTTTTTCACACAGCAC 522
99 rGSerProAlaProMetSerCysAspLysSerThrGln.ThrProSerPr 115
|||||
523 AGGAGCCGGCAGCCATAGTGTGACAAAGTCAACACAAACCCCAAGTCC 572
115 oProCysGlnAlaPheAsnHisTyrLeuSer.AlaMetAlaSerIleArg 131
|||||
573 TCCTTGCCAGGCTTCACCACTATCTCAGTTGCATGGCTTTTCATACGA 622
132 GlnSer.GlnGluGluProGluAspLeuArgProGluIle 144
|||||
623 CAGTCTCCAGGAGGAACCTGAGGATCTCGCGCCGGGAGATC 662

seq_name: gb_est1:AI971169

seq_documentation_block:

LOCUS AI971169 492 bp mRNA EST 08-MAR-2000

DEFINITION wt24h12.x1 NCI_CGAP_Pt28 Homo sapiens cDNA clone IMAGE:2488679 3' similar to TR:043522 O43522 B1ML. [1] ; mRNA sequence.

ACCESSION AI971169

VERSION AI971169.1 GI:5767995

KEYWORDS EST.

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 492)

AUTHORS NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.

TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index

JOURNAL Unpublished (1997)

COMMENT Contact: Robert Strausberg, Ph.D.

Email: cgaps-r@mail.nih.gov

Tissue Procurement: Michael J. Brownstein, M.D., Ph.D., Michael R. Emmert-Buck, M.D., Ph.D.

cDNA Library Preparation: M. Bento Soares, Ph.D.

DNA Sequencing by: Greg Lennon, Ph.D.

Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html

Insert length: 712 Std Error: 0.00

Seq primer: -40UP from Gibco

High quality sequence stop: 450.

FEATURES

Location/Qualifiers

1..492

/organism="Homo sapiens"

/db_xref="taxon:9606"

/clone="IMAGE:2488679"

/clone_lib="NCI_CGAP_Pr28"

/sex="male"

/dev_stage="adult"

/lab_host="DH10B"

/note="Organ: prostate; Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; plasmid DNA from the normalized library NCI_CGAP_Pr22 was prepared, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from a pool of 5,000 clones made from the same library (cloneIDs: 985608-986759, 1101192-1101959, and 1217928-1220615). Subtraction by Bento Soares and M. Fatima Bonaldo."

BASE COUNT 119 a 107 c 130 g 134 t 2 others

ORIGIN

alignment_scores:

Quality: 332.00 Length: 130

Ratio: 4.676 Gaps: 1

Percent Similarity: 54.615 Percent Identity: 53.846

alignment_block:

US-09-508-832-6 x AI971169/rev

Align seg 1/1 to reverse of: AI971169 from: 1 to: 492

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArgGluGlyG1 17
|||||
425 ATGGCAAAGCAACCTTCGTAGTGAAGTTCTGAGTGTGACAGAGAGGTAG 376
17 yGlnLeuGlnProAlaGluArgProProGlnLeuArgProGlyAlaProT 34
|||||
375 ACAATTGAGGCTGCGGAGAGGCTCCCGAGCTCAGAGCTGGGGCCCTA 326
34 hrSerLeuGlnThrGluProGlnGlyAsnProAspGlyGluGlyAspArg 50
|||||
325 CTCCCTACAGACAGAGCCACAA..... 303
51 CysProHisGlySerProGlnGlyProLeuAlaProProAlaSerProG1 67
303 303
67 yProPheAlaThrArgSerProLeuPheIlePheValArgArgSerL 84
303 303
84 euLeuSerArgSerSerSerGlyTyrPheSerPheAspThrAspArgSer 100
302GACAGAGAC 294
101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProC 117
|||||
293 CCAGCACCCATCAGTTGTGACAAATCAACACAAACNCAAGTCCCTCTG 244
117 sglnAlaPheAsnHisTyrLeuSerAlaMetAlaSerIle 130

|||||
243 CCAGGCTTCAACACTATCTCAGTCAATGAGTAGTCATC 204

seq_name: gb_est2:BF319454

seq_documentation_block: 389 bp mRNA EST 29-DEC-2000
LOCUS BF319454
DEFINITION uy59b09.xl McCarrey Eddy round spermatid Mus musculus cDNA clone IMAGE:3663833 3' similar to TR:054918 O54918 BCL2 INTERACTING
ACCESSION BF319454
VERSION BF319454
KEYWORDS: MEDIATOR OF CELL DEATH ; mRNA sequence.
SOURCE BF319454.1 GI:11268195
house mouse.
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 389)
AUTHORS Marra,M., Hillier,L., Kucaba,T., Martin,J., Beck,C., Wylie,T., Underwood,K., Sleptoe,M., Theising,B., Allen,M., Bowers,Y., Person B., Swaller,T., Gibbons,M., Pape,D., Harvey,N., Schurk,R., Ritter E., Kohn,S., Shin,T., Jackson,Y., Cardenas,M., McCann,R., Waterston,R. and Willson,R.
TITLE The WashU-NCI Mouse EST Project 1999
JOURNAL Unpublished (1999)
COMMENT Other ESTs: uy59b09.y1
Contact: Marra M/WashU-NCI Mouse EST Project 1999
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:1424601
High quality sequence stop: 325.

FEATURES

source
1..389
Location/Qualifiers
/organism="Mus musculus"
/strain="CD-1"
/db_xref="taxon:10090"
/clone="IMAGE:3663833"
/clone_lib="McCarrey Eddy round spermatid"
/sex="male"
/tissue_type="round spermatids, pooled from multiple mice"
/dev_stage="60 day"
/lab_host="DH10B (phage-resistant)"
/note="Organ: testis; Vector: pBluescript SK+ (Stratagene); Site_1: XhoII; Site_2: EcoRI; cDNA oligo dt-primed [5'-(GA)10-ACTAGCTCGAGTTTTTTTTTTT-3'] and directionally cloned using 5' linkers 5'-AATTCGGCAG-3' and 5'-CTCGTGGCG-3'. Size selection of >400bp material gives average insert size ranging from 1-2 kb. Library was mass excised (from lambda-UnizAP-XR) and resulting single-stranded phagemids were prepped and transformed into DH10B. Library contains 98.5% recombinants.
References: J. Androl. 20:635-639 and Gene 25:263-269.
Library constructed and donated by J. McCarrey, Ph.D. (Southwest Foundation for Biomedical Research, Dept. of Genetics); excision done by E.M. Eddy, Ph.D. (National Institutes of Health, National Institute of Environmental Health Sciences). Original lambda-based library is available through ATCC, catalog #63423."
BASE COUNT 100 a 104 c 89 g 96 t
ORIGIN

alignment_scores:

Quality: 249.00 Length: 53
Ratio: 4.882 Gaps: 1
Percent Similarity: 96.226 Percent Identity: 94.340

alignment_block:

US-09-508-832-6 x BF319454/rev ..

Align seg 1/1 to reverse of: BF319454 from: 1 to: 389

145 ArgIleAlaGlnGluLeuArgArgIleGly.AspGluPheAsnGluThrT 161
|||||
389 CGATTTGCAGGAACCTCGGGGATCGGAAGACGAGTTCAACGAACTT 340
|||||
161 YrThrArgArgValPheAlaAsnAspTyrArgGluAlaGluAspHisPto 177
|||||
339 ACACAGGAGGGGTGTTCGAATCATACCGCGAGGCTGAAGACACCT 290
|||||
178 GlnMetValIleLeuGlnLeuLeuArgPheIlePheArgLeuValTrpAr 194
|||||
289 CAAATGGTTATCTTACAACCTGTTACGCTTTATCTTCGTCGTGATGGAG 240
|||||
194 gArgHis 196
|||||
239 AAGGCAT 233
|||||

seq_name: gb_est1:AW629314

seq_documentation_block: 664 bp mRNA EST 31-MAR-2000
LOCUS AW629314
DEFINITION hi56e02.xl Soares_NFL_T_GBC_S1 Homo sapiens cDNA clone IMAGE:2976314 3' similar to TR:043522 O43522 B1ML. [1] ; mRNA
sequence.
ACCESSION AW629314
VERSION AW629314.1 GI:7376104
KEYWORDS EST.
SOURCE human.
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 664)
AUTHORS NCI-CCAP http://www.ncbi.nlm.nih.gov/ncicgap.
TITLE National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index
JOURNAL Unpublished (1997)
COMMENT Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
This clone is available royalty-free through LNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
Seq primer: -40UP from Gibco
High quality sequence stop: 458.

FEATURES

source
1..664
Location/Qualifiers
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone="IMAGE:2976314"
/clone_lib="Soares_NFL_T_GBC_S1"
/lab_host="DH10B"
/note="Organ: pooled; Vector: pT7T3D-Pac (Pharmacia) with a modified polylinker; Site_1: Not I; Site_2: Eco RI; Equal amounts of plasmid DNA from three normalized libraries (fetal lung NBHL19W, testis NHT, and B-cell NCI CGAP-GCB1) were mixed, and ss circles were made in vitro. Following HAP purification, this DNA was used as tracer in a subtractive hybridization reaction. The driver was PCR-amplified cDNAs from pools of 5,000 clones made from the same 3 libraries. The pools consisted of I.M.A.G.E. clones 297480-302087, 682632-687239, 726408-728711, and 729096-731399. Subtraction by Bento Soares and M. Fatima Bonaldo."
BASE COUNT 176 a 131 c 148 g 208 t 1 others
ORIGIN

alignment_scores:

Quality: 249.00 Length: 125
Ratio: 4.220 Gaps: 1
Percent Similarity: 47.200 Percent Identity: 43.200

alignment_block:

US-09-508-832-6 x AW629314/rev ..

Align seg 1/1 to reverse of: AW629314 from: 1 to: 664

```

3 LysGlnProSerAspValSerGluCysAspArgGluGlyGlyGlnLe 19
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
664 AAGCCACCTTTTGATGAAAGTTTGTAGTGGCCNGAGAGAGGTAGACAAAT 615
19 uGlnProAlaGluArgProGlnLeuArgProGlyAlaProThrSerL 36
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
614 GCAGCTGCGAAGAGGCTTCCCCAGTTCAGACTTGGGGCCCTACCTCCT 565
36 euGlnThrGluProGlnGlyAsnProAspGlyGlyGlyAspArgCysPro 52
:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
564 ACAAGACAGACGACAA..... 548
53 HisGlySerProGlnGlyProLeuAlaProProAlaSerProGlyProph 69
548 ..... 548
69 eAlaThrArgSerProLeuPheIlePheValArgArgSerSerLeuLeus 86
548 ..... 548
86 erArgSerSerGlyTyrPheSerPheAspThrAspArgSerProAla 102
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
547 .....GACAGAGCCGACGA 533
103 ProMetSerCysAspLysSerThrGlnThrProSerProCysGlnAl 119
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
532 CCCATGAGTTGTGACAAATCAACAAACCCCAAGTCTCTTGGCAGGC 483
119 aPheAsnHisTyrLeuSerAlaMet 127
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
482 CTTCAACCACTATCTCAGTGAATG 458

```

seq_name: gb_estl:AF209718

```

seq_documentation_block:
LOCUS AF209718 537 bp mRNA EST 30-MAY-2000
DEFINITION AF209718 Xenopus laevis intestine adult Xenopus laevis cDNA clone
pXlg10 similar to Mus musculus BimEL, mRNA sequence.

```

```

ACCESSION AF209718
VERSION AF209718.1 GI:8110110
KEYWORDS EST.
SOURCE African clawed frog.

```

```

ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Amphibia; Batrachia; Anura; Mesobatrachia; Pipidoidea; Pipidae;
Minter,R.

```

```

REFERENCE
AUTHORS Minter,R.
TITLE Development of Antibody Technology to Identify Natural Killer Cell
Surface Antigens in Xenopus laevis. Thesis (1999) University of
Durham, South Rd., Durham, UK
JOURNAL Unpublished (1999)
COMMENT Contact: Minter,R., Horton,J.D. and Watson,M.D.
Biological Sciences
University of Durham
South Road, Durham, DH1 3LE, UK
Email: martin.watson@durham.ac.uk.
Location/Qualifiers
1. .537
/organism="Xenopus laevis"
/db_xref="taxon:8355"
/clone="pXlg10"
/tissue_lib="Xenopus laevis intestine adult"
/tissue_type="intestine"
/cell_type="epithelial lymphocyte"
/dev_stage="adult"

```

```

BASE COUNT 126 a 129 c 143 g 139 t
ORIGIN
source
1. .537
/organism="Xenopus laevis"
/db_xref="taxon:8355"
/clone="pXlg10"
/tissue_lib="Xenopus laevis intestine adult"
/tissue_type="intestine"
/cell_type="epithelial lymphocyte"
/dev_stage="adult"

```

FEATURES

source

1. .537

/organism="Xenopus laevis"

/db_xref="taxon:8355"

/clone="pXlg10"

/tissue_lib="Xenopus laevis intestine adult"

/tissue_type="intestine"

/cell_type="epithelial lymphocyte"

/dev_stage="adult"

alignment_scores:

```

Quality: 202.00 Length: 107
Ratio: 2.730 Gaps: 3
Percent Similarity: 69.159 Percent Identity: 50.467

```

alignment_block:

US-09-508-832-6 x AF209718 ..

Align seg 1/1 to: AF209718 from: 1 to: 537

```

1 MetAlaLysGlnProSerAspValSerSerGluCysAspArg....GluG1 16
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
223 ATGGCCAAACACCGTCGTCTTGAGTCGGGAGTGAATAGTGGTGAAGG 272
16 yGlyGlnLeuGlnProAlaGluArgProGlnLeuArgPro..... 30
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
273 TGGCCAGTTACAAATCAACAGCAGCAGACATTTCTCATCTCTCCGCGAGAA 322
31 ..GlyAlaProThrSerLeuGlnThrGluProGlnGlyAsnProAspGly 46
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
323 GAGGGGCCCCACCTCTCTTAGCAGTCCTTTTCAAGGTAATCAATCAGAT 372
47 GluGlyAspArgCysProHisGlySerProGlnGlyProLeuAlaProPr 63
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
373 GAGGCTGGGAGCTCCTCAGCCAGCAGCTCTTGGGGTCTTACTTTATCGGC 422
63 oAlaSerProGlyProPheAlaThrArgSerProLeuPheIlePheValA 80
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
423 TTATAGCCCCCAGTTCTTTGTCAACAGATCACCCCATTCGATCGCTGTA 472
80. rArgSerSerLeuLeuSerArgSerSerSerGlyTyrPheSerPheAsp 96
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
473 GAGGATCATCACTGTCTCAAAACC.TCAAGTGGCTATTTTACATTC.... 518
97 ThrAspArgSerProAlaPro 103
... ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
519 ...GAAGGAGTCTCTGGGCT 536

```

seq_name: gb_estl:AW748960

```

seq_documentation_block:
LOCUS AW748960 157 bp mRNA EST 28-APR-2000
DEFINITION RC4-BT0312-081199-011-b02 BT0312 Homo sapiens cDNA, mRNA sequence.
ACCESSION AW748960
VERSION AW748960.1 GI:7663892
KEYWORDS EST.
SOURCE human.

```

```

ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 157)
AUTHORS Dias Neto,E., Garcia Correa,R., Verjovski-Almeida,S., Briones,M.R.,
Ngai,M.A., da Silva,W. Jr., Zago,M.A., Bordin,S., Costa,F.F.,
Goldman,G.H., Carvalhal,A.F., Matsukuma,A., Baia,G.S., Simpson,D.H.,
Brunstein,A., deOliveira,P., Bucher,P., Jongeneel,C.V., O'Hare
,M.J., Soares,F., Brentani,R.R., Reis,L.F., de Souza,S.J. and
Simpson,A.J.
Shotgun sequencing of the human transcriptome with ORF expressed
sequence tags
Proc. Natl. Acad. Sci. U.S.A. 97 (7), 3491-3496 (2000)
20202663
COMMENT
Contact: Simpson A.J.G.
Laboratory of Cancer Genetics
Ludwig Institute for Cancer Research
Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, Sao Paulo-SP,
Brazil
Tel: +55-11-2704922
Fax: +55-11-2707001
Email: asimpson@ludwig.org.br
This sequence was derived from the FAPESP/LICR Human Cancer Genome
Project. This entry can be seen in the following URL

```

(<http://www.ludwig.org.br/scripts/gethtml2.pl?t1=RC4&t2=RC4-BW0312-081199-011-b02&t3=1999-11-08&t4=1>)

[illegible]

```

1. 157
/organism="Homo sapiens"
/db_xref="taxon:9606"
/clone_lib="Br0312"
/dev_stage="Adult"
/note="Organ: breast; Vector
SmaI; A mini-library was made
from ORESTES PCR (U.S. Let
/16 - Ludwig Institute for
into the pUC 18 vector. Re
mRNA and cDNA amplification
stringency conditions."
38 a 48 c 28 g 43 t
BASE COUNT
ORIGIN

```

```

alignment_scores:
  Quality: 149.00      Length: 50
  Ratio: 3.386        Gaps: 3
  Percent Similarity: 88.000      Percent Identity: 80.000

alignment_block:
  US-09-508-832-6  x AW748960

```

Align seg 1/1 to: AW748960 from: 1 to: 157

58 ProPheAlaThrArgSerProLeuPheIlePheValArgArgSerLeu 84
||||| : : : : :
15 CCTTTT...GTACAGATCCCGCTTTTCATCTTTATAAGAGATC.TCCCT 60

84 uLeuSerArgSerSerGlyTyrPheSerPheAspThrAspArgSer. 100
; |||||
61 GCTGTACAGATCCTCCAGTGGGTATTCTCTTTGACACAGACGAGGCC 110

101 ProAlaProMetSerCysAspLysSerThrGlnThrProSerProPro 116
... : : : : :
111 AGCACCC...ATTGAGTTGTGACAAATCACCAACAACCCCAAGTCCTCCT 155

seq_name: qb_est1:AA629308

seq_documentation_block:					
LOCUS	AA629308	501 bp	mRNA	EST	16-OCT-1997
DEFINITION	Zu49g06.sl Soares_testis_NHT	Homo sapiens cDNA clone IMAGE:744730			
	3', mRNA sequence.				
ACCESSION	AA629308				
VERSION	AA629308.1	GI:2541695			
KEYWORDS	EST.				

SOURCE ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 1 (bases 1 to 501)
 Hillier, L., Allen, M., Bowles, L., Dubuque, T., Geisel, G., Jost, S.,
 Krizman, D., Kucaba, T., Lacy, M., Le, N., Lennon, G., Marra, M., Martin,
 J., Moore, B., Schellenberg, K., Steptoe, M., Tan, F., Theising, B.,
 White, Y., Wyllie, T., Waterston, R. and Wilson, R.

TITLE	JOURNAL	COMMENT
1. The Role of the Teacher in the Classroom	Journal of Educational Research	1980, Vol. 83, No. 1, pp. 1-10
2. The Impact of Technology on Education	Journal of Educational Research	1980, Vol. 83, No. 2, pp. 11-20
3. The Importance of Parental Involvement	Journal of Educational Research	1980, Vol. 83, No. 3, pp. 21-30
4. The Effect of Teacher Expectations on Student Achievement	Journal of Educational Research	1980, Vol. 83, No. 4, pp. 31-40
5. The Role of the School in the Community	Journal of Educational Research	1980, Vol. 83, No. 5, pp. 41-50
6. The Impact of Socioeconomic Status on Student Achievement	Journal of Educational Research	1980, Vol. 83, No. 6, pp. 51-60
7. The Importance of Teacher Education	Journal of Educational Research	1980, Vol. 83, No. 7, pp. 61-70
8. The Effect of Teacher Training on Student Achievement	Journal of Educational Research	1980, Vol. 83, No. 8, pp. 71-80
9. The Role of the School in the Community	Journal of Educational Research	1980, Vol. 83, No. 9, pp. 81-90
10. The Impact of Socioeconomic Status on Student Achievement	Journal of Educational Research	1980, Vol. 83, No. 10, pp. 91-100

Contact: Wilson RA
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through LNL ; contact
IMAGE Consortium (info@image.lnl.gov) for further info
Seq primer: -40ml3 fwd. ET from Amersham

source

FEATURES	High quality sequence stop: 471.
source	Location/Qualifiers
	1. .501

```

I. .501
source
/organism="Homo sapiens"
/db_xref="GBD:5932418"
/db_xref="taxon:9606"
/clone="IMAGE:744730"
/clone_lib="Soares_testis_NHT"
/sex="male"
/lab_host="DH10B"
/note="Vector: pT73D-Pac (Pharmacia) with a modified
polylinker; Site_1: Not I; Site_2: Eco RI; 1st strand cDNA
was prepared from mRNA obtained from Clontech Laboratories
, Inc., and primed with a Not I - oligo(dT) primer [5',
TGTTACATCTGTAAGCTGGAGCGCGCCCAATTTTTTTTTTTTTT 3'].
Double-stranded cDNA was ligated to Eco RI adaptors
(Pharmacia), digested with Not I and cloned into the Not I
and Eco RI sites of the modified pT73 vector. Library
went through one round of normalization to Cot5, and was
constructed by Bento Soares and M. Fatima Bonaldo."
155 a 112 c 97 g 137 t
BASE COUNT

```

alignment_scores:		
Quality:	127.00	Length: 32
Ratio:	4.536	Gaps: 0
Percent Similarity:	87.500	Percent Identity: 71.875

alignment_block: US-09-508-832-6 x AA629308/rev

Align seq 1/1 to reverse of: AA629308 from: 1 to: 501

165 ValPheAlaAsnAspTyrArgGluAlaGluAspHisProClnMetValI 181
||||| :|||:::|||||:
501 GTATTTTGTGAATAATTAACCAAGCAGCCGAGACCACCGAATGGTTAT 452

181 eueuClnLeuLeuArgPheLlePheArgLeuValTrpArgArgHis 196
||||| :|||:::|||||:
451 CTTACGACTGTTTAGGTATACATTGTTCGCCCTGGTGTTGGAGAATGCAT 406

seq_name: gb_est2:BF172831

seq_documentation_block:			
LOCUS	BF172831	210 bp	EST
DEFINITION	PCL5805 Myeloma (PCL) cDNA library Homo sapiens cDNA. mRNA		23-MAR-2001

ACCESSION	BF172831	
VERSION	BF172831	1
		GT-13439045

KEYWORDS EST.
SOURCE human

SOURCE	Human:
ORGANISM	Homo sapiens
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
AUTHORS	1 (bases 1 to 210)
TITLE	Claudio,J.O., Tang,H., Khan,E.M., Voralia,M., Li,Z., Cukerman,E., Francisco-Pabalan,O., Liew,C.C. and Stewart,A.K. The transcriptional phenotype of myeloma cells
JOURNAL	Unpublished (2000)
COMMENT	Contact: A. Keith Stewart, M.D.

Oncology Research
University Health Network
610 University Ave., 5-126, Toronto, Ontario, M5G 2M9, Canada
Tel: (416) 946-4639
Fax: (416) 946-6546
Email: k.stewart@utoronto.ca

PCR PRIMERS
 FORWARD: 5'-GCCAAGCTCGAATTAAACCTCACTAAAGG-3'
 BACKWARD: 5'-CCAGTGAATTGTAATACGACTCACTATAGGCG-3'
 Seq primer: 5'-GAAATTAACCTCACTAAAGG-3'

COMMENT On Nov 16, 2000 this sequence version replaced gi:11188497.

Contact: Wing RA
Clemson University Genomics Institute
Clemson University
100 Jordan Hall, Clemson, SC 29634, USA
Tel: 864 656 7288
Fax: 864 656 4293
Email: rwing@clemson.edu
Seq primer: AATTACCCCTCACTAAAGGG
High quality sequence stop: 747.

FEATURES

Location/Qualifiers

1..768
/organism="Hordeum vulgare"
/cultivar="Morex"
/db_xref="taxon:4513"
/clone="HVSMEF0019D03f"
/clone.lib="Hordeum vulgare seedling root EST library
HVCN0007 (etiolated and unstressed)"
/tissue_type="Seedling root"
/lab_host="TJCI21"
/note="Vector: lambdaZAP; Site_1: EcoRI; Site_2: XhoI; For
more details on library preparation and sequence analysis
see http://www.genome.clemson.edu/projects/barley/ To
order a clone see http://www.genome.clemson.edu/orders"
98 a 322 c 178 g 167 t 3 others

BASE COUNT
ORIGIN

alignment_scores:

Quality: 118.50 Length: 134
Ratio: 1.852 Gaps: 5
Percent Similarity: 47.761 Percent Identity: 32.836

alignment block:

US-09-508-832-6 x BF259468 ..

Align seg 1/1 to: BF259468 from: 1 to: 768

4 GlnProSerAspValSerSerGluCysAspArgGluGlyGlnLeuG1 20
149 CAGCCACCGCGCTCACCTATCCCGGACCG.....GC 183
20 nProAlaGluArgProGlnLeuArgProGlyAlaProThrSerLeuG 37
184 GCCTNTCCGNCACCGCTTCGGCGCTNCCGCGCCCTCCACCTTCGCGC 233
37 lnThrGluProGlnGlyAsnProAspGlyGluGlyAspArgCysProHis 53
234 CGCCACCCCG.....TGCCCTTCA 253
54 GlySerProGlnGlyProLeuAlaPro.....ProAlaSerPr 66
254 TGTCCTTCGACATACCGCTCAGTCCCACTCCACGCGCCGCTTCACC 303
66 oGlyProPheAlaThrArgSerProLeuPheValArgArgSerS 83
304 GGCCCATCGCGCGCTCGGTGCTCTTCGAAGACGAGCGCGCTCT 353
83 erLeuLeuSerArgSer.....SerSerGlyTyrPheSerPhe 95
354 CGAGGAGCTCGGCATCAACACGCGCCAGATCTCGCGGAGACCGCTCTCA 403
96 AspThrAspArgSerProAlaProMetSerCysAspLysSerThrGlnTh 112
404 TCCTCCACCGCTCCGCTCCGCGGACCGGT.....CGTCCACGACGAC 447
112 rProSerProProCysGlnAlaPheAsnHisTyrLeuSerAlaMetAlas 129
448 GCGGATCTCTCGGCGCCCTCTGTTCTTATCTTATCTCTGCTCTTCA 497
129 er 129
498 GC 499

seq_name: gb_htc:BC007683

seq_documentation_block:

LOCUS BC007683 1350 bp mRNA HTC 12-JUL-2001
DEFINITION Homo sapiens, postmeiotic segregation increased 2-like 9, clone
IMAGE:3637150, mRNA.

ACCESSION BC007683

VERSION BC007683.1 GI:14712737

KEYWORDS

SOURCE human.

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1350)

AUTHORS Strausberg, R.

TITLE Direct Submission

JOURNAL Submitted (11-MAY-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA

REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov

COMMENT Contact: MGC help desk

Email: cgapbs-remail.nih.gov

Tissue Procurement: ATCC

cDNA Library Preparation: Rubin Laboratory

DNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)

DNA Sequencing by: National Institutes of Health Intramural

Sequencing Center (NISC),

Gaithersburg, Maryland;

Web site: http://www.nisc.nih.gov/

Contact: nisc.mgc@nih.gov

Shvchenko, Y., Wetherby, K.D., Beckstrom-Sternberg, S.M.,
Benjamin, B., Blakesley, R.W., Bouffard, G.G., Brinkley, C., Brooks, S.,
Dietrich, N.L., Guan, X., Gupta, J., Ho, S.-L., Karlus, E., Legaspi, R.,
Lim, M., Maduro, Q.L., Masiello, C., Mastrian, S.D., McCloskey, J.C.,
McDowell, J., Pearson, R., Snyder, B., Stantripop, S., Thomas, P.J.,
Tiongson, E.E., Touchman, J.W., Tsurgeon, C., Vogt, J.L., Walker, M.A.,
Zhang, L.-H. and Green, E.D.

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAL Plate: 12 Row: f Column: 16

This clone was selected for full length sequencing because it

passed the following selection criteria: matched mRNA gi: 3327049

This clone has the following problem: incomplete processing.

FEATURES

Location/Qualifiers

1..1350
/organism="Homo sapiens"
/db_xref="LocusID:5387"
/db_xref="taxon:9606"
/clone="IMAGE:3637150"
/tissue_type="Placenta, choriocarcinoma"
/clone.lib="NIH_MGC_21"
/lab_host="DH10B-R"
/note="Vector: pOTB7"
BASE COUNT 333 a 326 c 416 g 275 t
ORIGIN

alignment_scores:

Quality: 115.00 Length: 187
Ratio: 1.127 Gaps: 12
Percent Similarity: 54.545 Percent Identity: 32.086

alignment_block:

US-09-508-832-6 x BC007683 ..

Align seg 1/1 to: BC007683 from: 1 to: 1350

14 ArgGluGlyGlyGlnLeuGlnProAlaGluArgProProGlnLeuArgPr 30
||||:||||| :|||
98 CGAAGTGGCGGGAGGCGGAGGGCGGGGACCC.....GGGCC 138

THIS PAGE BLANK (USPTO)